

GenCore version 5.1.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search.. using sw model

Run on: June 13, 2003, 15:02:56 ; Search time 38 seconds
(without alignments)
578.588 Million cell updates/sec

Title: US-09-830-964-1

Perfect score: 846

Sequence: 1 APPRLICDSRVLYLEAK.....SNFLRGKLYTGEACRTGD 165

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- 1: /SID22/gcgdata/geneseq/geneseq-emb1/AA1980.DAT:*
- 2: /SID22/gcgdata/geneseq/geneseq-emb1/AA1981.DAT:*
- 3: /SID22/gcgdata/geneseq/geneseq-emb1/AA1982.DAT:*
- 4: /SID22/gcgdata/geneseq/geneseq-emb1/AA1983.DAT:*
- 5: /SID22/gcgdata/geneseq/geneseq-emb1/AA1984.DAT:*
- 6: /SID22/gcgdata/geneseq/geneseq-emb1/AA1985.DAT:*
- 7: /SID22/gcgdata/geneseq/geneseq-emb1/AA1986.DAT:*
- 8: /SID22/gcgdata/geneseq/geneseq-emb1/AA1987.DAT:*
- 9: /SID22/gcgdata/geneseq/geneseq-emb1/AA1988.DAT:*
- 10: /SID22/gcgdata/geneseq/geneseq-emb1/AA1989.DAT:*
- 11: /SID22/gcgdata/geneseq/geneseq-emb1/AA1990.DAT:*
- 12: /SID22/gcgdata/geneseq/geneseq-emb1/AA1991.DAT:*
- 13: /SID22/gcgdata/geneseq/geneseq-emb1/AA1992.DAT:*
- 14: /SID22/gcgdata/geneseq/geneseq-emb1/AA1993.DAT:*
- 15: /SID22/gcgdata/geneseq/geneseq-emb1/AA1994.DAT:*
- 16: /SID22/gcgdata/geneseq/geneseq-emb1/AA1995.DAT:*
- 17: /SID22/gcgdata/geneseq/geneseq-emb1/AA1996.DAT:*
- 18: /SID22/gcgdata/geneseq/geneseq-emb1/AA1997.DAT:*
- 19: /SID22/gcgdata/geneseq/geneseq-emb1/AA1998.DAT:*
- 20: /SID22/gcgdata/geneseq/geneseq-emb1/AA1999.DAT:*
- 21: /SID22/gcgdata/geneseq/geneseq-emb1/AA2000.DAT:*
- 22: /SID22/gcgdata/geneseq/geneseq-emb1/AA2001.DAT:*
- 23: /SID22/gcgdata/geneseq/geneseq-emb1/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | DB ID | Description |
|------------|-------|-------------|--------|-------|-------------|
| 1 | 846 | 100.0 | 165 | 21 | AA94605 |
| 2 | 846 | 100.0 | 165 | 21 | AA803760 |
| 3 | 846 | 100.0 | 165 | 21 | AA99705 |
| 4 | 846 | 100.0 | 165 | 21 | AA93445 |
| 5 | 846 | 100.0 | 165 | 22 | AA84525 |
| 6 | 846 | 100.0 | 165 | 22 | AA86697 |
| 7 | 846 | 100.0 | 165 | 23 | ABB77896 |
| 8 | 846 | 100.0 | 165 | 23 | AA53061 |
| 9 | 846 | 100.0 | 166 | 8 | AA970398 |
| 10 | 846 | 100.0 | 166 | 13 | AA233593 |

| | | | | | | |
|----|-----|-------|-----|----|----------|-------------------------|
| 11 | 846 | 100.0 | 166 | 19 | AAW77780 | Human EPO receptor |
| 12 | 846 | 100.0 | 166 | 19 | AAW58404 | Human erythropoietin |
| 13 | 846 | 100.0 | 166 | 21 | ABB07030 | Modified erythropoietin |
| 14 | 846 | 100.0 | 166 | 22 | AAE02641 | Human erythropoietin |
| 15 | 846 | 100.0 | 166 | 22 | AAE56698 | Human erythropoietin |
| 16 | 846 | 100.0 | 166 | 23 | ABB77897 | Amino acid sequence |
| 17 | 846 | 100.0 | 166 | 23 | AAW53062 | Human erythropoietin |
| 18 | 846 | 100.0 | 167 | 6 | AAW50298 | Human recombinant |
| 19 | 846 | 100.0 | 167 | 6 | AAW50299 | Human recombinant |
| 20 | 846 | 100.0 | 169 | 23 | ABB77899 | Amino acid sequence |
| 21 | 846 | 100.0 | 174 | 23 | ABB77898 | Amino acid sequence |
| 22 | 846 | 100.0 | 174 | 23 | ABB77900 | Amino acid sequence |
| 23 | 846 | 100.0 | 188 | 7 | AAW60599 | Clone lambda HEPOF |
| 24 | 846 | 100.0 | 188 | 9 | AAW61195 | Erythropoietin enc |
| 25 | 846 | 100.0 | 193 | 6 | AAW50300 | Human erythropoietin |
| 26 | 846 | 100.0 | 193 | 7 | AAW60597 | Clone lambda HEPOF |
| 27 | 846 | 100.0 | 193 | 8 | AAW70256 | Sequence of human |
| 28 | 846 | 100.0 | 193 | 15 | AAW65499 | Human prepro-eryth |
| 29 | 846 | 100.0 | 193 | 16 | AAW61982 | Human erythropoietin |
| 30 | 846 | 100.0 | 193 | 16 | AAW71137 | Human erythropoietin |
| 31 | 846 | 100.0 | 193 | 16 | AAW74141 | Human erythropoietin |
| 32 | 846 | 100.0 | 193 | 17 | AAW98397 | Human erythropoietin |
| 33 | 846 | 100.0 | 193 | 21 | AAW94530 | Human erythropoietin |
| 34 | 846 | 100.0 | 193 | 21 | AAW93638 | Amino acid sequence |
| 35 | 846 | 100.0 | 193 | 21 | AAW99704 | Human non-glycosyl |
| 36 | 846 | 100.0 | 193 | 21 | AAW43398 | Human erythropoietin |
| 37 | 846 | 100.0 | 193 | 22 | AAW85573 | Human erythropoietin |
| 38 | 846 | 100.0 | 193 | 22 | AAW34978 | Human erythropoietin |
| 39 | 846 | 100.0 | 193 | 23 | AAE15341 | Human erythropoietin |
| 40 | 846 | 100.0 | 194 | 16 | AAW71167 | Human erythropoietin |
| 41 | 846 | 100.0 | 194 | 19 | AAW62048 | Human erythropoietin |
| 42 | 846 | 100.0 | 194 | 21 | AAW10654 | Human erythropoietin |
| 43 | 846 | 100.0 | 196 | 23 | ABB77902 | Amino acid sequence |
| 44 | 846 | 100.0 | 201 | 23 | ABB77901 | Amino acid sequence |
| 45 | 846 | 100.0 | 201 | 23 | ABB77903 | Amino acid sequence |

ALIGNMENTS

RESULT 1
AA94605
ID AA94605 standard; Protein; 165 AA.
XX
AC AA94605;
XX
DT 28-NOV-2000 (first entry)
XX
DE Human erythropoietin.
XX
KW Human; erythropoietin; EPO; purification; anaemia.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Modified-site 24 /note= "N-Glycosylation site"
FT Modified-site 38 /note= "N-Glycosylation site"
FT Modified-site 83 /note= "N-Glycosylation site"
FT Modified-site 126 /note= "N-Glycosylation site"
FT Modified-site /note= "O-Glycosylation site"
XX
XX WO2000027869-A1.
PN
XX
XX 18-MAY-2000.
PD
XX
XX 08-NOV-1999; 99WO-US26241.
PF
XX
XX 06-NOV-1998; 98AR-0105610.
PR
XX 23-FEB-1999; 99AR-0100860.
XX

PA (STER-) STERREBELD BIOTECHNOLOGIE NORTH AMERICA.
 XX Carcagno CM, Criscuolo M, Melo C, Vidal JA;
 PI WPI; 2000-376485/32.
 XX Novel methods for purifying recombinant human erythropoietin from
 PT mammalian cell culture reagents -
 XX Claim 16; Page 18; 30pp; English.
 XX The present invention relates to a method for purifying erythropoietin
 CC (EPO) for treatment of disease, especially anaemia. The method involves
 CC treating cell culture supernatants with differential precipitation,
 CC hydrophobic interaction chromatography, diafiltration, anionic and
 CC cationic exchange chromatography and molecular exclusion
 CC chromatography. The present sequence is the protein from the culture
 CC supernatant of transfected cell lines, after purification by the above
 CC process. The sequence shows total homology with natural human EPO.
 CC The advantage of this method is that high purity and quality EPO is
 CC produced. A further advantage is that the process does not involve the
 CC use of organic solvents that may harm the environment.
 XX SQ Sequence 165 AA;
 Query Match 100.0%; Score 846; DB 21; Length 165;
 Best Local Similarity 100.0%; Pred. NO. 1.1e-86;
 Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 APRRLICDSRVLYRLLEAKEAENITTCGAHCSLNENITVPTDKVNFYANKRMEVGQQA 60
 DB 1 APRRLICDSRVLYRLLEAKEAENITTCGAHCSLNENITVPTDKVNFYANKRMEVGQQA 60
 QY 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKEAIS 120
 DB 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKEAIS 120
 QY 121 PPDASAAPLRTITADTFKRLFRVYSNLFGRGKLYTGEACRTGD 165
 DB 121 PPDASAAPLRTITADTFKRLFRVYSNLFGRGKLYTGEACRTGD 165
 RESULT 2
 AAB03760
 ID AAB03760 standard; protein; 165 AA.
 AC AAB03760;
 XX 04-OCT-2000 (first entry)
 XX Human erythropoietin (EPO) amino acid sequence.
 XX Erythropoietin; EPO; human; erythroblast differentiation; anaemia;
 KW large scale production; renal failure.
 XX Homo sapiens.
 XX WO200027997-A1.
 XX 18-MAY-2000.
 XX 08-NOV-1999; 99WO-US26240.
 XX 06-NOV-1998; 98AR-0105611.
 XX 23-FEB-1999; 99AR-0100681.
 XX (STER-) STERREBELD BIOTECHNOLOGIE NORTH AMERICA.
 XX Carcagno CM, Criscuolo M, Melo C, Vidal JA;
 PI WPI; 2000-376519/32.
 XX A novel method for the massive culture of recombinant mammalian cells

PT producing recombinant human erythropoietin -
 XX Example 8; Page 11-12; 23pp; English.
 XX This sequence represents the human erythropoietin amino acid sequence.
 CC Erythropoietin is a glycoprotein that stimulates erythroblast
 CC differentiation in the bone marrow. The present invention relates to a
 CC method for the large scale production of human EPO from recombinant
 CC mammalian cells. The method comprises culturing mammalian cells which
 CC express recombinant human EPO in culture medium comprising insulin.
 CC Erythropoietin can be used to treat anaemia derived from renal failure.
 CC The method allows for the industrial scale production of EPO, and
 CC overcomes the problems of low reproducibility and output quality which
 CC are encountered with previous production methods.
 XX SQ Sequence 165 AA;
 Query Match 100.0%; Score 846; DB 21; Length 165;
 Best Local Similarity 100.0%; Pred. NO. 1.1e-86;
 Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 APRRLICDSRVLYRLLEAKEAENITTCGAHCSLNENITVPTDKVNFYANKRMEVGQQA 60
 DB 1 APRRLICDSRVLYRLLEAKEAENITTCGAHCSLNENITVPTDKVNFYANKRMEVGQQA 60
 QY 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKEAIS 120
 DB 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKEAIS 120
 QY 121 PPDASAAPLRTITADTFKRLFRVYSNLFGRGKLYTGEACRTGD 165
 DB 121 PPDASAAPLRTITADTFKRLFRVYSNLFGRGKLYTGEACRTGD 165
 RESULT 3
 AAY99705
 ID AAY99705 standard; protein; 165 AA.
 AC AAY99705;
 XX 15-SEP-2000 (first entry)
 XX Non-glycosylated erythropoietin analogue NGE-166delta.
 XX Human; non-glycosylated erythropoietin analogue; NGEA; haematocrit;
 KW antianaemic; anaemia; erythropoiesis promoter; mutant; mutein.
 XX Homo sapiens.
 XX Synthetic.
 XX WO200032772-A2.
 XX 08-JUN-2000.
 XX 23-NOV-1999; 99WO-US27801.
 XX 30-NOV-1998; 98US-0110289.
 XX (ELIL) LILLY & CO ELI.
 XX Beals JM, Glaesner W, Micanovic R, Millican RL, Witcher DR;
 DR WPI; 2000-412320/35.
 XX N-PSDB; AAA48373.
 XX Non-glycosylated erythropoietic compound useful for increasing
 PT hematocrit level in mammal with insufficient hematocrit levels in
 PT conditions such as anemia, comprises protein covalently bonded to
 PT polymer.
 XX Claim 2; Page 93-94; 94pp; English.
 XX The present sequence is a non-glycosylated erythropoietin analogue

CC (NGEA) designated NGE-166delta. The protein sequence is identical to
 CC the sequence of wild-type human non-glycosylated erythropoietin NGE
 CC except that Arg at position 166 is deleted. NGE promotes erythropoiesis
 CC and can therefore be used to increase haematocrit levels in mammals
 CC with conditions such as anaemia, in which levels of haematocrit are
 CC insufficient. NGE analogues can also be used to treat such conditions.
 CC NGEAs do not themselves cause a significant increase in haematocrit but
 CC they acquire that property once they are derivatised with polyethylene
 CC glycol polymers. The analogues can be produced using a linkerless
 CC aldehyde modification process. They show stability and bioactivity in
 CC vivo. The nucleotide sequence encoding this protein was constructed
 CC synthetically by in vitro hybridisation using a set of six overlapping
 CC oligonucleotides from the positive strand of human erythropoietin cDNA
 CC with six complementary oligonucleotides (negative strand). The codon
 CC usage was 100% optimised for E. coli codon usage. The hybridised
 CC oligonucleotides were ligated with T4 DNA ligase and the ligation product
 CC amplified by PCR. The nucleotide sequence was used to express the protein
 CC in host cells.

XX Sequence 165 AA;

Query Match 100.0%; Score 846; DB 21; Length 165;
 Best Local Similarity 100.0%; Pred. No. 1.1e-86;
 Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APPRLICDSRVLYLLEAKEAENITTCGAHCSLNENITVPDTKYNFYAKRMEVGQQA 60
 DB 1 APPRLICDSRVLYLLEAKEAENITTCGAHCSLNENITVPDTKYNFYAKRMEVGQQA 60
 QY 61 VEVWQGLALLSEAVLRGQALLVNSQWPQLHVDKAVSGRLSLTLLRALGAQKEAIS 120
 DB 61 VEVWQGLALLSEAVLRGQALLVNSQWPQLHVDKAVSGRLSLTLLRALGAQKEAIS 120
 QY 121 PPDAASAAPLRTITADTFRKLFVYSNFLRGKLYTGACRTGD 165
 DB 121 PPDAASAAPLRTITADTFRKLFVYSNFLRGKLYTGACRTGD 165

RESULT 4

AA93445
 ID AAY93445 standard; protein; 165 AA.

XX AAY93445;

DT 04-SEP-2000 (first entry)

DE Amino acid sequence of human erythropoietin.

KW Human; erythropoietin; EPO; anaemia; renal failure.

XX Homo sapiens.

OS WO200028066-A1.

PN 18-MAY-2000.

XX 08-NOV-1999; 99WO-US26238.

XX 06-NOV-1998; 98AR-0105609.

PR 23-FEB-1999; 99AR-0100679.

XX (STER-) STERRENBELD BIOTECHNOLOGIE NORTH AMERICA.

XX Carcagno CM, Criscuolo M, Melo C, Vidal JA;

XX WPI: 2000-376574/32.

XX New host cell producing recombinant human erythropoietin (EPO) used for
 PT large scale production of EPO

PS Claim 1; Page 26-27; 51pp; English.

XX The present sequence represents human erythropoietin protein. The

CC specification describes a host cell line which is used to produce
 CC human erythropoietin (EPO). EPO is a glycoprotein. The cell line
 CC is used for the production of recombinant human erythropoietin. The
 CC protein is used for the treatment of anaemia, especially anaemia derived
 CC from renal failure.

XX Sequence 165 AA;

Query Match 100.0%; Score 846; DB 21; Length 165;
 Best Local Similarity 100.0%; Pred. No. 1.1e-86;
 Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APPRLICDSRVLYLLEAKEAENITTCGAHCSLNENITVPDTKYNFYAKRMEVGQQA 60
 DB 1 APPRLICDSRVLYLLEAKEAENITTCGAHCSLNENITVPDTKYNFYAKRMEVGQQA 60

QY 61 VEVWQGLALLSEAVLRGQALLVNSQWPQLHVDKAVSGRLSLTLLRALGAQKEAIS 120
 DB 61 VEVWQGLALLSEAVLRGQALLVNSQWPQLHVDKAVSGRLSLTLLRALGAQKEAIS 120

QY 121 PPDAASAAPLRTITADTFRKLFVYSNFLRGKLYTGACRTGD 165

DB 121 PPDAASAAPLRTITADTFRKLFVYSNFLRGKLYTGACRTGD 165

RESULT 5

AA84525

ID AAB84525 standard; protein; 165 AA.

XX AAB84525;

DT 05-SEP-2001 (first entry)

DE Amino acid sequence of human erythropoietin (EPO) protein.

KW Erythropoietin; EPO; erythropoietin stimulating protein; NESF;
 XX sustained release.

OS Homo sapiens.

PN WO200130320-A1.

XX 03-MAY-2001.

XX 23-OCT-2000; 2000WO-US29257.

XX 22-OCT-1999; 99US-0426566.

PR 13-OCT-2000; 2000US-2222222.

XX (AMGE-) AMGEN INC.

XX Burke P, Klumb L, Murphy K, Herberger J, French DL;

XX WPI: 2001-417552/44.

XX Sustained release composition comprises an active biological
 PT ingredient, notably a protein or other biopolymer, particularly
 PT erythropoietin stimulating protein, in biocompatible, biodegradable
 PT polymeric microparticles

PS Disclosure; Page 56; 61pp; English.

XX The present sequence encodes a human erythropoietin (EPO) protein.

CC The specification describes a composition for the sustained release of
 CC biologically active EPO stimulating protein (NESF). The reduced
 CC frequency of administration of NESF, which requires preferably injection
 CC by skilled personnel, improves patient compliance. Also, sustained
 CC release reduces the nature and severity of any side effects of the drug.

XX Sequence 165 AA;

Query Match 100.0%; Score 846; DB 22; Length 165;

Best Local Similarity 100.0%; Pred. No. 1.1e-86;

Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APRRLICDSRVLERYLLEAKEAENITTCGAHCSSLNENITVPDTKVNFYAKRMEVGQQA 60
 DB 1 APRRLICDSRVLERYLLEAKEAENITTCGAHCSSLNENITVPDTKVNFYAKRMEVGQQA 60

QY 61 VEVWQGLALLSEAVLRQALLVNSSQPWEPLQLHVDKAVSGRLSLTLLRALGAQKEAIS 120
 DB 61 VEVWQGLALLSEAVLRQALLVNSSQPWEPLQLHVDKAVSGRLSLTLLRALGAQKEAIS 120

QY 121 PPDAASAAPLRTITADTFRKFLFRVYSNLFRLGKLYTGEACRTGD 165
 DB 121 PPDAASAAPLRTITADTFRKFLFRVYSNLFRLGKLYTGEACRTGD 165

RESULT 6
 AAB66697
 ID AAB66697 standard; protein; 165 AA.
 XX
 AC AAB66697;
 XX
 DT 06-APR-2001 (first entry)
 XX
 DE Human erythropoietin protein #1.
 XX
 KW Erythropoietin; EPO; reticulocytes; red blood cell;
 KW ethylene glycol; chronic renal failure; AIDS; cancer.
 XX
 OS Homo sapiens.
 XX
 PN WO200102017-A2.
 XX
 PD 11-JAN-2001.
 XX
 PF 28-JUN-2000; 2000WO-EP06009.
 XX
 PR 02-JUL-1999; 99US-0142243.
 PR 05-AUG-1999; 99US-0147452.
 PR 30-AUG-1999; 99US-0151454.
 XX
 PA (HOFF) HOFFMANN LA ROCHE & CO AG F.
 PI Burg J, Hilger B, Josel H;
 XX WPI; 2001-147051/15.
 DR
 PS Novel erythropoietin-glycoprotein conjugate useful for treating
 PT diseases correlated with anemia in chronic renal failure patients, AIDS
 PT and for treating cancer, is linked to polyethylene glycol through
 PT linker -
 XX
 PS Claim 19; Fig 1; 40pp; English.
 XX
 CC The present invention relates to a conjugate comprising, human
 CC erythropoietin glycoprotein (EPO) having at least one free
 CC amino group and having in vivo biological activity of causing
 CC an increase the production of reticulocytes and red blood cells,
 CC covalently linked to 1-3 lower-alkoxy poly(ethylene glycol) groups
 CC through a linker. The invention is useful for preparation of
 CC medicaments for the treatment of prophylaxis of disease correlated
 CC with anemia in chronic renal failure patients (CRF), AIDS and for
 CC the treatment of cancer patients undergoing chemotherapy.
 XX
 SQ Sequence 165 AA;
 Query Match 100.0%; Score 846; DB 22; Length 165;
 Best Local Similarity 100.0%; Pred. No. 1.1e-86;
 Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APRRLICDSRVLERYLLEAKEAENITTCGAHCSSLNENITVPDTKVNFYAKRMEVGQQA 60
 DB 1 APRRLICDSRVLERYLLEAKEAENITTCGAHCSSLNENITVPDTKVNFYAKRMEVGQQA 60

QY 61 VEVWQGLALLSEAVLRQALLVNSSQPWEPLQLHVDKAVSGRLSLTLLRALGAQKEAIS 120
 DB 61 VEVWQGLALLSEAVLRQALLVNSSQPWEPLQLHVDKAVSGRLSLTLLRALGAQKEAIS 120

QY 121 PPDAASAAPLRTITADTFRKFLFRVYSNLFRLGKLYTGEACRTGD 165
 DB 121 PPDAASAAPLRTITADTFRKFLFRVYSNLFRLGKLYTGEACRTGD 165

RESULT 7
 ABB77896
 ID ABB77896 standard; protein; 165 AA.
 XX
 AC ABB77896;
 XX
 DT 07-OCT-2002 (first entry)
 XX
 DE Amino acid sequence of a human erythropoietin (EPO).
 XX
 KW Human; erythropoietin; EPO; glycoprotein; reticulocyte production;
 KW red blood cell production; anaemia; chronic renal failure;
 KW acquired immunodeficiency syndrome; AIDS; cancer; bone marrow;
 KW committed erythroid progenitor.
 XX
 OS Homo sapiens.
 XX
 PN WO200249673-A2.
 XX
 PD 27-JUN-2002.
 XX
 PF 08-DEC-2001; 2001WO-EPI4434.
 XX
 PR 20-DEC-2000; 2000EP-0127891.
 XX
 PA (HOFF) HOFFMANN LA ROCHE & CO AG F.
 XX
 PI Burg J, Engel A, Franze R, Hilger B, Schurig HE, Tischer W;
 PI Wozny M;
 XX WPI; 2002-565640/60.
 DR
 PS Novel conjugate of erythropoietin glycoprotein with polyethylene
 PT glycol, useful for treating diseases correlated with anaemia in chronic
 PT renal failure patients and acquired immunodeficiency syndrome -
 XX
 PS Claim 26; Fig 1; 40pp; English.
 XX
 CC The present sequence represents a human erythropoietin (EPO) protein.
 CC It was used to produce conjugates of the invention. The specification
 CC describes a conjugate comprising an EPO glycoprotein having an N-terminal
 CC alpha-amino group, chosen from human EPO (hEPO) or its analogues (where
 CC hEPO is modified by addition of 1-6 glycosylation sites or a
 CC rearrangement of a glycosylation site). The glycoprotein is covalently
 CC linked to a poly(ethylene glycol) group. The EPO glycoprotein has in vivo
 CC biological activity of causing bone marrow cells to increase production
 CC of reticulocytes and red blood cells. The conjugate increased circulating
 CC half-life and plasma residence time, decreased clearance, increased
 CC clinical activity in vivo, improved potency and stability, when compared
 CC to unmodified EPO. The EPO conjugate is useful for preparing medicaments
 CC for the treatment and prophylaxis of diseases correlated with anaemia in
 CC chronic renal failure patients (CRF), acquired immunodeficiency syndrome
 CC (AIDS) and for treating cancer patients undergoing chemotherapy. It is
 CC also useful for treating patients by stimulating the division and
 CC differentiation of committed erythroid progenitors in the bone marrow.
 XX
 SQ Sequence 165 AA;
 Query Match 100.0%; Score 846; DB 23; Length 165;
 Best Local Similarity 100.0%; Pred. No. 1.1e-86;
 Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APRRLICDSRVLERYLLEAKEAENITTCGAHCSSLNENITVPDTKVNFYAKRMEVGQQA 60
 DB 1 APRRLICDSRVLERYLLEAKEAENITTCGAHCSSLNENITVPDTKVNFYAKRMEVGQQA 60

Db 1 APPRLICDSRVLYRLLEAKEAENITTCGAHCNLSNENITVPDTKVNFYAWKRMEVGOQA 60
 QY 61 VEVWQGLALLSEAVLRGQALLVNSQWPPELQHLVDKAVSGLSLTLTLLRALGAQKEAIS 120
 Db 61 VEVWQGLALLSEAVLRGQALLVNSQWPPELQHLVDKAVSGLSLTLTLLRALGAQKEAIS 120
 QY 121 PPDAASAAPLRTITADTFKRLFRVYSNPLRGKLLKLTGECRTGD 165
 Db 121 PPDAASAAPLRTITADTFKRLFRVYSNPLRGKLLKLTGECRTGD 165

RESULT 8
 AAM53061
 ID AAM53061 standard; protein: 165 AA.
 XX
 AC AAM53061;
 XX
 DT 25-MAR-2002 (first entry)
 XX
 DE Human erythropoietin (hEPO), 165 residue form.
 KW Human; erythropoietin; EPO; hEPO; haemostatic; red blood cell;
 KW blood disorder; anaemia; chronic renal failure; CRF; AIDS;
 KW acquired immunodeficiency syndrome; cancer chemotherapy; haemostatic;
 KW anti-HIV; antianaemic.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT Disulfide-bond 7..161
 FT Modified-site /note= "N-glycosylated"
 FT Disulfide-bond 29..33
 FT Modified-site /note= "N-glycosylated"
 FT Modified-site 83
 FT Modified-site /note= "N-glycosylated"
 FT Modified-site 126
 FT Modified-site /note= "O-glycosylated"
 XX
 PN WO200187329-A1.
 XX
 PD 22-NOV-2001.
 XX
 PF 08-MAY-2001; 2001WO-EP05187.
 XX
 PR 15-MAY-2000; 2000EP-0110355.
 XX
 PA (HOFF) HOFFMANN LA ROCHE & CO AG F.
 XX
 PI Papadimitriou A;
 XX
 DR WPI; 2002-082943/11.
 XX
 PT Composition useful in the treatment of e.g. AIDS comprises an
 PT erythropoietin protein, and a multiple charged inorganic anion in a
 PT buffer
 XX
 PS Claim 28; Fig 1; 64pp; English.
 XX
 CC The invention relates to liquid pharmaceutical compositions comprising
 CC an erythropoietin (EPO) protein, a multiple negatively charged inorganic
 CC anion in a buffer which maintains the pH of the solution from 5.5-7.0,
 CC and optionally at least one excipient. The erythropoietin used in the
 CC composition is preferably human (AAM53061 or AAM53062) a human
 CC erythropoietin variant containing additional glycosylation sites
 CC (AAM53064-AAM53107), or an erythropoietin with the C-terminal addition
 CC of a C-terminal fragment of human chorionic gonadotropin (AAM53063).
 CC Erythropoietin is a glycoprotein essential for the formation of red blood
 CC cells and is therefore useful in the treatment of blood disorders
 CC characterised by low or defective red blood cell production. The
 CC compositions of the invention can be used in the treatment and prevention
 CC of anaemia in chronic renal failure patients (CRF), AIDS (acquired

CC immunodeficiency syndrome), and/or for the treatment of cancer patients
 CC undergoing chemotherapy. Unlike prior art erythropoietin compositions,
 CC the compositions of the invention do not contain human serum albumin
 CC (thereby avoiding the possibility of viral infections and allergic
 CC reactions associated with this component), are liquid rather than
 CC lyophilisates (and therefore do not need to be reconstituted before
 CC administration), and are stable at elevated temperatures such as 25
 CC degrees Celsius and even 40 degrees Celsius, and therefore can be stored
 CC without refrigeration for prolonged periods without degradation and loss
 CC of activity. The present sequence represents the 165 residue form
 CC of human erythropoietin which is specifically claimed for use in a
 CC composition of the invention.
 XX
 SQ Sequence 165 AA;
 Query Match 100.0%; Score 846; DB 23; Length 165;
 Best Local Similarity 100.0%; Pred No. 1..1e-86;
 Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APPRLICDSRVLYRLLEAKEAENITTCGAHCNLSNENITVPDTKVNFYAWKRMEVGOQA 60
 Db 1 APPRLICDSRVLYRLLEAKEAENITTCGAHCNLSNENITVPDTKVNFYAWKRMEVGOQA 60
 QY 61 VEVWQGLALLSEAVLRGQALLVNSQWPPELQHLVDKAVSGLSLTLTLLRALGAQKEAIS 120
 Db 61 VEVWQGLALLSEAVLRGQALLVNSQWPPELQHLVDKAVSGLSLTLTLLRALGAQKEAIS 120
 QY 121 PPDAASAAPLRTITADTFKRLFRVYSNPLRGKLLKLTGECRTGD 165
 Db 121 PPDAASAAPLRTITADTFKRLFRVYSNPLRGKLLKLTGECRTGD 165

RESULT 9
 AAP70398
 ID AAP70398 standard; protein: 166 AA.
 XX
 AC AAP70398;
 XX
 DT 19-FEB-1991 (first entry)
 XX
 DE Sequence of human erythropoietin (EPO).
 XX
 KW Mega-karyocyte-platelet growth factor; hormone;
 KW mega-karyocyte colony stimulating factor; therapy;
 KW small acetyl cholinesterase positive cell;
 KW erythrocyte growth effect.
 XX
 OS Homo sapiens.
 XX
 PN JP62149624-A.
 XX
 PD 03-JUL-1987.
 XX
 PF 15-AUG-1986; 86JP-0191542.
 XX
 PR 13-SEP-1985; 85JP-0203049.
 PR 15-AUG-1986; 86JP-0191542.
 XX
 PA (KAWA/) KAWAKITA M.
 XX
 DR WPI; 1987-224837/32.
 XX
 PT Megakaryocyte-platelet growth factor - contains as active
 PT component human erythropoietin and is used to treat diseases
 PT caused by decrease in platelets
 XX
 PS Disclosure; Page 181; 8pp; Japanese.
 XX
 CC All of the Cys residues in the SQ are labelled "SH". Megakaryocyte-
 CC platelet growth factor contains human EPO as an active principle.
 CC Human EPO has a megakaryocyte colony-stimulating activity and
 CC increases the ratio of small acetyl cholinesterase positive cell
 CC (SACHB+) which is immature megakaryocyte. Human EPO effects

CC megakaryocyte-platelet system other than an erythrocyte growth
 CC effect. Megakaryocyte-platelet growth is usable as a remedy for
 CC diseases caused by a platelet decrease.

XX
 SQ Sequence 166 AA;
 Query Match 100.0%; Score 846; DB 8; Length 166;
 Best Local Similarity 100.0%; Pred. No. 1.le-86;
 Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 APPRLICDSRVLELYLLEAKEAENITTCGAHCNSLNENITVPDTKVNFAWKRMVEVGQA 60
 Db 1 APPRLICDSRVLELYLLEAKEAENITTCGAHCNSLNENITVPDTKVNFAWKRMVEVGQA 60
 Qy 61 VEVWQGLALLSEAVLRGQALLVNSQWPPEQLQHVDAKAVSGLRSLTLLRALGAQKEAIS 120
 Db 61 VEVWQGLALLSEAVLRGQALLVNSQWPPEQLQHVDAKAVSGLRSLTLLRALGAQKEAIS 120
 Qy 121 PPDASAAPLRTITADTFKRLFRVYSNPLRGKLYTGEACRTGD 165
 Db 121 PPDASAAPLRTITADTFKRLFRVYSNPLRGKLYTGEACRTGD 165

RESULT 10
 AAR23593
 ID AAR23593 standard; Protein; 166 AA.

XX AAR23593;
 AC
 DT 20-OCT-1992 (first entry)
 XX
 DE Recombinant hematopoietic molecule portion 2.

XX Erythropoietin; EPO; erythrocytes; IL-3; haematopoiesis.

XX Homo sapiens.

XX WO9206116-A.

XX 16-APR-1992.

XX 26-SEP-1991; 91WO-US07053.

XX 28-SEP-1990; 90US-0589958.

XX (ORTH) ORTHO PHARM CORP.

XX Rosen JI;

XX WPI; 1992-150819/18.

XX Recombinant hematopoietic molecules useful in treating
 PT anaemia(s) - comprise IL-3 or GM-CSF, EPO, G-CSF, IL-5 or M-CSF
 PT and has early and later myeloid differentiation activity

XX Disclosure; Page 32; 82pp; English.

XX This protein sequence given comprises the entire amino acid sequence
 CC of human erythropoietin (EPO). EPO leads to the maturation of
 CC erythrocytes and is therefore designated as a late myeloid
 CC differentiation factor (MDF). Within the scope of the invention
 CC hybrid molecules were produced which contain at least a portion of an
 CC early MDF and at least a portion of a late MDF covalently linked. The
 CC EPO sequence given is effective within the scope of the invention in
 CC full or in a truncated version. Amino acids 7-161 act as a
 CC late MDF when recombined with an early MDF eg. IL-3.
 CC These compounds can be used to promote hematopoiesis in a patient.
 CC The bonding of the early and late factors allows a very high conc. of
 CC late MDF at the surface of a cell which the early MDF is bound. It
 CC also allows the early MDA to act more specifically to stimulate only
 CC the desired lineage, thus reducing undesirable effects. These
 CC compounds are useful for treating anaemias of various origins eg. renal
 CC failure and AIDS. It is easier to produce and administer one

CC recombinant molecule rather than two separate molecules.

XX
 SQ Sequence 166 AA;

Query Match 100.0%; Score 846; DB 13; Length 166;
 Best Local Similarity 100.0%; Pred. No. 1.le-86;
 Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 APPRLICDSRVLELYLLEAKEAENITTCGAHCNSLNENITVPDTKVNFAWKRMVEVGQA 60
 Db 1 APPRLICDSRVLELYLLEAKEAENITTCGAHCNSLNENITVPDTKVNFAWKRMVEVGQA 60
 Qy 61 VEVWQGLALLSEAVLRGQALLVNSQWPPEQLQHVDAKAVSGLRSLTLLRALGAQKEAIS 120
 Db 61 VEVWQGLALLSEAVLRGQALLVNSQWPPEQLQHVDAKAVSGLRSLTLLRALGAQKEAIS 120
 Qy 121 PPDASAAPLRTITADTFKRLFRVYSNPLRGKLYTGEACRTGD 165
 Db 121 PPDASAAPLRTITADTFKRLFRVYSNPLRGKLYTGEACRTGD 165

RESULT 11
 AAW77780
 ID AAW77780 standard; Protein; 166 AA.

XX AAW77780;
 AC
 DT 24-NOV-1998 (first entry)
 XX
 DE Human EPO receptor agonist polypeptide.

XX Haematopoietic receptor agonist; erythropoietin receptor agonist;
 KW EPO; human; chimeric protein; stem cell expansion; tumour;
 KW infection; autoimmune disease; haematopoietic disorder; therapy;
 KW dendritic cell.

XX Homo sapiens.

XX Key Location/Qualifiers

FT Misc-difference 1..6
 FT Misc-difference 1..6
 FT Misc-difference 1..6

FT Misc-difference 162..166
 FT Misc-difference 162..166
 FT Misc-difference 162..166

FT Misc-difference 23..24
 FT Misc-difference 23..24
 FT Misc-difference 23..24

FT Misc-difference 24..25
 FT Misc-difference 24..25
 FT Misc-difference 24..25

FT Misc-difference 25..26
 FT Misc-difference 25..26
 FT Misc-difference 25..26

FT Misc-difference 26..27
 FT Misc-difference 26..27
 FT Misc-difference 26..27

FT Misc-difference 27..28
 FT Misc-difference 27..28
 FT Misc-difference 27..28

FT Misc-difference 28..29
 FT Misc-difference 28..29
 FT Misc-difference 28..29

FT Misc-difference 29..30
 FT Misc-difference 29..30
 FT Misc-difference 29..30

FT Misc-difference 30..31
 FT Misc-difference 30..31
 FT Misc-difference 30..31

FT Misc-difference 31..32
 FT Misc-difference 31..32
 FT Misc-difference 31..32

FT Misc-difference 32..33
 FT Misc-difference 32..33
 FT Misc-difference 32..33

FT Misc-difference 33..34
 FT Misc-difference 33..34
 FT Misc-difference 33..34

FT Misc-difference 34..35
 FT Misc-difference 34..35
 FT Misc-difference 34..35

FT Misc-difference 35..36
 FT Misc-difference 35..36
 FT Misc-difference 35..36

FT Misc-difference 36..37
 FT Misc-difference 36..37
 FT Misc-difference 36..37

FT Misc-difference 37..38 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 38..39 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 39..40 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 40..41 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 41..42 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 42..43 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 43..44 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 44..45 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 45..46 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 46..47 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 47..48 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 48..49 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 49..50 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 50..51 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 51..52 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 52..53 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 53..54 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 54..55 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 55..56 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 56..57 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 57..58 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 77..78 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 78..79 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 79..80 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 81..82 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 82..83 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 84..85 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 85..86 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 86..87 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 87..88 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 88..89 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 108..109 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 109..110 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 110..111 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 111..112 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 112..113 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 113..114 /note= "possible positions of new C- and N-termini"
FT FT

FT Misc-difference 114..115 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 115..116 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 116..117 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 117..118 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 118..119 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 119..120 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 120..121 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 121..122 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 122..123 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 123..124 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 124..125 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 125..126 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 126..127 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 127..128 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 128..129 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 129..130 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 130..131 /note= "possible positions of new C- and N-termini"
FT FT
FT Misc-difference 131..132 /note= "possible positions of new C- and N-termini"
FT FT
XX W09817810-A2.
PN
XX 30-APR-1998.
PD
XX 23-OCT-1997; 97WO-US20037.
PF
XX 25-OCT-1996; 96US-0029629.
PR
XX (SEAR) SEARLE & CO G D.
PA
XX Feng Y, McKearn JP, McWherter CA, Minnerly JC, Minster NI;
PI Staten NR, Streeter PR, Summers NL, Woulfe SL;
XX WPI; 1998-261504/23.
DR
XX Multi-functional chimeric haematopoietic receptor agonist - useful
PT to treat haematopoietic disorders, tumours, infections or autoimmune
PT diseases
XX
PS Claim 1; Page 762; 84pp; English.
XX
CC A human erythropoietin (EPO) receptor agonist polypeptide comprises
CC a modified EPO amino acid sequence of the formula provided in
CC AAW77780, in which the N-terminus is joined to the C-terminus directly
CC or via a linker, the polypeptide having new C- and N-termini at one
CC of the positions indicated. Novel claimed multi-functional chimeric
CC haematopoietic receptor agonists (see AAW77812-22) have the formula
CC R1-L1-R2, R2-L1-R1, R1-R2 or R2-R1, where L is a linker and R1 and
CC R2 are independently selected from: (a) the human EPO receptor
CC agonist; (b) a human stem cell factor receptor agonist polypeptide
CC (see AAW77781); (c) a human flt-3 receptor agonist polypeptide (see
CC AAW77782); (d) a modified human granulocyte colony stimulating factor
CC (G-CSF) polypeptide (see AAW77783); (e) modified human interleukin-3
CC polypeptide (see AAW77784); (f) modified human c-mpl ligand polypeptide
CC (see AAW77785); and (g) a factor selected from the group consisting of

CC a CSF, a cytokine, a lymphokine, an interleukin and a haematopoietic
 CC growth factor, provided that at least R1 or R2 is selected from (a),
 CC (b) or (c) as above. The multi-functional chimeric haematopoietic
 CC receptor agonist can be used to stimulate the production of

Query Match 100.0%; Score 846; DB 19; Length 166;
 Best Local Similarity 100.0%; Pred. No. 1.1e-86;
 Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APPRLICDSRVLYRLLEAKEAENITTCGAHCSLNENITVPDTKYNFYAKRMEVGQQA 60
 DB 1 APPRLICDSRVLYRLLEAKEAENITTCGAHCSLNENITVPDTKYNFYAKRMEVGQQA 60
 QY 61 VEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKEATS 120
 DB 61 VEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKEATS 120
 QY 121 PPDAAASAPLRTITADTFKRLFRVYSNFLRGKLYTGEACRTGD 165
 DB 121 PPDAAASAPLRTITADTFKRLFRVYSNFLRGKLYTGEACRTGD 165

RESULT 12
 AAW58404
 ID AAW58404 standard; Protein: 166 AA.
 XX AAW58404;
 XX 12-OCT-1998 (first entry)
 DT Human erythropoietin.
 DE
 XX Erythropoietin receptor agonist; EPO; human; anaemia;
 KW haematopoietic deficiency; red blood cell; erythroid progenitor;
 KW bone marrow suppression.
 XX Homo sapiens.
 OS
 XX WO9818926-A1.
 PN 07-MAY-1998.
 PD
 XX 23-OCT-1997; 97WO-US18703.
 PF
 XX 25-OCT-1996; 96US-0034044.
 PR
 XX (SEAR) SEARLE & CO G D.
 PA
 XX Feng Y, McWherter CA, Summers N;
 PI
 XX WPI: 1998-272221/24.
 DR N-PSDB; AAV31031.
 DR
 XX Human erythropoietin receptor agonist polypeptide - used to
 PT stimulate the production of red blood cells in a patient
 PT
 XX Claim 1; Page 93; 112pp; English.

A claimed human erythropoietin (EPO) receptor agonist polypeptide
 CC comprises a modified EPO amino acid sequence given in AAW58404,
 CC where (a) optionally 1-6 amino acids from the N-terminus and 1-5
 CC from the C-terminus can be deleted, (b) the N-terminus is joined to
 CC the C-terminus directly or through a linker (see AAW58405-12) capable
 CC of joining the N-terminus to the C-terminus, (c) there are new C-
 CC and N-termini at any two consecutive amino acids from amino acids
 CC 23-24 to 38-39, 40-41 to 41-42, 43-44 to 48-49, 50-51 to 57-58,
 CC 77-78 to 82-83, 84-85 to 88-89, and 108-109 to 131-132, and (d)
 CC optionally the agonist polypeptide is preceded by Met, Ala, or
 CC Met-Ala. 60 Of these circularly permuted EPO receptor agonists
 CC (see AAW58413-72) are claimed. Also claimed are: nucleic acid
 CC molecules (see AAV30971-V31030) encoding novel EPO receptor agonists;
 CC a method of producing an EPO receptor agonist using transformed or
 CC transfected host cells; and methods for stimulating the production

CC of haematopoietic cells, for selective ex vivo expansion of
 CC erythroid progenitors, and treating patients having a haematopoietic
 CC disorder using the EPO receptor agonists. The EPO receptor
 CC agonists retain one or more activities of native EPO and may also
 CC show improved haematopoietic cell-stimulating activity and/or an
 CC improved activity profile which may include reduction of undesirable
 CC biological activities associated with native EPO and/or have
 CC improved physical properties such as increased solubility,
 CC stability and refold efficiency.

SQ Sequence 166 AA;

Query Match 100.0%; Score 846; DB 19; Length 166;
 Best Local Similarity 100.0%; Pred. No. 1.1e-86;
 Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APPRLICDSRVLYRLLEAKEAENITTCGAHCSLNENITVPDTKYNFYAKRMEVGQQA 60

DB 1 APPRLICDSRVLYRLLEAKEAENITTCGAHCSLNENITVPDTKYNFYAKRMEVGQQA 60

QY 61 VEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKEATS 120

DB 61 VEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKEATS 120

QY 121 PPDAAASAPLRTITADTFKRLFRVYSNFLRGKLYTGEACRTGD 165

DB 121 PPDAAASAPLRTITADTFKRLFRVYSNFLRGKLYTGEACRTGD 165

RESULT 13

ABB07030

ID ABB07030 standard; Protein: 166 AA.

AC ABB07030;

DT 21-JUN-2002 (first entry)

DE Modified erythropoietin related gene protein sequence.

DE Modified erythropoietin; EPO.

OS Unidentified.

OS KR145802-B1.

PN 01-AUG-1998.

PD 31-MAY-1994; 94KR-0012082.

PF 31-MAY-1994; 94KR-0012082.

PR (GLDS) LG CHEM CO LTD.

PS Kim C, Song Y, Lee T;

PI WPI: 2000-234250/20.

DR N-PSDB; ABL50878.

DR MODIFIED ERYTHROPOIETIN GENE AND EXPRESSION VECTORS THEREOF -

XX Disclosure; Page 14; 15pp; Korean.

XX The present invention describes modified erythropoietin (EPO) genes

CC and expression vectors comprising the genes. The present sequence

CC represents a protein sequence from the present invention.

XX SQ Sequence 166 AA;

Query Match 100.0%; Score 846; DB 21; Length 166;

Best Local Similarity 100.0%; Pred. No. 1.1e-86;

Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APPRLICDSRVLYRLLEAKEAENITTCGAHCSLNENITVPDTKYNFYAKRMEVGQQA 60

Db 1 APRRLICDSRVLYLLEAKEAENITTCGAHCNENITVPDTKYNFYAKRMEVQQA 60
 QY 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQHLHVDKAVSGLSLTLTLRALGAQKEAIS 120
 Db 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQHLHVDKAVSGLSLTLTLRALGAQKEAIS 120
 QY 121 PPDAASAAPLRTITADTFRKLFVYSNFRGKLVKLYTGEACRTGD 165
 Db 121 PPDAASAAPLRTITADTFRKLFVYSNFRGKLVKLYTGEACRTGD 165

RESULT 14

AAE02641
 ID AAE02641 standard; Protein; 166 AA.

XX AC AAE02641;

XX DT 06-AUG-2001 (first entry)

XX DE Human erythropoietin (EPO) mature protein.

XX KW Human; erythropoietin; EPO; antianaemic; nephrotrophic; anti-HIV;
 KW vaccine; haemostatic; immunoglobulin; Ig; EPO deficient disease;
 KW anaemia; renal failure; Human Immunodeficiency Virus; HIV;
 KW haematopoietic growth factor.

XX OS Homo sapiens.

XX PN WO200136489-A2.

XX PD 25-MAY-2001.

XX PF 03-NOV-2000; 2000WO-EP10843.

XX PR 12-NOV-1999; 99US-0164855.

XX PA (MERE) MERCK PATENT GMBH.

XX PI Hartmann A, Brandt S, Rieke E, Sobel C, Lo K, Way JC, Gillies S;

XX DR WPI; 2001-367563/38.

XX DR N-PSDB; AAD06893.

XX PT Novel modified erythropoietin forms such as fusion proteins, comprising
 PT Fc portion of an immunoglobulin molecule and a target molecule having
 PT the biological activity of erythropoietin forms

XX PS Example 1; Page 22; 58pp; English.

XX CC The present sequence is human erythropoietin (EPO) mature protein. EPO
 CC has improved biological activity and an extended serum half life greater
 CC than 20 hours. The present invention relates to modified EPO forms such
 CC as fusion proteins comprising a Fc portion of an immunoglobulin (Ig)
 CC molecule and an EPO molecule (Fc-EPO). The Fc portion is fused covalently
 CC through its C-terminus directly or indirectly to the EPO molecule, and
 CC where the Fc portion as well as EPO portion may be modified or mutated.
 CC The invention also relates to non-fused EPO molecules which have a
 CC pattern of cysteines or disulphide bonding which is distinct from human
 CC or animal EPO. Pharmaceutical compositions containing EPO are useful in
 CC the treatment of EPO deficient diseases such as anaemia, renal failure,
 CC HIV infection, blood loss and chronic disease that can be treated with
 CC haematopoietic growth factor.

XX SQ Sequence 166 AA;

Query Match 100.0%; Score 846; DB 22; Length 166;

Best Local Similarity 100.0%; Pred. No. 1.1e-86;

Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APRRLICDSRVLYLLEAKEAENITTCGAHCNENITVPDTKYNFYAKRMEVQQA 60

Db 1 APRRLICDSRVLYLLEAKEAENITTCGAHCNENITVPDTKYNFYAKRMEVQQA 60

QY 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQHLHVDKAVSGLSLTLTLRALGAQKEAIS 120
 Db 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQHLHVDKAVSGLSLTLTLRALGAQKEAIS 120
 QY 121 PPDAASAAPLRTITADTFRKLFVYSNFRGKLVKLYTGEACRTGD 165
 Db 121 PPDAASAAPLRTITADTFRKLFVYSNFRGKLVKLYTGEACRTGD 165

RESULT 15

AAE02641

ID AAE02641 standard; Protein; 166 AA.

XX AC AAE02641;

XX DT 06-APR-2001 (first entry)

XX DE Human erythropoietin protein #2.

XX KW Erythropoietin; EPO; reticulocytes; red blood cell;
 KW ethylene glycol; chronic renal failure; AIDS; cancer.

XX OS Homo sapiens.

XX PN WO200102017-A2.

XX PD 11-JAN-2001.

XX PF 28-JUN-2000; 2000WO-EP06009.

XX PR 02-JUL-1999; 99US-0142243.

XX PR 05-AUG-1999; 99US-0147452.

XX PR 30-AUG-1999; 99US-0151454.

XX PA (HOFF) HOFEMANN LA ROCHE & CO AG F.

XX PI Burg J, Hilger B, Josel H;

XX DR WPI; 2001-147051/15.

XX PT Novel erythropoietin-glycoprotein conjugate useful for treating
 PT diseases correlated with anemia in chronic renal failure patients, AIDS
 PT and for treating cancer, is linked to polyethylene glycol through
 PT linker

XX PS Claim 19; Fig 2; 40pp; English.

XX CC The present invention relates to a conjugate comprising, human
 CC erythropoietin glycoprotein (EPO) having at least one free
 CC amino group and having in vivo biological activity of causing
 CC an increase the production of reticulocytes and red blood cells,
 CC covalently linked to 1-3 lower-alkoxy poly(ethylene glycol) groups
 CC through a linker. The invention is useful for preparation of
 CC medicaments for the treatment of prophylaxis of disease correlated
 CC with anemia in chronic renal failure patients (CRF), AIDS and for
 CC the treatment of cancer patients undergoing chemotherapy.

XX SQ Sequence 166 AA;

Query Match 100.0%; Score 846; DB 22; Length 166;

Best Local Similarity 100.0%; Pred. No. 1.1e-86;

Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APRRLICDSRVLYLLEAKEAENITTCGAHCNENITVPDTKYNFYAKRMEVQQA 60

Db 1 APRRLICDSRVLYLLEAKEAENITTCGAHCNENITVPDTKYNFYAKRMEVQQA 60

QY 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQHLHVDKAVSGLSLTLTLRALGAQKEAIS 120

Db 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQHLHVDKAVSGLSLTLTLRALGAQKEAIS 120

QY 121 PPDAASAAPLRTITADTFRKLFVYSNFRGKLVKLYTGEACRTGD 165

Db 121 PPDAASAPLRTITADTFERKLFVYSNFLRGKLYTGEACRTGD 165

Search completed: June 13, 2003, 15:03:44
Job time : 40 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run On: June 13, 2003, 15:03:00 ; Search time 22 Seconds
(without alignments)
220.672 Million cell updates/sec

Title: US-09-830-964-1

Perfect score: 846

Sequence: 1 APRRLCDRSRLVLEAKEAENITTCGAEHCNSLNENITVPTKVNFWANKRMEVGQQA 165

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 262574 seqs, 29422922 residues

Total number of hits satisfying chosen parameters: 262574

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

- Issued_Patents_AA:*
1: /cgn2_6/ptodata/1/iaa/5A_COMB.pep.*
2: /cgn2_6/ptodata/1/iaa/5B_COMB.pep.*
3: /cgn2_6/ptodata/1/iaa/6A_COMB.pep.*
4: /cgn2_6/ptodata/1/iaa/6B_COMB.pep.*
5: /cgn2_6/ptodata/1/iaa/PCTUS_COMB.pep.*
6: /cgn2_6/ptodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | DB ID | Description |
|------------|-------|-------------|--------|-------|-------------------|
| 1 | 846 | 100.0 | 165 | 4 | US-09-604-871-1 |
| 2 | 846 | 100.0 | 166 | 1 | US-08-318-193-70 |
| 3 | 846 | 100.0 | 166 | 4 | US-09-604-871-2 |
| 4 | 846 | 100.0 | 166 | 5 | PCT-US94-04361-37 |
| 5 | 846 | 100.0 | 193 | 1 | US-07-903-220-1 |
| 6 | 846 | 100.0 | 193 | 2 | US-08-883-795A-34 |
| 7 | 843 | 99.6 | 412 | 4 | US-09-366-009-34 |
| 8 | 830 | 98.1 | 166 | 5 | PCT-US94-04361-45 |
| 9 | 764.5 | 90.4 | 165 | 5 | PCT-US94-04361-38 |
| 10 | 759.5 | 89.8 | 165 | 5 | PCT-US94-04361-39 |
| 11 | 713 | 84.3 | 166 | 5 | PCT-US94-04361-41 |
| 12 | 701 | 82.9 | 166 | 5 | PCT-US94-04361-44 |
| 13 | 689 | 81.4 | 166 | 5 | PCT-US94-04361-40 |
| 14 | 678.5 | 80.2 | 167 | 5 | PCT-US94-04361-42 |
| 15 | 678 | 80.1 | 168 | 5 | PCT-US94-04361-43 |
| 16 | 193 | 22.8 | 36 | 5 | PCT-US94-04361-50 |
| 17 | 128 | 15.1 | 27 | 5 | PCT-US94-04361-51 |
| 18 | 114.5 | 13.5 | 34 | 5 | PCT-US94-04361-52 |
| 19 | 107 | 12.6 | 21 | 5 | PCT-US94-04361-49 |
| 20 | 103 | 12.2 | 20 | 2 | US-08-759-599-9 |
| 21 | 103 | 12.2 | 20 | 4 | US-09-294-457-9 |
| 22 | 101 | 11.9 | 20 | 5 | PCT-US94-04361-58 |
| 23 | 92 | 10.9 | 332 | 4 | US-08-875-533-66 |
| 24 | 91 | 10.8 | 17 | 1 | US-08-232-513A-11 |
| 25 | 91 | 10.8 | 17 | 4 | US-09-231-159-16 |
| 26 | 91 | 10.8 | 17 | 4 | US-08-611-307-16 |
| 27 | 91 | 10.8 | 312 | 4 | US-08-875-533-67 |

| | | | | | | |
|----|----|------|-----|---|-------------------|-------------------|
| 28 | 89 | 10.5 | 153 | 4 | US-08-875-533-65 | Sequence 65, Appl |
| 29 | 89 | 10.5 | 165 | 1 | US-08-413-803-29 | Sequence 29, Appl |
| 30 | 89 | 10.5 | 174 | 3 | US-08-471-045-56 | Sequence 56, Appl |
| 31 | 89 | 10.5 | 174 | 3 | US-08-469-712A-56 | Sequence 56, Appl |
| 32 | 89 | 10.5 | 174 | 4 | US-08-446-871-56 | Sequence 56, Appl |
| 33 | 89 | 10.5 | 174 | 4 | US-08-468-910-56 | Sequence 56, Appl |
| 34 | 89 | 10.5 | 174 | 4 | US-08-761-907-56 | Sequence 56, Appl |
| 35 | 89 | 10.5 | 174 | 5 | PCT-US95-03776-27 | Sequence 27, Appl |
| 36 | 89 | 10.5 | 195 | 1 | US-08-388-779A-4 | Sequence 4, Appl |
| 37 | 89 | 10.5 | 195 | 1 | US-08-591-070A-4 | Sequence 4, Appl |
| 38 | 89 | 10.5 | 195 | 2 | US-08-927-855-4 | Sequence 4, Appl |
| 39 | 89 | 10.5 | 285 | 4 | US-08-875-533-69 | Sequence 69, Appl |
| 40 | 89 | 10.5 | 285 | 4 | US-08-875-533-70 | Sequence 70, Appl |
| 41 | 89 | 10.5 | 288 | 4 | US-08-875-533-71 | Sequence 71, Appl |
| 42 | 89 | 10.5 | 288 | 4 | US-08-875-533-73 | Sequence 73, Appl |
| 43 | 89 | 10.5 | 332 | 4 | US-08-875-533-22 | Sequence 22, Appl |
| 44 | 89 | 10.5 | 332 | 5 | PCT-US95-03776-25 | Sequence 25, Appl |
| 45 | 89 | 10.5 | 353 | 1 | US-08-330-517-2 | Sequence 2, Appl |

ALIGNMENTS

RESULT 1

US-09-604-871-1
; Sequence 1, Application US/09604871
; Patent No. 6340742
; GENERAL INFORMATION:
; APPLICANT: Burg, Josef
; APPLICANT: Hilger, Bernd
; APPLICANT: Joesel, Hans-Peter
; TITLE OF INVENTION: ERYTHROPOIETIN CONJUGATES
; FILE REFERENCE: 1098 nonprovisional
; CURRENT APPLICATION NUMBER: US/09/604,871
; CURRENT FILING DATE: 2000-06-28
; PRIOR APPLICATION NUMBER: 60/151,454
; PRIOR FILING DATE: 1999-08-30
; PRIOR APPLICATION NUMBER: 60/147,452
; PRIOR FILING DATE: 1999-08-05
; PRIOR APPLICATION NUMBER: 60/142,243
; PRIOR FILING DATE: 1999-07-02
; NUMBER OF SEQ ID NOS: 3
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 165
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-604-871-1

Query Match 100.0%; Score 846; DB 4; Length 165;
Best Local Similarity 100.0%; Pred. No. 5.3e-100;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

| | | |
|----|-----|--|
| QY | 1 | APRRLCDRSRLVLEAKEAENITTCGAEHCNSLNENITVPTKVNFWANKRMEVGQQA 60 |
| DB | 1 | APRRLCDRSRLVLEAKEAENITTCGAEHCNSLNENITVPTKVNFWANKRMEVGQQA 60 |
| QY | 61 | VEWQGLALLSEAVLRGQALLVNSQWPEQLQHVDAKAVSGLRSLTTLRLALCAQKEAIS 120 |
| DB | 61 | VEWQGLALLSEAVLRGQALLVNSQWPEQLQHVDAKAVSGLRSLTTLRLALCAQKEAIS 120 |
| QY | 121 | PPDAASAAPLRTITADTFKRLFRVSNFLRGKLYTGACRTGD 165 |
| DB | 121 | PPDAASAAPLRTITADTFKRLFRVSNFLRGKLYTGACRTGD 165 |

RESULT 2

US-08-318-193-70
; Sequence 70, Application US/08318193
; Patent No. 5641663
; GENERAL INFORMATION:
; APPLICANT: GARVIN, Robert T.
; APPLICANT: MALEK, Lawrence T.

;; TITLE OF INVENTION: AN EXPRESSION SYSTEM FOR THE SECRETION
;; TITLE OF INVENTION: OF BIOACTIVE HUMAN GRANULOCYTE MACROPHAGE COLONY
;; TITLE OF INVENTION: STIMULATING FACTOR (GM-CSF) AND OTHER HETEROLOGOUS
;; TITLE OF INVENTION: PROTEINS FROM STREPTOMYCES
;; NUMBER OF SEQUENCES: 91
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Foley & Lardner
;; STREET: 1800 Diagonal Road, Suite 500
;; CITY: Alexandria
;; STATE: Virginia
;; COUNTRY: USA
;; ZIP: 22313-0299
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; OPERATING SYSTEM: IBM PC compatible
;; SOFTWARE: PC-DOS/MS-DOS
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/318,193
;; FILING DATE:
;; CLASSIFICATION: 435
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US/07/935,314
;; FILING DATE:
;; ATTORNEY/AGENT INFORMATION:
;; NAME: BENT, Stephen A.
;; REGISTRATION NUMBER: 29,768
;; REFERENCE/DOCKET NUMBER: 18740/116 CACO
;; TELEPHONE: (703)836-9300
;; TELEFAX: (703)683-4109
;; TELEX: 899149
;; INFORMATION FOR SEQ ID NO: 70:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 166 amino acids
;; TYPE: amino acid
;; TOPOLOGY: linear
;; MOLECULE TYPE: protein
US-08-318-193-70

Query Match 100.0%; Score 846; DB 1; Length 166;
Best Local Similarity 100.0%; Pred. No. 5.3e-100;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APRRLICDSRVLYLLEAEENITTCGAHCSSLNENITVPDTKYNFYANKRMVEVGQQA 60
|||||
Db 1 APRRLICDSRVLYLLEAEENITTCGAHCSSLNENITVPDTKYNFYANKRMVEVGQQA 60
|||||
QY 61 VEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLSLTLTLRALGAQKEAIS 120
|||||
Db 61 VEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLSLTLTLRALGAQKEAIS 120
|||||
QY 121 PPDAASAAPLRTITADTFKRLFRVYSNFLRGKCLKLYTGEACRTGD 165
|||||
Db 121 PPDAASAAPLRTITADTFKRLFRVYSNFLRGKCLKLYTGEACRTGD 165
|||||

RESULT 3
US-09-604-871-2
;; Sequence 2, Application US/09604871
;; Patent No. 6340742
;; GENERAL INFORMATION:
;; APPLICANT: Burg, Josef
;; APPLICANT: Hilger, Bernd
;; APPLICANT: Josel, Hans-Peter
;; FILE OF INVENTION: ERYTHROPOIETIN CONJUGATES
;; FILE REFERENCE: 1098 nonprovisional
;; CURRENT APPLICATION NUMBER: US/09/604,871
;; CURRENT FILING DATE: 2000-06-28
;; PRIOR APPLICATION NUMBER: 60/151,454
;; PRIOR FILING DATE: 1999-08-30
;; PRIOR APPLICATION NUMBER: 60/147,452

;; PRIOR FILING DATE: 1999-08-05
;; PRIOR APPLICATION NUMBER: 60/142,243
;; PRIOR FILING DATE: 1999-07-02
;; NUMBER OF SEQ ID NOS: 3
;; SOFTWARE: PatentIn Ver. 2.1
;; SEQ ID NO 2
;; LENGTH: 166
;; TYPE: PRT
;; ORGANISM: Homo sapiens
US-09-604-871-2

Query Match 100.0%; Score 846; DB 4; Length 166;
Best Local Similarity 100.0%; Pred. No. 5.3e-100;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APRRLICDSRVLYLLEAEENITTCGAHCSSLNENITVPDTKYNFYANKRMVEVGQQA 60
|||||
Db 1 APRRLICDSRVLYLLEAEENITTCGAHCSSLNENITVPDTKYNFYANKRMVEVGQQA 60
|||||
QY 61 VEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLSLTLTLRALGAQKEAIS 120
|||||
Db 61 VEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLSLTLTLRALGAQKEAIS 120
|||||
QY 121 PPDAASAAPLRTITADTFKRLFRVYSNFLRGKCLKLYTGEACRTGD 165
|||||
Db 121 PPDAASAAPLRTITADTFKRLFRVYSNFLRGKCLKLYTGEACRTGD 165
|||||

RESULT 4
PCT-US94-04361-37
;; Sequence 37, Application PC/TUS9404361
;; GENERAL INFORMATION:
;; APPLICANT: Brigham and Women's Hospital
;; APPLICANT: 75 Francis Street
;; APPLICANT: Boston, MA 02115
;; APPLICANT: Bunn, H. Franklin
;; APPLICANT: Wen, Danyl
;; APPLICANT: Showers, Mark O.
;; TITLE OF INVENTION: Erythropoietin Muteins With Enhanced
;; TITLE OF INVENTION: Activity
;; NUMBER OF SEQUENCES: 59
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Sterne, Kessler, Goldstein & Fox
;; STREET: 1100 New York Avenue, Suite 600
;; CITY: Washington
;; STATE: D.C.
;; COUNTRY: U.S.A.
;; ZIP: 20005-3934
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PatentIn Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: PCT/US94/04361
;; FILING DATE: Herewith
;; CLASSIFICATION:
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/049,802
;; FILING DATE: 21-APR-1993
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Cimbala, Michele A.
;; REGISTRATION NUMBER: 33,851
;; REFERENCE/DOCKET NUMBER: 0627.336PC01
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (202) 371-2600
;; TELEFAX: (202) 371-2540
;; INFORMATION FOR SEQ ID NO: 37:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 166 amino acids
;; TYPE: amino acid
;; TOPOLOGY: both
PCT-US94-04361-37

Query Match 100.0%; Score 846; DB 5; Length 166;
Best Local Similarity 100.0%; Pred. No. 5.3e-100; Indels 0; Gaps 0;
Matches 165; Conservative 0; Mismatches 0;

Qy 1 APPRLICDSRVLYRLLLEAKEAENITTCGAHCNENITVPDTKVNFAWKRMVEVQQA 60
Db 1 APPRLICDSRVLYRLLLEAKEAENITTCGAHCNENITVPDTKVNFAWKRMVEVQQA 60
Qy 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKEAIS 120
Db 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKEAIS 120
Qy 121 PPDAASAAPLRTITADTFRKLFVYSNLFGRGKLYTGACRTGD 165
Db 121 PPDAASAAPLRTITADTFRKLFVYSNLFGRGKLYTGACRTGD 165

RESULT 5
US-07-903-220-1
; Sequence 1, Application US/07903220
; Patent No. 532837
; GENERAL INFORMATION:
; APPLICANT: Hewick, Rodney M.
; TITLE OF INVENTION: METHOD FOR THE PURIFICATION OF
; TITLE OF INVENTION: ERYTHROPOIETIN AND ERYTHROPOIETIN COMPOSITION
; NUMBER OF SEQUENCES: 1
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Paul H. Heller
; STREET: Kenyon & Kenyon, One Broadway
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10004

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/903.220
; FILING DATE: 19920731
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Brown, Scott A.
; REGISTRATION NUMBER: 32,724
; REFERENCE/DOCKET NUMBER: 1248/27
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 429-1776
; TELEFAX: (202) 429-0796
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 193 amino acids
; TYPE: AMINO ACID
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; HYPOTHETICAL: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens

US-07-903-220-1
Query Match 100.0%; Score 846; DB 1; Length 193;
Best Local Similarity 100.0%; Pred. No. 6.8e-100;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 APPRLICDSRVLYRLLLEAKEAENITTCGAHCNENITVPDTKVNFAWKRMVEVQQA 60
Db 28 APPRLICDSRVLYRLLLEAKEAENITTCGAHCNENITVPDTKVNFAWKRMVEVQQA 87
Qy 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKEAIS 120
Db 88 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKEAIS 147

Qy 121 PPDAASAAPLRTITADTFRKLFVYSNLFGRGKLYTGACRTGD 165
Db 148 PPDAASAAPLRTITADTFRKLFVYSNLFGRGKLYTGACRTGD 192

RESULT 6
US-08-883-795A-34
; Sequence 34, Application US/08883795A
; Patent No. 5985607
; GENERAL INFORMATION:
; APPLICANT: Delcuve, Genevieve
; APPLICANT: Awang, Gregor
; TITLE OF INVENTION: Recombinant DNA Molecules and Expression
; TITLE OF INVENTION: Vectors for Tissue Plasminogen Activator
; NUMBER OF SEQUENCES: 39
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BERESKIN & PARR
; STREET: 40 King Street West
; CITY: Toronto
; STATE: Ontario
; COUNTRY: Canada
; ZIP: M5H 3Y2
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/883,795A
; FILING DATE: 27-JUN-1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Gravelle, Micheline
; REGISTRATION NUMBER: 40,261
; REFERENCE/DOCKET NUMBER: 7841-062
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (416) 364-7311
; TELEFAX: (416) 361-1398
; INFORMATION FOR SEQ ID NO: 34:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 193 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein

US-08-883-795A-34
Query Match 100.0%; Score 846; DB 2; Length 193;
Best Local Similarity 100.0%; Pred. No. 6.8e-100;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 APPRLICDSRVLYRLLLEAKEAENITTCGAHCNENITVPDTKVNFAWKRMVEVQQA 60
Db 28 APPRLICDSRVLYRLLLEAKEAENITTCGAHCNENITVPDTKVNFAWKRMVEVQQA 87
Qy 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKEAIS 120
Db 88 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKEAIS 147
Qy 121 PPDAASAAPLRTITADTFRKLFVYSNLFGRGKLYTGACRTGD 165
Db 148 PPDAASAAPLRTITADTFRKLFVYSNLFGRGKLYTGACRTGD 192

RESULT 7
US-09-366-009-34
; Sequence 34, Application US/09366009
; Patent No. 6426042
; GENERAL INFORMATION:
; APPLICANT: Asada, Kiyozo
; Umori, Takashi
; Ueno, Takashi
; Koyama, No. 6426042uto
; Hashino, Kimikazu

```

RESULT 9
PCT-US94-04361-38
: Sequence 38, Application PC/TUS9404361
: GENERAL INFORMATION:
: APPLICANT: Brigham and Women's Hospital
: APPLICANT: 75 Francis Street
: APPLICANT: Boston, MA 02115
: APPLICANT: Bunn, H. Franklin
: APPLICANT: Wen, Danyi
: APPLICANT: Showers, Mark O.
: TITLE OF INVENTION: Erythropoietin Muteins With Enhanced
: NUMBER OF SEQUENCES: 59
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Sterne, Kessler, Goldstein & Fox
: STREET: 1100 New York Avenue, Suite 600
: CITY: Washington
: STATE: D.C.
: COUNTRY: U.S.A.
: ZIP: 20005-3934
: COMPUTER READABLE FORM:
: MEDIA TYPE: Floppy disk

```

COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/04361
FILING DATE: Herewith

PRIOR APPLICATION DATA: .
 APPLICATION NUMBER: 08/049,802
 FILING DATE: 21-APR-1993
 ATTORNEY/AGENT INFORMATION:
 NAME: Cimbala, Michele A.
 REGISTRATION NUMBER: 33,851
 REFERENCE/DOCKET NUMBER: 0627.336PC01
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (202) 371-2600
 TELEFAX: (202) 371-2540
 INFORMATION FOR SEQ ID NO: 38:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 165 amino acids
 TYPE: amino acid
 TOPOLOGY: both

| | Very Match | 90.4% | Score 764.5 | DB 5 | Length 165 |
|-----|---|--------------|-------------|-------------------|------------|
| | at Local | Similarity | 91.5% | Pred. No. 1.4e-89 | |
| | atches 151 | Conservative | 7 | Mismatches 6 | Indels 1 |
| 1 | APPLICDSRVLEERYLLEAKEAENITTCGAEHCSLENENITVPDTKVNFYAWK | | | | |
| 1 | APPLICDSRVLEERYLLEAKEAENITVTMGSCSLENENITVPDTKVNFYAWK | | | | |
| 61 | VEVWQGLALLSEAVLRQALLVNSOPWPELQHLVDKAVSGLRSLTITLLRAL | | | | |
| 61 | VEVWQGLALLSEAVLRQAVLANSOPPELQIHWDKAISGLRSITITLLRAL | | | | |
| 121 | PPDAASAAPLRTITATDFKFLRVYSNLFRLGKLKLYTGACRTGD | | | | |
| 120 | LPDAASAAPLRTITATDFCKFLRVYSNLFRLGKIKLYTGACRRGD | | | | |

JT 10
 US94-04361-39
 Sequence 39, Application PC/TUS9404361
 GENERAL INFORMATION:
 APPLICANT: Brigham and Women's Hospital
 APPLICANT: 75 Francis Street
 APPLICANT: Boston, MA 02115
 APPLICANT: Bunn, H. Franklin
 APPLICANT: Wen, Danyi
 APPLICANT: Showers, Mark O.
 TITLE OF INVENTION: Erythropoietin Muteins With Enhanced
 TITLE OF INVENTION: Activity
 NUMBER OF SEQUENCES: 59
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Sterne, Kessler, Goldstein & Fox
 STREET: 1100 New York Avenue, Suite 600
 CITY: Washington
 STATE: D.C.
 COUNTRY: U.S.A.
 ZIP: 20005-3934
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent In Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: PCT/US94/04361
 FILING DATE: Herewith
 CLASSIFICATION:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/049,802
 FILING DATE: 21-APR-1993

ATTORNEY/AGENT INFORMATION:
NAME: Cimbala, Michele A.
REGISTRATION NUMBER: 33,851
REFERENCE/DOCKET NUMBER: 0627.336PC01
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 371-2600
TELEFAX: (202) 371-2540
INFORMATION FOR SEQ ID NO: 39:
SEQUENCE CHARACTERISTICS:
LENGTH: 165 amino acids
TYPE: amino acid
TOPOLOGY: both
DCCT-INS94-04361-39

| | Query Match | 89.9% | Score 759.5; | DB 5; | Length 165; |
|----|---|--------|--------------------|-----------|-------------|
| | Best Local Similarity | 90.3%; | Pred. No. 5.9e-89; | | |
| | Matches 149; Conservative | 9; | Mismatches 6; | Indels 1; | Gaps 1; |
| Qy | 1 APPRLCDSRVLLERYLLEAKAEENITGTCAEHCSSLNENITVPTDKVNFYAWKRMVEGQQA | 60 | | | |
| | : : : : : : : : : : : : | | | | |
| Db | 1 APPRLCDSRVLLERYLLEAKAENVTMGCSECSLNENIIVPTDKVNFYAWKRIVEGQQA | 60 | | | |
| | : : : : : : : : : : : | | | | |
| Qy | 61 VEVWQGLALLSEAVLRQALLVNSSOPFPEQLQHVDKAVSGLSRLTTLRALGAQKEAIS | 120 | | | |
| | : : : : : : : : : : : | | | | |
| Db | 61 VEVWQGLALLSEAVLRQAVLVANSSOPFPEQLHMDKAISGLRSITTLRALGAQ-EAIS | 119 | | | |
| | : : : : : : : : : : : | | | | |
| Qy | 121 PPDAAASAPLRTTTADTFRKLFRVYSNFLRGKLUKYTGECARTGD | 165 | | | |
| | : : : : : : : : : : : | | | | |
| b | 120 LPDAAASAPLRTTTADTFCKLFVYSNFLRGKLUKYTGECARRGD | 164 | | | |
| | : : : : : : : : : : : | | | | |

RESULT 11
PCT-US94-04361-44
; Sequence 44, Application PC/TUS9404361
; GENERAL INFORMATION:
; APPLICANT: Brigham and Women's Hospital
; APPLICANT: 75 Francis Street
; APPLICANT: Boston, MA 02115
; APPLICANT: Bunn, H. Franklin
; APPLICANT: Wen, Danyl
; APPLICANT: Showers, Mark O.
; TITLE OF INVENTION: Erythropoietin Muteins With Enhanced
; TITLE OF INVENTION: Activity
; NUMBER OF SEQUENCES: 59
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sterne, Kessler, Goldstein & Fox
; STREET: 1100 New York Avenue, Suite 600
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20005-3934
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC Compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/04361
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/049,802
; FILING DATE: 21-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Cimbala, Michele A.
; REGISTRATION NUMBER: 33,851
; REFERENCE/DOCKET NUMBER: 0627.336PC01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 371-2600
; TELEFAX: (202) 371-2540
; INFORMATION FOR SEQ ID NO: 44:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 166 amino acids

```
; TYPE: amino acid
; TOPOLOGY: both
PCT-US94-04361-44

Query Match      84.3%; Score 713; DB 5; Length 166;
Best Local Similarity 84.2%; Pred. No. 5.2e-83;
Matches 139; Conservative 9; Mismatches 17; Indels 0; Gaps 0;

Qy 1 APPRLICDSRVLYRLLEAKAEENITTCGAHCISLNEITVPDVKVNFYAWKRMVEGQQA 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 APPRLICDSRVLYRLLEAKAEENITTCGAHCISLNEITVPDVKVNFYAWKRMVEGQQA 60

Qy 61 VEVWGLALLSEAVLRGOALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 VEVWGLALLSEAVLRGOALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120

Qy 121 PPDAASAAPLRTITADTFKFLFRVYSNFLRGKLYTGACRTGD 165
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 121 PPDAASAAPLRTITADTFKFLFRVYSNFLRGKLYTGACRTGD 165

Qy 121 PPDAASAAPLRTITADTFKFLFRVYSNFLRGKLYTGACRTGD 165
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 121 PPDAASAAPLRTITADTFKFLFRVYSNFLRGKLYTGACRTGD 165

RESULT 13
PCT-US94-04361-40
; Sequence 40, Application PC/TUS9404361
; GENERAL INFORMATION:
; APPLICANT: Brigham and Women's Hospital
; APPLICANT: 75 Francis Street
; APPLICANT: Boston, MA 02115
; APPLICANT: Bunn, H. Franklin
; APPLICANT: Wen, Danyi
; APPLICANT: Showers, Mark O.
; TITLE OF INVENTION: Erythropoietin Muteins With Enhanced
; TITLE OF INVENTION: Activity
; NUMBER OF SEQUENCES: 59
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sterne, Kessler, Goldstein & Fox
; STREET: 1100 New York Avenue, Suite 600
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20005-3934
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/04361
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/049,802
; FILING DATE: 21-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Cimbala, Michele A.
; REGISTRATION NUMBER: 33,851
; REFERENCE/DOCKET NUMBER: 0627.336PC01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 371-2600
; TELEFAX: (202) 371-2540
; INFORMATION FOR SEQ ID NO: 40:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 166 amino acids
; TYPE: amino acid
; TOPOLOGY: both
PCT-US94-04361-40

Query Match      81.4%; Score 689; DB 5; Length 166;
Best Local Similarity 80.0%; Pred. No. 6.1e-80;
Matches 132; Conservative 14; Mismatches 19; Indels 0; Gaps 0;

Qy 1 APPRLICDSRVLYRLLEAKAEENITTCGAHCISLNEITVPDVKVNFYAWKRMVEGQQA 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 APPRLICDSRVLYRLLEAKAEENITTCGAHCISLNEITVPDVKVNFYAWKRMVEGQQA 60

Qy 61 VEVWGLALLSEAVLRGOALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 VEVWGLALLSEAVLRGOALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120

Qy 121 PPDAASAAPLRTITADTFKFLFRVYSNFLRGKLYTGACRTGD 165
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 121 PPDAASAAPLRTITADTFKFLFRVYSNFLRGKLYTGACRTGD 165

; TYPE: amino acid
; TOPOLOGY: both
PCT-US94-04361-41

Query Match      84.3%; Score 713; DB 5; Length 166;
Best Local Similarity 84.2%; Pred. No. 5.2e-83;
Matches 139; Conservative 9; Mismatches 17; Indels 0; Gaps 0;

Qy 1 APPRLICDSRVLYRLLEAKAEENITTCGAHCISLNEITVPDVKVNFYAWKRMVEGQQA 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 APPRLICDSRVLYRLLEAKAEENITTCGAHCISLNEITVPDVKVNFYAWKRMVEGQQA 60

Qy 61 VEVWGLALLSEAVLRGOALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 61 VEVWGLALLSEAVLRGOALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120

Qy 121 PPDAASAAPLRTITADTFKFLFRVYSNFLRGKLYTGACRTGD 165
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 121 PPDAASAAPLRTITADTFKFLFRVYSNFLRGKLYTGACRTGD 165

RESULT 12
PCT-US94-04361-41
; Sequence 41, Application PC/TUS9404361
; GENERAL INFORMATION:
; APPLICANT: Brigham and Women's Hospital
; APPLICANT: 75 Francis Street
; APPLICANT: Boston, MA 02115
; APPLICANT: Bunn, H. Franklin
; APPLICANT: Wen, Danyi
; APPLICANT: Showers, Mark O.
; TITLE OF INVENTION: Erythropoietin Muteins With Enhanced
; TITLE OF INVENTION: Activity
; NUMBER OF SEQUENCES: 59
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sterne, Kessler, Goldstein & Fox
; STREET: 1100 New York Avenue, Suite 600
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20005-3934
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/04361
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/049,802
; FILING DATE: 21-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Cimbala, Michele A.
; REGISTRATION NUMBER: 33,851
; REFERENCE/DOCKET NUMBER: 0627.336PC01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 371-2600
; TELEFAX: (202) 371-2540
; INFORMATION FOR SEQ ID NO: 41:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 166 amino acids
; TYPE: amino acid
; TOPOLOGY: both
PCT-US94-04361-41

Query Match      82.9%; Score 701; DB 5; Length 166;
Best Local Similarity 82.4%; Pred. No. 1.8e-81;
Matches 136; Conservative 13; Mismatches 16; Indels 0; Gaps 0;

Qy 1 APPRLICDSRVLYRLLEAKAEENITTCGAHCISLNEITVPDVKVNFYAWKRMVEGQQA 60
    |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
Db 1 APPRLICDSRVLYRLLEAKAEENITTCGAHCISLNEITVPDVKVNFYAWKRMVEGQQA 60
```


RESULT 14

PCT-US94-04361-42
; Sequence 42, Application PC/TUS9404361
; GENERAL INFORMATION:
; APPLICANT: Brigham and Women's Hospital
; APPLICANT: 75 Francis Street
; APPLICANT: Boston, MA 02115
; APPLICANT: Bunn, H. Franklin
; APPLICANT: Wen, Danyl
; APPLICANT: Showers, Mark O.
; TITLE OF INVENTION: Erythropoietin Muteins With Enhanced
; NUMBER OF SEQUENCES: 59
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sterne, Kessler, Goldstein & Fox
; STREET: 1100 New York Avenue, Suite 600
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20005-3934
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/04361
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/049,802
; FILING DATE: 21-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Cimbala, Michele A.
; REGISTRATION NUMBER: 33,851
; REFERENCE/DOCKET NUMBER: 0627.336PC01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 371-2600
; TELEFAX: (202) 371-2540
; INFORMATION FOR SEQ ID NO: 42:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 167 amino acids
; TYPE: amino acid
; TOPOLOGY: both
PCT-US94-04361-42

Query Match 80.2%; Score 678.5; DB 5; Length 167;
Best Local Similarity 81.3%; Pred. No. 1.3e-78;
Matches 135; Conservative 9; Mismatches 21; Indels 1; Gaps 1;
Qy 1 APPRLICDSRVLYRLLEAKAEENITTCAGHCNENITVPDTKYNFYANKRMEVQQA 60
Db 1 APPRLICDSRVLYRLLEAKAEENITTCAGHCNENITVPDTKYNFYANKRMEVQQA 60
Qy 61 VEVWQGLALLSAVLRGQALLVNSQPWEPLQLHVDKAVSGLSLTLRLALGAQKEAIP 120
Db 61 VEVWQGLALLSAVLRGQALLVNSQPWEPLQLHVDKAVSGLSLTLRLALGAQKEAIP 120
Qy 121 PPDA--SAAPLRTITADTKFLFRVYSNLFRLGKLYTGEACRTGD 165
Db 121 LPDATPSAAPLRTITADTKFLFRVYSNLFRLGKLYTGEACRTGD 166


RESULT 15

PCT-US94-04361-43
; Sequence 43, Application PC/TUS9404361
; GENERAL INFORMATION:
; APPLICANT: Brigham and Women's Hospital
; APPLICANT: 75 Francis Street
; APPLICANT: Boston, MA 02115
; APPLICANT: Bunn, H. Franklin
; APPLICANT: Wen, Danyl

; APPLICANT: Showers, Mark O.
; TITLE OF INVENTION: Erythropoietin Muteins With Enhanced
; NUMBER OF SEQUENCES: 59
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sterne, Kessler, Goldstein & Fox
; STREET: 1100 New York Avenue, Suite 600
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20005-3934
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US94/04361
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/049,802
; FILING DATE: 21-APR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Cimbala, Michele A.
; REGISTRATION NUMBER: 33,851
; REFERENCE/DOCKET NUMBER: 0627.336PC01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 371-2600
; TELEFAX: (202) 371-2540
; INFORMATION FOR SEQ ID NO: 43:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 168 amino acids
; TYPE: amino acid
; TOPOLOGY: both
PCT-US94-04361-43

Query Match 80.1%; Score 678; DB 5; Length 168;
Best Local Similarity 82.0%; Pred. No. 1.6e-78;
Matches 137; Conservative 7; Mismatches 21; Indels 2; Gaps 1;
Qy 1 APPRLICDSRVLYRLLEAKAEENITTCAGHCNENITVPDTKYNFYANKRMEVQQA 60
Db 1 APPRLICDSRVLYRLLEAKAEENITTCAGHCNENITVPDTKYNFYANKRMEVQQA 60
Qy 61 VEVWQGLALLSAVLRGQALLVNSQPWEPLQLHVDKAVSGLSLTLRLALGAQKEAIP 120
Db 61 VEVWQGLALLSAVLRGQALLVNSQPWEPLQLHVDKAVSGLSLTLRLALGAQKEAIP 120
Qy 121 PPDA--ASAPLRTITADTKFLFRVYSNLFRLGKLYTGEACRTGD 165
Db 121 LPDASPSSATPLRTFAVDTLCKLFRVYSNLFRLGKLYTGEACRRRD 167

Search completed: June 13, 2003, 15:05:04
Job time : 24 secs



GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: June 13, 2003, 15:04:47 ; Search time 47 Seconds
(without alignments)
375.342 Million cell updates/sec

Title: US-09-830-964-1
Perfect score: 846
Sequence: 1 APPRLICDSRVLELYLEAK.....SNFLRGKLYTGEACRTGD 165

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 408643 seqs, 106915682 residues
Total number of hits satisfying chosen parameters: 408643

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published_Applications_AA.*
1: /cgn2_6/ptodata/1/pubpaa/US08_NEW_PUB.pep.*
2: /cgn2_6/ptodata/1/pubpaa/PCT_NEW_PUB.pep.*
3: /cgn2_6/ptodata/1/pubpaa/US06_NEW_PUB.pep.*
4: /cgn2_6/ptodata/1/pubpaa/US06_PUBCOMB.pep.*
5: /cgn2_6/ptodata/1/pubpaa/US07_NEW_PUB.pep.*
6: /cgn2_6/ptodata/1/pubpaa/US07_PUBCOMB.pep.*
7: /cgn2_6/ptodata/1/pubpaa/PCTUS_PUBCOMB.pep.*
8: /cgn2_6/ptodata/1/pubpaa/US08_PUBCOMB.pep.*
9: /cgn2_6/ptodata/1/pubpaa/US09_NEW_PUB.pep.*
10: /cgn2_6/ptodata/1/pubpaa/US09_PUBCOMB.pep.*
11: /cgn2_6/ptodata/1/pubpaa/US10_NEW_PUB.pep.*
12: /cgn2_6/ptodata/1/pubpaa/US10_PUBCOMB.pep.*
13: /cgn2_6/ptodata/1/pubpaa/US60_NEW_PUB.pep.*
14: /cgn2_6/ptodata/1/pubpaa/US60_PUBCOMB.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match % | Length | ID | Description |
|------------|-------|---------------|--------|---------------------|--------------------|
| 1 | 846 | 100.0 | 165 | 9 US-10-241-356-1 | Sequence 1, Appli |
| 2 | 846 | 100.0 | 165 | 9 US-09-945-517-1 | Sequence 1, Appli |
| 3 | 846 | 100.0 | 165 | 10 US-09-853-731-1 | Sequence 1, Appli |
| 4 | 846 | 100.0 | 165 | 12 US-10-014-363-1 | Sequence 1, Appli |
| 5 | 846 | 100.0 | 166 | 9 US-10-241-356-2 | Sequence 2, Appli |
| 6 | 846 | 100.0 | 166 | 10 US-09-853-731-2 | Sequence 2, Appli |
| 7 | 846 | 100.0 | 166 | 12 US-10-014-363-2 | Sequence 2, Appli |
| 8 | 846 | 100.0 | 169 | 12 US-10-014-363-4 | Sequence 4, Appli |
| 9 | 846 | 100.0 | 174 | 12 US-10-014-363-3 | Sequence 3, Appli |
| 10 | 846 | 100.0 | 174 | 12 US-10-014-363-5 | Sequence 5, Appli |
| 11 | 846 | 100.0 | 193 | 9 US-10-113-824-2 | Sequence 4, Appli |
| 12 | 846 | 100.0 | 193 | 9 US-09-813-775C-4 | Sequence 2, Appli |
| 13 | 846 | 100.0 | 435 | 9 US-09-932-812-22 | Sequence 22, Appli |
| 14 | 846 | 100.0 | 436 | 9 US-09-932-812-18 | Sequence 18, Appli |
| 15 | 846 | 100.0 | 437 | 9 US-09-932-812-20 | Sequence 20, Appli |
| 16 | 843 | 99.6 | 412 | 9 US-09-775-964-34 | Sequence 34, Appli |
| 17 | 838 | 99.1 | 193 | 9 US-09-813-775C-2 | Sequence 2, Appli |
| 18 | 834 | 98.6 | 193 | 9 US-09-813-775C-5 | Sequence 5, Appli |
| 19 | 825 | 97.5 | 166 | 9 US-09-813-775C-30 | Sequence 30, Appli |

| | | | | | | |
|----|-----|------|-----|---|-------------------|--------------------|
| 20 | 825 | 97.5 | 193 | 9 | US-09-813-775C-46 | Sequence 46, Appli |
| 21 | 824 | 97.4 | 166 | 9 | US-09-813-775C-22 | Sequence 22, Appli |
| 22 | 824 | 97.4 | 166 | 9 | US-09-813-775C-32 | Sequence 32, Appli |
| 23 | 824 | 97.4 | 193 | 9 | US-09-813-775C-38 | Sequence 38, Appli |
| 24 | 824 | 97.4 | 193 | 9 | US-09-813-775C-48 | Sequence 48, Appli |
| 25 | 822 | 97.2 | 166 | 9 | US-09-813-775C-20 | Sequence 20, Appli |
| 26 | 822 | 97.2 | 166 | 9 | US-09-813-775C-24 | Sequence 24, Appli |
| 27 | 822 | 97.2 | 193 | 9 | US-09-813-775C-36 | Sequence 36, Appli |
| 28 | 822 | 97.2 | 193 | 9 | US-09-813-775C-40 | Sequence 40, Appli |
| 29 | 821 | 97.0 | 166 | 9 | US-09-813-775C-26 | Sequence 26, Appli |
| 30 | 821 | 97.0 | 166 | 9 | US-09-813-775C-31 | Sequence 31, Appli |
| 31 | 821 | 97.0 | 193 | 9 | US-09-813-775C-42 | Sequence 42, Appli |
| 32 | 821 | 97.0 | 193 | 9 | US-09-813-775C-47 | Sequence 47, Appli |
| 33 | 820 | 96.9 | 166 | 9 | US-09-813-775C-18 | Sequence 18, Appli |
| 34 | 820 | 96.9 | 166 | 9 | US-09-813-775C-23 | Sequence 23, Appli |
| 35 | 820 | 96.9 | 166 | 9 | US-09-813-775C-28 | Sequence 28, Appli |
| 36 | 820 | 96.9 | 166 | 9 | US-09-813-775C-33 | Sequence 33, Appli |
| 37 | 820 | 96.9 | 193 | 9 | US-09-813-775C-34 | Sequence 34, Appli |
| 38 | 820 | 96.9 | 193 | 9 | US-09-813-775C-39 | Sequence 39, Appli |
| 39 | 820 | 96.9 | 193 | 9 | US-09-813-775C-44 | Sequence 44, Appli |
| 40 | 820 | 96.9 | 193 | 9 | US-09-813-775C-49 | Sequence 49, Appli |
| 41 | 818 | 96.7 | 166 | 9 | US-09-813-775C-21 | Sequence 21, Appli |
| 42 | 818 | 96.7 | 166 | 9 | US-09-813-775C-25 | Sequence 25, Appli |
| 43 | 818 | 96.7 | 193 | 9 | US-09-813-775C-37 | Sequence 37, Appli |
| 44 | 818 | 96.7 | 193 | 9 | US-09-813-775C-41 | Sequence 41, Appli |
| 45 | 817 | 96.6 | 166 | 9 | US-09-813-775C-27 | Sequence 27, Appli |

ALIGNMENTS

RESULT 1
US-10-241-356-1
; Sequence 1, Application US/10241356
; Publication No. US2003007753A1
; GENERAL INFORMATION:
; APPLICANT: TISCHER, WILHELM
; TITLE OF INVENTION: DIGLYCOSYLATED ERYTHROPOIETIN
; FILE REFERENCE: 20971
; CURRENT APPLICATION NUMBER: US/10/241,356
; CURRENT FILING DATE: 2002-09-11
; PRIOR APPLICATION NUMBER: EP 01122555.4
; PRIOR FILING DATE: 2001-09-25
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 165
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-241-356-1

| | | | | |
|-----------------------|-----------------|---|-----------|-------------|
| Query Match | 100.0% | Score 846: | DB 9: | Length 165: |
| Best Local Similarity | 100.0% | Pred. No. 8.7e-84: | | |
| Matches 165; | Conservative 0; | Mismatches 0; | Indels 0; | Gaps 0; |
| QY | 1 | APPRLICDSRVLELYLEAKEAENITTCGAHCNSLNENITVPDTKVNFYAKRMVEVGQQA | 60 | |
| Db | 1 | APPRLICDSRVLELYLEAKEAENITTCGAHCNSLNENITVPDTKVNFYAKRMVEVGQQA | 60 | |
| QY | 61 | VEWOGALLSVAVLGGQALLVNSSQPWEPLQHLVDKAVSGLSRLTTLRLALGAQKEAIS | 120 | |
| Db | 61 | VEWOGALLSVAVLGGQALLVNSSQPWEPLQHLVDKAVSGLSRLTTLRLALGAQKEAIS | 120 | |
| QY | 121 | PPDAASAAPLRTITADTFKFLFRVSNFLRGKLYTGEACRTGD | 165 | |
| Db | 121 | PPDAASAAPLRTITADTFKFLFRVSNFLRGKLYTGEACRTGD | 165 | |

RESULT 2
US-09-945-517-1
; Sequence 1, Application US/09945517
; Publication No. US20030104996A1
; GENERAL INFORMATION:

```
; APPLICANT: Li, Tiansheng
; APPLICANT: Chang, Byeong
; APPLICANT: Sloey, Christopher
; TITLE OF INVENTION: L-METHIONINE AS A STABILIZER FOR NESP/EPO IN HSA-FREE FORMULATION
; FILE REFERENCE: A-803
; CURRENT APPLICATION NUMBER: US/09/945,517
; CURRENT FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 165
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-945-517-1

Query Match      100.0%; Score 846; DB 9; Length 165;
Best Local Similarity 100.0%; Pred. No. 8.7e-84;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APRRLICDSRVLYRLLEAKAEENITTCGAHCSSLNENITVPDTKVNFYAKRMVEVGQQA 60
Db 1 APRRLICDSRVLYRLLEAKAEENITTCGAHCSSLNENITVPDTKVNFYAKRMVEVGQQA 60
QY 61 VEVWQGLALLSEAVLRGQALLVNSQWPPEPLQHLVDKAVSGLSRLTLLRALGAQKEAIS 120
Db 61 VEVWQGLALLSEAVLRGQALLVNSQWPPEPLQHLVDKAVSGLSRLTLLRALGAQKEAIS 120
QY 121 PPDAASAPLRTITADTFRKLFVYSNLFRLGKLYTGEACRTGD 165
Db 121 PPDAASAPLRTITADTFRKLFVYSNLFRLGKLYTGEACRTGD 165

RESULT 3
US-09-853-731-1
; Sequence 1, Application US/09853731
; Patent No. US20020037841A1
; GENERAL INFORMATION:
; APPLICANT: Papadimitriou, Apollon
; TITLE OF INVENTION: Erythropoietin Composition
; FILE REFERENCE: 20619 US
; CURRENT APPLICATION NUMBER: US/09/853,731
; CURRENT FILING DATE: 2001-05-11
; PRIOR APPLICATION NUMBER: EP/00110355.5
; PRIOR FILING DATE: 2000-05-15
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 165
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-853-731-1

Query Match      100.0%; Score 846; DB 10; Length 165;
Best Local Similarity 100.0%; Pred. No. 8.7e-84;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APRRLICDSRVLYRLLEAKAEENITTCGAHCSSLNENITVPDTKVNFYAKRMVEVGQQA 60
Db 1 APRRLICDSRVLYRLLEAKAEENITTCGAHCSSLNENITVPDTKVNFYAKRMVEVGQQA 60
QY 61 VEVWQGLALLSEAVLRGQALLVNSQWPPEPLQHLVDKAVSGLSRLTLLRALGAQKEAIS 120
Db 61 VEVWQGLALLSEAVLRGQALLVNSQWPPEPLQHLVDKAVSGLSRLTLLRALGAQKEAIS 120
QY 121 PPDAASAPLRTITADTFRKLFVYSNLFRLGKLYTGEACRTGD 165
Db 121 PPDAASAPLRTITADTFRKLFVYSNLFRLGKLYTGEACRTGD 165

RESULT 4
US-10-014-363-1
; Sequence 1, Application US/10014363
; Patent No. US20020115833A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Burg, Josef
; APPLICANT: Engel, Alfred
; APPLICANT: Franze, Reinhard
; APPLICANT: Hilger, Bernd
; APPLICANT: Schurig, Hartmut Ernst
; APPLICANT: Tischer, Wilhelm
; APPLICANT: Wozny, Manfred
; TITLE OF INVENTION: Erythropoietin Conjugates
; FILE REFERENCE: Case 20805
; CURRENT APPLICATION NUMBER: US/10/014,363
; CURRENT FILING DATE: 2001-12-11
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 165
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-014-363-1

Query Match      100.0%; Score 846; DB 12; Length 165;
Best Local Similarity 100.0%; Pred. No. 8.7e-84;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APRRLICDSRVLYRLLEAKAEENITTCGAHCSSLNENITVPDTKVNFYAKRMVEVGQQA 60
Db 1 APRRLICDSRVLYRLLEAKAEENITTCGAHCSSLNENITVPDTKVNFYAKRMVEVGQQA 60
QY 61 VEVWQGLALLSEAVLRGQALLVNSQWPPEPLQHLVDKAVSGLSRLTLLRALGAQKEAIS 120
Db 61 VEVWQGLALLSEAVLRGQALLVNSQWPPEPLQHLVDKAVSGLSRLTLLRALGAQKEAIS 120
QY 121 PPDAASAPLRTITADTFRKLFVYSNLFRLGKLYTGEACRTGD 165
Db 121 PPDAASAPLRTITADTFRKLFVYSNLFRLGKLYTGEACRTGD 165

RESULT 5
US-10-241-356-2
; Sequence 2, Application US/10241356
; Publication No. US2003007753A1
; GENERAL INFORMATION:
; APPLICANT: TISCHER, WILHELM
; TITLE OF INVENTION: DIGLYCOSYLATED ERYTHROPOIETIN
; FILE REFERENCE: 20971
; CURRENT APPLICATION NUMBER: US/10/241,356
; CURRENT FILING DATE: 2002-09-11
; PRIOR APPLICATION NUMBER: EP 01122555.4
; PRIOR FILING DATE: 2001-09-25
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 166
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-241-356-2

Query Match      100.0%; Score 846; DB 9; Length 166;
Best Local Similarity 100.0%; Pred. No. 8.7e-84;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APRRLICDSRVLYRLLEAKAEENITTCGAHCSSLNENITVPDTKVNFYAKRMVEVGQQA 60
Db 1 APRRLICDSRVLYRLLEAKAEENITTCGAHCSSLNENITVPDTKVNFYAKRMVEVGQQA 60
QY 61 VEVWQGLALLSEAVLRGQALLVNSQWPPEPLQHLVDKAVSGLSRLTLLRALGAQKEAIS 120
Db 61 VEVWQGLALLSEAVLRGQALLVNSQWPPEPLQHLVDKAVSGLSRLTLLRALGAQKEAIS 120
QY 121 PPDAASAPLRTITADTFRKLFVYSNLFRLGKLYTGEACRTGD 165
Db 121 PPDAASAPLRTITADTFRKLFVYSNLFRLGKLYTGEACRTGD 165
```

```

RESULT 6
US-09-853-731-2
; Sequence 2, Application US/09853731
; Patent No. US20020037841A1
; GENERAL INFORMATION:
; APPLICANT: Papadimitriou, Apollon
; TITLE OF INVENTION: Erythropoietin Composition
; FILE REFERENCE: 20619 US
; CURRENT APPLICATION NUMBER: US/09/853,731
; PRIOR FILING DATE: 2001-05-11
; PRIOR APPLICATION NUMBER: EP/00110355.5
; PRIOR FILING DATE: 2000-05-15
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
; LENGTH: 166
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-853-731-2

Query Match      100.0%; Score 846; DB 10; Length 166;
Best Local Similarity 100.0%; Pred. No. 8.7e-84;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 APRLICDSRVLYRLLEAKAEENITTCACAEHCSLNENITVPDTKVNFYAWKRMVEVQQA 60
Db 1 APRLICDSRVLYRLLEAKAEENITTCACAEHCSLNENITVPDTKVNFYAWKRMVEVQQA 60

Qy 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLRSLLTLLRALGAQKEAIS 120
Db 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLRSLLTLLRALGAQKEAIS 120

Qy 121 PPDAASAAPLRTITADTFRKLFVYSNFRGKGLKLYTGEACRTGD 165
Db 121 PPDAASAAPLRTITADTFRKLFVYSNFRGKGLKLYTGEACRTGD 165

RESULT 7
US-10-014-363-2
; Sequence 2, Application US/10014363
; Patent No. US20020115833A1
; GENERAL INFORMATION:
; APPLICANT: Burg, Josef
; APPLICANT: Engel, Alfred
; APPLICANT: Franze, Reinhard
; APPLICANT: Hilger, Bernd
; APPLICANT: Schurig, Hartmut Ernst
; APPLICANT: Fischer, Wilhelm
; APPLICANT: Wozny, Manfred
; TITLE OF INVENTION: Erythropoietin Conjugates
; FILE REFERENCE: Case 20805
; CURRENT APPLICATION NUMBER: US/10/014,363
; CURRENT FILING DATE: 2001-12-11
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 166
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-014-363-2

Query Match      100.0%; Score 846; DB 12; Length 166;
Best Local Similarity 100.0%; Pred. No. 8.7e-84;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 APRLICDSRVLYRLLEAKAEENITTCACAEHCSLNENITVPDTKVNFYAWKRMVEVQQA 60
Db 1 APRLICDSRVLYRLLEAKAEENITTCACAEHCSLNENITVPDTKVNFYAWKRMVEVQQA 60

Qy 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLRSLLTLLRALGAQKEAIS 120
Db 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLRSLLTLLRALGAQKEAIS 120

Qy 121 PPDAASAAPLRTITADTFRKLFVYSNFRGKGLKLYTGEACRTGD 165
Db 121 PPDAASAAPLRTITADTFRKLFVYSNFRGKGLKLYTGEACRTGD 165

RESULT 8
US-10-014-363-4
; Sequence 4, Application US/10014363
; Patent No. US20020115833A1
; GENERAL INFORMATION:
; APPLICANT: Burg, Josef
; APPLICANT: Engel, Alfred
; APPLICANT: Franze, Reinhard
; APPLICANT: Hilger, Bernd
; APPLICANT: Schurig, Hartmut Ernst
; APPLICANT: Fischer, Wilhelm
; APPLICANT: Wozny, Manfred
; TITLE OF INVENTION: Erythropoietin Conjugates
; FILE REFERENCE: Case 20805
; CURRENT APPLICATION NUMBER: US/10/014,363
; CURRENT FILING DATE: 2001-12-11
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 169
; TYPE: PRT
; ORGANISM: CHO/dhfr-
US-10-014-363-4

Query Match      100.0%; Score 846; DB 12; Length 169;
Best Local Similarity 100.0%; Pred. No. 9e-84;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 APRLICDSRVLYRLLEAKAEENITTCACAEHCSLNENITVPDTKVNFYAWKRMVEVQQA 60
Db 4 APRLICDSRVLYRLLEAKAEENITTCACAEHCSLNENITVPDTKVNFYAWKRMVEVQQA 63

Qy 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLRSLLTLLRALGAQKEAIS 120
Db 64 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLRSLLTLLRALGAQKEAIS 123

Qy 121 PPDAASAAPLRTITADTFRKLFVYSNFRGKGLKLYTGEACRTGD 165
Db 124 PPDAASAAPLRTITADTFRKLFVYSNFRGKGLKLYTGEACRTGD 168

RESULT 9
US-10-014-363-3
; Sequence 3, Application US/10014363
; Patent No. US20020115833A1
; GENERAL INFORMATION:
; APPLICANT: Burg, Josef
; APPLICANT: Engel, Alfred
; APPLICANT: Franze, Reinhard
; APPLICANT: Hilger, Bernd
; APPLICANT: Schurig, Hartmut Ernst
; APPLICANT: Fischer, Wilhelm
; APPLICANT: Wozny, Manfred
; TITLE OF INVENTION: Erythropoietin Conjugates
; FILE REFERENCE: Case 20805
; CURRENT APPLICATION NUMBER: US/10/014,363
; CURRENT FILING DATE: 2001-12-11
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 174
; TYPE: PRT
; ORGANISM: CHO/dhfr-
US-10-014-363-3

Query Match      100.0%; Score 846; DB 12; Length 174;
Best Local Similarity 100.0%; Pred. No. 9.3e-84;

```

```

Qy 121 PPDAASAAPLRTITADTFRKLFVYSNFRGKGLKLYTGEACRTGD 165
Db 121 PPDAASAAPLRTITADTFRKLFVYSNFRGKGLKLYTGEACRTGD 165

RESULT 8
US-10-014-363-4
; Sequence 4, Application US/10014363
; Patent No. US20020115833A1
; GENERAL INFORMATION:
; APPLICANT: Burg, Josef
; APPLICANT: Engel, Alfred
; APPLICANT: Franze, Reinhard
; APPLICANT: Hilger, Bernd
; APPLICANT: Schurig, Hartmut Ernst
; APPLICANT: Fischer, Wilhelm
; APPLICANT: Wozny, Manfred
; TITLE OF INVENTION: Erythropoietin Conjugates
; FILE REFERENCE: Case 20805
; CURRENT APPLICATION NUMBER: US/10/014,363
; CURRENT FILING DATE: 2001-12-11
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 169
; TYPE: PRT
; ORGANISM: CHO/dhfr-
US-10-014-363-4

Query Match      100.0%; Score 846; DB 12; Length 169;
Best Local Similarity 100.0%; Pred. No. 9e-84;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 APRLICDSRVLYRLLEAKAEENITTCACAEHCSLNENITVPDTKVNFYAWKRMVEVQQA 60
Db 4 APRLICDSRVLYRLLEAKAEENITTCACAEHCSLNENITVPDTKVNFYAWKRMVEVQQA 63

Qy 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLRSLLTLLRALGAQKEAIS 120
Db 64 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLRSLLTLLRALGAQKEAIS 123

Qy 121 PPDAASAAPLRTITADTFRKLFVYSNFRGKGLKLYTGEACRTGD 165
Db 124 PPDAASAAPLRTITADTFRKLFVYSNFRGKGLKLYTGEACRTGD 168

RESULT 9
US-10-014-363-3
; Sequence 3, Application US/10014363
; Patent No. US20020115833A1
; GENERAL INFORMATION:
; APPLICANT: Burg, Josef
; APPLICANT: Engel, Alfred
; APPLICANT: Franze, Reinhard
; APPLICANT: Hilger, Bernd
; APPLICANT: Schurig, Hartmut Ernst
; APPLICANT: Fischer, Wilhelm
; APPLICANT: Wozny, Manfred
; TITLE OF INVENTION: Erythropoietin Conjugates
; FILE REFERENCE: Case 20805
; CURRENT APPLICATION NUMBER: US/10/014,363
; CURRENT FILING DATE: 2001-12-11
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 174
; TYPE: PRT
; ORGANISM: CHO/dhfr-
US-10-014-363-3

Query Match      100.0%; Score 846; DB 12; Length 174;
Best Local Similarity 100.0%; Pred. No. 9.3e-84;

```


APPLICANT: Sun, Bill N
APPLICANT: Sun, Cecily R
TITLE OF INVENTION: Fc fusion proteins of human erythropoietin with increased biological activity
FILE REFERENCE: US/09/932,812
CURRENT APPLICATION NUMBER: US/09/932,812
CURRENT FILING DATE: 2001-10-30
NUMBER OF SEQ ID NOS: 22
SOFTWARE: PatentIn version 3.1
SEQ ID NO 22
LENGTH: 435
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: HuEPO-L-vFc gammal with a 27-amino acid leader peptide (Figure 2)
US-09-932-812-22

Query Match 100.0%; Score 846; DB 9; Length 435;
Best Local Similarity 100.0%; Pred. No. 3.4e-83;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 APRRLICDSRVLYRLLEAKAEENITTCGAHCSLNENITVPDTKVNFKYAKRMEVGQQA 60
Db 28 APRRLICDSRVLYRLLEAKAEENITTCGAHCSLNENITVPDTKVNFKYAKRMEVGQQA 87
Qy 61 VEVWQGLALLSEAVLRQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120
Db 88 VEVWQGLALLSEAVLRQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 147
Qy 121 PPDAASAAPLRTITADTFKRLFRVSNFLRGKLYTGACRTGD 165
Db 148 PPDAASAAPLRTITADTFKRLFRVSNFLRGKLYTGACRTGD 192


RESULT 14
US-09-932-812-18
Sequence 18, Application US/09932812
Publication No. US20030082749A1
GENERAL INFORMATION:
APPLICANT: Sun, Lee-Hwei K
APPLICANT: Sun, Cecily R
TITLE OF INVENTION: Fc fusion proteins of human erythropoietin with increased biological activity
FILE REFERENCE: US/09/932,812
CURRENT APPLICATION NUMBER: US/09/932,812
CURRENT FILING DATE: 2001-10-30
NUMBER OF SEQ ID NOS: 22
SOFTWARE: PatentIn version 3.1
SEQ ID NO 18
LENGTH: 436
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: HuEPO-L-vFc gamma2 with a 27-amino acid leader peptide (Figure 2)
US-09-932-812-18

Query Match 100.0%; Score 846; DB 9; Length 436;
Best Local Similarity 100.0%; Pred. No. 3.4e-83;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 APRRLICDSRVLYRLLEAKAEENITTCGAHCSLNENITVPDTKVNFKYAKRMEVGQQA 60
Db 28 APRRLICDSRVLYRLLEAKAEENITTCGAHCSLNENITVPDTKVNFKYAKRMEVGQQA 87
Qy 61 VEVWQGLALLSEAVLRQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120
Db 88 VEVWQGLALLSEAVLRQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 147
Qy 121 PPDAASAAPLRTITADTFKRLFRVSNFLRGKLYTGACRTGD 165
Db 148 PPDAASAAPLRTITADTFKRLFRVSNFLRGKLYTGACRTGD 192

RESULT 15
US-09-932-812-20
Sequence 20, Application US/09932812
Publication No. US20030082749A1
GENERAL INFORMATION:
APPLICANT: Sun, Lee-Hwei K
APPLICANT: Sun, Bill N
APPLICANT: Sun, Cecily R
TITLE OF INVENTION: Fc fusion proteins of human erythropoietin with increased biological activity
FILE REFERENCE: US/09/932,812
CURRENT APPLICATION NUMBER: US/09/932,812
CURRENT FILING DATE: 2001-10-30
NUMBER OF SEQ ID NOS: 22
SOFTWARE: PatentIn version 3.1
SEQ ID NO 20
LENGTH: 437
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: HuEPO-L-vFc gamma4 with a 27-amino acid leader peptide (Figure 2)
US-09-932-812-20

Query Match 100.0%; Score 846; DB 9; Length 437;
Best Local Similarity 100.0%; Pred. No. 3.4e-83;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 APRRLICDSRVLYRLLEAKAEENITTCGAHCSLNENITVPDTKVNFKYAKRMEVGQQA 60
Db 28 APRRLICDSRVLYRLLEAKAEENITTCGAHCSLNENITVPDTKVNFKYAKRMEVGQQA 87
Qy 61 VEVWQGLALLSEAVLRQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120
Db 88 VEVWQGLALLSEAVLRQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 147
Qy 121 PPDAASAAPLRTITADTFKRLFRVSNFLRGKLYTGACRTGD 165
Db 148 PPDAASAAPLRTITADTFKRLFRVSNFLRGKLYTGACRTGD 192

Search completed: June 13, 2003, 15:13:52
Job time: 48 secs



GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: June 13, 2003, 15:03:00 ; Search time 310 seconds
(without alignments)
343.164 Million cell updates/sec

Title: US-09-830-964-1

Perfect score: 846

Sequence: 1 APRRLICDSRVRLRYLEAK.....SNFLRGKLYTGACRTGD 165

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 4569144 seqs, 644733110 residues

Total number of hits satisfying chosen parameters: 4569144

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database :

Pending_Patents_AA_Main:*

- 1: /cgn2_6/ptodata/1/paa/PCTUS_COMB.pap.*
- 2: /cgn2_6/ptodata/1/paa/US06_COMB.pap.*
- 3: /cgn2_6/ptodata/1/paa/US07_COMB.pap.*
- 4: /cgn2_6/ptodata/1/paa/US08_COMB.pap.*
- 5: /cgn2_6/ptodata/1/paa/US081_COMB.pap.*
- 6: /cgn2_6/ptodata/1/paa/US082_COMB.pap.*
- 7: /cgn2_6/ptodata/1/paa/US083_COMB.pap.*
- 8: /cgn2_6/ptodata/1/paa/US084_COMB.pap.*
- 9: /cgn2_6/ptodata/1/paa/US085_COMB.pap.*
- 10: /cgn2_6/ptodata/1/paa/US086_COMB.pap.*
- 11: /cgn2_6/ptodata/1/paa/US087_COMB.pap.*
- 12: /cgn2_6/ptodata/1/paa/US088_COMB.pap.*
- 13: /cgn2_6/ptodata/1/paa/US089_COMB.pap.*
- 14: /cgn2_6/ptodata/1/paa/US090_COMB.pap.*
- 15: /cgn2_6/ptodata/1/paa/US091_COMB.pap.*
- 16: /cgn2_6/ptodata/1/paa/US092_COMB.pap.*
- 17: /cgn2_6/ptodata/1/paa/US093_COMB.pap.*
- 18: /cgn2_6/ptodata/1/paa/US094_COMB.pap.*
- 19: /cgn2_6/ptodata/1/paa/US095_COMB.pap.*
- 20: /cgn2_6/ptodata/1/paa/US096_COMB.pap.*
- 21: /cgn2_6/ptodata/1/paa/US097_COMB.pap.*
- 22: /cgn2_6/ptodata/1/paa/US098_COMB.pap.*
- 23: /cgn2_6/ptodata/1/paa/US099_COMB.pap.*
- 24: /cgn2_6/ptodata/1/paa/US100_COMB.pap.*
- 25: /cgn2_6/ptodata/1/paa/US101_COMB.pap.*
- 26: /cgn2_6/ptodata/1/paa/US102_COMB.pap.*
- 27: /cgn2_6/ptodata/1/paa/US60_COMB.pap.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | DB ID | Description |
|------------|-------|-------------|--------|-------|------------------|
| 1 | 846 | 100.0 | 165 | 1 | PCT-US99-26238-1 |
| 2 | 846 | 100.0 | 165 | 1 | PCT-US99-26240-1 |
| 3 | 846 | 100.0 | 165 | 1 | PCT-US99-26241-1 |
| 4 | 846 | 100.0 | 165 | 18 | US-09-426-566-1 |
| 5 | 846 | 100.0 | 165 | 20 | US-09-604-938-1 |
| 6 | 846 | 100.0 | 165 | 22 | US-09-830-964-1 |

| | | | | | | |
|----|-----|-------|-----|----|------------------|--------------------|
| 7 | 846 | 100.0 | 165 | 22 | US-09-830-967-1 | Sequence 1, Appli |
| 8 | 846 | 100.0 | 165 | 22 | US-09-830-968-1 | Sequence 1, Appli |
| 9 | 846 | 100.0 | 165 | 22 | US-09-853-731-1 | Sequence 1, Appli |
| 10 | 846 | 100.0 | 165 | 22 | US-09-854-018-1 | Sequence 1, Appli |
| 11 | 846 | 100.0 | 165 | 23 | US-09-945-517-1 | Sequence 1, Appli |
| 12 | 846 | 100.0 | 165 | 24 | US-10-014-363-1 | Sequence 1, Appli |
| 13 | 846 | 100.0 | 165 | 26 | US-10-241-356-1 | Sequence 1, Appli |
| 14 | 846 | 100.0 | 166 | 1 | PCT-US98-14497-2 | Sequence 2, Appli |
| 15 | 846 | 100.0 | 166 | 3 | US-07-766-964A-3 | Sequence 3, Appli |
| 16 | 846 | 100.0 | 166 | 4 | US-08-049-802-37 | Sequence 37, Appli |
| 17 | 846 | 100.0 | 166 | 4 | US-08-223-263-7 | Sequence 7, Appli |
| 18 | 846 | 100.0 | 166 | 6 | US-08-232-263A-7 | Sequence 7, Appli |
| 19 | 846 | 100.0 | 166 | 6 | US-08-232-533-37 | Sequence 7, Appli |
| 20 | 846 | 100.0 | 166 | 6 | US-08-249-376-7 | Sequence 7, Appli |
| 21 | 846 | 100.0 | 166 | 6 | US-08-249-376A-7 | Sequence 7, Appli |
| 22 | 846 | 100.0 | 166 | 6 | US-08-249-376B-7 | Sequence 7, Appli |
| 23 | 846 | 100.0 | 166 | 7 | US-08-374-540-7 | Sequence 7, Appli |
| 24 | 846 | 100.0 | 166 | 8 | US-08-422-020-7 | Sequence 7, Appli |
| 25 | 846 | 100.0 | 166 | 8 | US-08-422-020A-7 | Sequence 7, Appli |
| 26 | 846 | 100.0 | 166 | 8 | US-08-422-194-7 | Sequence 7, Appli |
| 27 | 846 | 100.0 | 166 | 8 | US-08-422-194A-7 | Sequence 7, Appli |
| 28 | 846 | 100.0 | 166 | 8 | US-08-422-548-7 | Sequence 7, Appli |
| 29 | 846 | 100.0 | 166 | 8 | US-08-422-727-7 | Sequence 7, Appli |
| 30 | 846 | 100.0 | 166 | 8 | US-08-422-727A-7 | Sequence 7, Appli |
| 31 | 846 | 100.0 | 166 | 8 | US-08-423-194-7 | Sequence 7, Appli |
| 32 | 846 | 100.0 | 166 | 8 | US-08-423-194A-7 | Sequence 7, Appli |
| 33 | 846 | 100.0 | 166 | 8 | US-08-425-016-7 | Sequence 7, Appli |
| 34 | 846 | 100.0 | 166 | 8 | US-08-425-016A-7 | Sequence 7, Appli |
| 35 | 846 | 100.0 | 166 | 8 | US-08-425-016B-7 | Sequence 7, Appli |
| 36 | 846 | 100.0 | 166 | 8 | US-08-425-020-7 | Sequence 7, Appli |
| 37 | 846 | 100.0 | 166 | 8 | US-08-425-020A-7 | Sequence 7, Appli |
| 38 | 846 | 100.0 | 166 | 8 | US-08-425-095-7 | Sequence 7, Appli |
| 39 | 846 | 100.0 | 166 | 8 | US-08-425-095A-7 | Sequence 7, Appli |
| 40 | 846 | 100.0 | 166 | 8 | US-08-433-098A-7 | Sequence 7, Appli |
| 41 | 846 | 100.0 | 166 | 8 | US-08-433-098B-7 | Sequence 7, Appli |
| 42 | 846 | 100.0 | 166 | 8 | US-08-433-103-7 | Sequence 7, Appli |
| 43 | 846 | 100.0 | 166 | 8 | US-08-433-103A-7 | Sequence 7, Appli |
| 44 | 846 | 100.0 | 166 | 8 | US-08-433-766-7 | Sequence 7, Appli |
| 45 | 846 | 100.0 | 166 | 8 | US-08-433-767-7 | Sequence 7, Appli |

ALIGNMENTS

RESULT 1

PCT-US99-26238-1

; Sequence 1, Application PC/TUS9926238

; GENERAL INFORMATION:

; APPLICANT: Sterrenbeid Biotechnologie North America, Inc.

; APPLICANT: Carcagno, Carlos Miguel

; APPLICANT: Criscuolo, Marcelo

; APPLICANT: Melo, Carlos

; APPLICANT: Vidal, Juan Alejandro

; TITLE OF INVENTION: Host Cells Expressing Recombinant Human Erythropoietin

; FILE REFERENCE: 1792.002PC02

; CURRENT APPLICATION NUMBER: PCT/US99/26238

; CURRENT FILING DATE: 1999-11-08

; EARLIER APPLICATION NUMBER: AR 99-01-00679

; EARLIER FILING DATE: 1999-02-23

; EARLIER APPLICATION NUMBER: AR 98-01-05609

; EARLIER FILING DATE: 1998-11-06

; NUMBER OF SEQ ID NOS: 5

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 1

; LENGTH: 165

; TYPE: PRT

; ORGANISM: Homo sapiens

PCT-US99-26238-1

Query Match 100.0%; Score 846; DB 1; Length 165;

Best Local Similarity 100.0%; Pred. No. 1.2e-89;

Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APPRLICDSRVLELYLLEAKEAENITTCGAHCSLNENITVPDVKVNFYAWKRMVEVGQQA 60
DB 1 APPRLICDSRVLELYLLEAKEAENITTCGAHCSLNENITVPDVKVNFYAWKRMVEVGQQA 60
QY 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSLTTLLRALGAQKEAIS 120
DB 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSLTTLLRALGAQKEAIS 120
QY 121 PDAASAAPLRTITADTFRKLFRVYSNLFGRGKLKLYTGEACRTGD 165
DB 121 PDAASAAPLRTITADTFRKLFRVYSNLFGRGKLKLYTGEACRTGD 165

RESULT 2

PCT-US99-26240-1
Query Match 100.0%; Score 846; DB 1; Length 165;
Best Local Similarity 100.0%; Pred. No. 1.2e-89;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Sequence 1, Application PC/TUS9926240
GENERAL INFORMATION:
APPLICANT: Sterrenbeld Biotechnologie North America, Inc.
APPLICANT: Carcagno, Carlos Miguel
APPLICANT: Criscuolo, Marcelo
APPLICANT: Melo, Carlos
APPLICANT: Vidal, Juan Alejandro
TITLE OF INVENTION: Method for the Massive Culture of Cells Producing Recombinant Human Erythropoietin
FILE REFERENCE: 1792.004PC02
CURRENT APPLICATION NUMBER: PCT/US99/26240
CURRENT FILING DATE: 1999-11-08
EARLIER APPLICATION NUMBER: AR 99-01-00681
EARLIER FILING DATE: 1999-02-23
EARLIER APPLICATION NUMBER: AR 98-01-05611
EARLIER FILING DATE: 1998-11-06
NUMBER OF SEQ ID NOS: 1
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 1
LENGTH: 165
TYPE: PRT
ORGANISM: Homo sapiens
PCT-US99-26240-1

Query Match 100.0%; Score 846; DB 1; Length 165;
Best Local Similarity 100.0%; Pred. No. 1.2e-89;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 APPRLICDSRVLELYLLEAKEAENITTCGAHCSLNENITVPDVKVNFYAWKRMVEVGQQA 60
DB 1 APPRLICDSRVLELYLLEAKEAENITTCGAHCSLNENITVPDVKVNFYAWKRMVEVGQQA 60
QY 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSLTTLLRALGAQKEAIS 120
DB 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSLTTLLRALGAQKEAIS 120
QY 121 PDAASAAPLRTITADTFRKLFRVYSNLFGRGKLKLYTGEACRTGD 165
DB 121 PDAASAAPLRTITADTFRKLFRVYSNLFGRGKLKLYTGEACRTGD 165

RESULT 3

PCT-US99-26241-1
Query Match 100.0%; Score 846; DB 1; Length 165;
Best Local Similarity 100.0%; Pred. No. 1.2e-89;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Sequence 1, Application PC/TUS9926241
GENERAL INFORMATION:
APPLICANT: Sterrenbeld Biotechnologie North America, Inc.
APPLICANT: Carcagno, Carlos Miguel
APPLICANT: Criscuolo, Marcelo
APPLICANT: Melo, Carlos
APPLICANT: Vidal, Juan Alejandro
TITLE OF INVENTION: Methods of Purifying Recombinant Human Erythropoietin from Cell Culture Supernatants
FILE REFERENCE: 1792.003PC02
CURRENT APPLICATION NUMBER: PCT/US99/26241
CURRENT FILING DATE: 1999-11-08
EARLIER APPLICATION NUMBER: AR 99-01-00680
EARLIER FILING DATE: 1999-02-23
EARLIER APPLICATION NUMBER: AR 98-01-05610

; EARLIER FILING DATE: 1998-11-06
; NUMBER OF SEQ ID NOS: 1
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 165
; TYPE: PRT
; ORGANISM: Homo sapiens
PCT-US99-26241-1

Query Match 100.0%; Score 846; DB 1; Length 165;
Best Local Similarity 100.0%; Pred. No. 1.2e-89;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 APPRLICDSRVLELYLLEAKEAENITTCGAHCSLNENITVPDVKVNFYAWKRMVEVGQQA 60
DB 1 APPRLICDSRVLELYLLEAKEAENITTCGAHCSLNENITVPDVKVNFYAWKRMVEVGQQA 60
QY 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSLTTLLRALGAQKEAIS 120
DB 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSLTTLLRALGAQKEAIS 120
QY 121 PDAASAAPLRTITADTFRKLFRVYSNLFGRGKLKLYTGEACRTGD 165
DB 121 PDAASAAPLRTITADTFRKLFRVYSNLFGRGKLKLYTGEACRTGD 165

RESULT 4

US-09-426-566-1
Query Match 100.0%; Score 846; DB 18; Length 165;
Best Local Similarity 100.0%; Pred. No. 1.2e-89;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Sequence 1, Application US/09426566
GENERAL INFORMATION:
APPLICANT: Burke, Paul
APPLICANT: Klumb, Lisa
APPLICANT: Murphy, Keith
APPLICANT: Herberger, John
APPLICANT: French, Donna
TITLE OF INVENTION: BIODEGRADABLE MICROPARTICLES FOR THE SUSTAINED DELIVERY OF NOVEL ERYTHROPOIETIN STIMULATING PROTEIN
FILE REFERENCE: A-626
CURRENT APPLICATION NUMBER: US/09/426,566
CURRENT FILING DATE: 1999-10-22
NUMBER OF SEQ ID NOS: 2
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 1
LENGTH: 165
TYPE: PRT
ORGANISM: HUMAN
US-09-426-566-1

Query Match 100.0%; Score 846; DB 18; Length 165;
Best Local Similarity 100.0%; Pred. No. 1.2e-89;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 APPRLICDSRVLELYLLEAKEAENITTCGAHCSLNENITVPDVKVNFYAWKRMVEVGQQA 60
DB 1 APPRLICDSRVLELYLLEAKEAENITTCGAHCSLNENITVPDVKVNFYAWKRMVEVGQQA 60
QY 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSLTTLLRALGAQKEAIS 120
DB 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSLTTLLRALGAQKEAIS 120
QY 121 PDAASAAPLRTITADTFRKLFRVYSNLFGRGKLKLYTGEACRTGD 165
DB 121 PDAASAAPLRTITADTFRKLFRVYSNLFGRGKLKLYTGEACRTGD 165

RESULT 5

US-09-604-938-1
Query Match 100.0%; Score 846; DB 18; Length 165;
Best Local Similarity 100.0%; Pred. No. 1.2e-89;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Sequence 1, Application US/09604938
GENERAL INFORMATION:
APPLICANT: Bailon, Pascal
APPLICANT: Herberger, John
APPLICANT: French, Donna
TITLE OF INVENTION: ERYTHROPOIETIN CONJUGATES
FILE REFERENCE: 1097 nonprovisional
CURRENT APPLICATION NUMBER: US/09/604,938

```

; CURRENT FILING DATE: 2000-06-27
; PRIOR APPLICATION NUMBER: 60/166,151
; PRIOR FILING DATE: 1999-11-17
; PRIOR APPLICATION NUMBER: 60/151,548
; PRIOR FILING DATE: 1999-08-13
; PRIOR APPLICATION NUMBER: 60/150,225
; PRIOR FILING DATE: 1999-08-23
; PRIOR APPLICATION NUMBER: 60/142,254
; PRIOR FILING DATE: 1999-07-02
; NUMBER OF SEQ ID NOS: 3
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 165
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-830-964-1

```

```

Query Match      100.0%; Score 846; DB 20; Length 165;
Best Local Similarity 100.0%; Pred. No. 1.2e-89;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 APPRLICDSRVLYRLLEAKAEENITTCGAHCSLNENITVPDTKVNFAWKRMVEVGQQA 60
Db 1 APPRLICDSRVLYRLLEAKAEENITTCGAHCSLNENITVPDTKVNFAWKRMVEVGQQA 60

Qy 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120
Db 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120

Qy 121 PPDAASAAPLRTITADTFKRLFRVYSNPLRGKLLKLYTGEACRTGD 165
Db 121 PPDAASAAPLRTITADTFKRLFRVYSNPLRGKLLKLYTGEACRTGD 165

```

```

RESULT 6
US-09-830-964-1
; Sequence 1, Application US/09830964
; GENERAL INFORMATION:
; APPLICANT: Sterrenbeld Biotechnologie North America, Inc.
; APPLICANT: Carcagno, Carlos Miguel
; APPLICANT: Criscuolo, Marcelo
; APPLICANT: Melo, Carlos
; APPLICANT: Vidal, Juan Alejandro
; TITLE OF INVENTION: Methods of Purifying Recombinant Human
; TITLE OF INVENTION: Erythropoietin from Cell Culture Supernatants
; FILE REFERENCE: 1909.0030002
; CURRENT APPLICATION NUMBER: US/09/830,964
; CURRENT FILING DATE: 1999-11-08
; PRIOR APPLICATION NUMBER: AR 99-01-00680
; PRIOR FILING DATE: 1999-02-23
; PRIOR APPLICATION NUMBER: AR 98-01-05610
; PRIOR FILING DATE: 1998-11-06
; NUMBER OF SEQ ID NOS: 1
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 165
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-830-964-1

```

```

Query Match      100.0%; Score 846; DB 22; Length 165;
Best Local Similarity 100.0%; Pred. No. 1.2e-89;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 APPRLICDSRVLYRLLEAKAEENITTCGAHCSLNENITVPDTKVNFAWKRMVEVGQQA 60
Db 1 APPRLICDSRVLYRLLEAKAEENITTCGAHCSLNENITVPDTKVNFAWKRMVEVGQQA 60

Qy 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120
Db 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120

Qy 121 PPDAASAAPLRTITADTFKRLFRVYSNPLRGKLLKLYTGEACRTGD 165

```

```

Db 121 PPDAASAAPLRTITADTFKRLFRVYSNPLRGKLLKLYTGEACRTGD 165

RESULT 7
US-09-830-967-1
; Sequence 1, Application US/09830967
; GENERAL INFORMATION:
; APPLICANT: Sterrenbeld Biotechnologie North America, Inc.
; APPLICANT: Carcagno, Carlos Miguel
; APPLICANT: Criscuolo, Marcelo
; APPLICANT: Melo, Carlos
; APPLICANT: Vidal, Juan Alejandro
; TITLE OF INVENTION: Host Cells Expressing Recombinant Human Erythropoietin
; FILE REFERENCE: 1909.0020002
; CURRENT APPLICATION NUMBER: US/09/830,967
; CURRENT FILING DATE: 1999-11-08
; PRIOR APPLICATION NUMBER: AR 99-01-00679
; PRIOR FILING DATE: 1999-02-23
; PRIOR APPLICATION NUMBER: AR 98-01-05609
; PRIOR FILING DATE: 1998-11-06
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 165
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-830-967-1

```

```

Query Match      100.0%; Score 846; DB 22; Length 165;
Best Local Similarity 100.0%; Pred. No. 1.2e-89;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 APPRLICDSRVLYRLLEAKAEENITTCGAHCSLNENITVPDTKVNFAWKRMVEVGQQA 60
Db 1 APPRLICDSRVLYRLLEAKAEENITTCGAHCSLNENITVPDTKVNFAWKRMVEVGQQA 60

Qy 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120
Db 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120

Qy 121 PPDAASAAPLRTITADTFKRLFRVYSNPLRGKLLKLYTGEACRTGD 165
Db 121 PPDAASAAPLRTITADTFKRLFRVYSNPLRGKLLKLYTGEACRTGD 165

```

```

RESULT 8
US-09-830-968-1
; Sequence 1, Application US/09830968
; GENERAL INFORMATION:
; APPLICANT: Sterrenbeld Biotechnologie North America, Inc.
; APPLICANT: Carcagno, Carlos Miguel
; APPLICANT: Criscuolo, Marcelo
; APPLICANT: Melo, Carlos
; APPLICANT: Vidal, Juan Alejandro
; TITLE OF INVENTION: Method for the Massive Culture of Cells
; TITLE OF INVENTION: Producing Recombinant Human Erythropoietin
; FILE REFERENCE: 1909.0040002
; CURRENT APPLICATION NUMBER: US/09/830,968
; CURRENT FILING DATE: 1999-11-08
; PRIOR APPLICATION NUMBER: AR 99-01-00681
; PRIOR FILING DATE: 1999-02-23
; PRIOR APPLICATION NUMBER: AR 98-01-05611
; PRIOR FILING DATE: 1998-11-06
; NUMBER OF SEQ ID NOS: 1
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 165
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-830-968-1

```

```

Query Match      100.0%; Score 846; DB 22; Length 165;

```

Best Local Similarity 100.0%; Pred. No. 1.2e-89;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APPRLICDSRVLYRLLEAKEAENITTCGAHCSSLNENITVPDTKVNFYAWKRMEVGQQA 60
DB 1 APPRLICDSRVLYRLLEAKEAENITTCGAHCSSLNENITVPDTKVNFYAWKRMEVGQQA 60

QY 61 VEVWQGLALLSEAVLRGOALLVNSSQPWEPLQLHVDKAVSGLSRLTTLRALGAQKEAIS 120
DB 61 VEVWQGLALLSEAVLRGOALLVNSSQPWEPLQLHVDKAVSGLSRLTTLRALGAQKEAIS 120

QY 121 PPDAASAAPLRTITADTFKRLFRVYSNFLRGKCLKLYTGEACRTGD 165
DB 121 PPDAASAAPLRTITADTFKRLFRVYSNFLRGKCLKLYTGEACRTGD 165

RESULT 9

US-09-853-731-1
: Sequence 1, Application US/09853731
: GENERAL INFORMATION:
: APPLICANT: Papadimitriou, Apollon
: TITLE OF INVENTION: Erythropoietin Composition
: FILE REFERENCE: 20619 US
: CURRENT APPLICATION NUMBER: US/09/853,731
: CURRENT FILING DATE: 2001-05-11
: PRIOR APPLICATION NUMBER: EP/00110355.5
: PRIOR FILING DATE: 2000-05-15
: NUMBER OF SEQ ID NOS: 2
: SOFTWARE: PatentIn version 3.0
: SEQ ID NO 1
: LENGTH: 165
: TYPE: PRT
: ORGANISM: Homo sapiens

US-09-853-731-1

Query Match 100.0%; Score 846; DB 22; Length 165;
Best Local Similarity 100.0%; Pred. No. 1.2e-89;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APPRLICDSRVLYRLLEAKEAENITTCGAHCSSLNENITVPDTKVNFYAWKRMEVGQQA 60
DB 1 APPRLICDSRVLYRLLEAKEAENITTCGAHCSSLNENITVPDTKVNFYAWKRMEVGQQA 60

QY 61 VEVWQGLALLSEAVLRGOALLVNSSQPWEPLQLHVDKAVSGLSRLTTLRALGAQKEAIS 120
DB 61 VEVWQGLALLSEAVLRGOALLVNSSQPWEPLQLHVDKAVSGLSRLTTLRALGAQKEAIS 120

QY 121 PPDAASAAPLRTITADTFKRLFRVYSNFLRGKCLKLYTGEACRTGD 165
DB 121 PPDAASAAPLRTITADTFKRLFRVYSNFLRGKCLKLYTGEACRTGD 165

RESULT 10

US-09-854-018-1
: Sequence 1, Application US/09854018
: GENERAL INFORMATION:
: APPLICANT: Herberger, John
: TITLE OF INVENTION: Secondary Drying of Microparticles Using Pressurized Carbon Dioxide
: FILE REFERENCE: A-786
: CURRENT APPLICATION NUMBER: US/09/854,018
: CURRENT FILING DATE: 2001-05-10
: NUMBER OF SEQ ID NOS: 2
: SOFTWARE: PatentIn version 3.0
: SEQ ID NO 1
: LENGTH: 165
: TYPE: PRT
: ORGANISM: Human

US-09-854-018-1

Query Match 100.0%; Score 846; DB 22; Length 165;
Best Local Similarity 100.0%; Pred. No. 1.2e-89;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APPRLICDSRVLYRLLEAKEAENITTCGAHCSSLNENITVPDTKVNFYAWKRMEVGQQA 60
DB 1 APPRLICDSRVLYRLLEAKEAENITTCGAHCSSLNENITVPDTKVNFYAWKRMEVGQQA 60

QY 61 VEVWQGLALLSEAVLRGOALLVNSSQPWEPLQLHVDKAVSGLSRLTTLRALGAQKEAIS 120
DB 61 VEVWQGLALLSEAVLRGOALLVNSSQPWEPLQLHVDKAVSGLSRLTTLRALGAQKEAIS 120

QY 121 PPDAASAAPLRTITADTFKRLFRVYSNFLRGKCLKLYTGEACRTGD 165
DB 121 PPDAASAAPLRTITADTFKRLFRVYSNFLRGKCLKLYTGEACRTGD 165

RESULT 11

US-09-945-517-1
: Sequence 1, Application US/09945517
: GENERAL INFORMATION:
: APPLICANT: Li, Tiansheng
: APPLICANT: Chang, Byeong
: APPLICANT: Sloey, Christopher
: TITLE OF INVENTION: L-METHIONINE AS A STABILIZER FOR NESP/EPO IN HSA-FREE FORMULATIONS
: FILE REFERENCE: A-803
: CURRENT APPLICATION NUMBER: US/09/945,517
: CURRENT FILING DATE: 2001-08-30
: NUMBER OF SEQ ID NOS: 2
: SOFTWARE: PatentIn version 3.0
: SEQ ID NO 1
: LENGTH: 165
: TYPE: PRT
: ORGANISM: Homo sapiens

US-09-945-517-1

Query Match 100.0%; Score 846; DB 23; Length 165;
Best Local Similarity 100.0%; Pred. No. 1.2e-89;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APPRLICDSRVLYRLLEAKEAENITTCGAHCSSLNENITVPDTKVNFYAWKRMEVGQQA 60
DB 1 APPRLICDSRVLYRLLEAKEAENITTCGAHCSSLNENITVPDTKVNFYAWKRMEVGQQA 60

QY 61 VEVWQGLALLSEAVLRGOALLVNSSQPWEPLQLHVDKAVSGLSRLTTLRALGAQKEAIS 120
DB 61 VEVWQGLALLSEAVLRGOALLVNSSQPWEPLQLHVDKAVSGLSRLTTLRALGAQKEAIS 120

QY 121 PPDAASAAPLRTITADTFKRLFRVYSNFLRGKCLKLYTGEACRTGD 165
DB 121 PPDAASAAPLRTITADTFKRLFRVYSNFLRGKCLKLYTGEACRTGD 165

RESULT 12

US-10-014-363-1
: Sequence 1, Application US/10014363
: GENERAL INFORMATION:
: APPLICANT: Burg, Josef
: APPLICANT: Engel, Alfred
: APPLICANT: Franze, Reinhard
: APPLICANT: Hilger, Bernd
: APPLICANT: Schurig, Hartmut Ernst
: APPLICANT: Tischer, Wilhelm
: APPLICANT: Wozny, Manfred
: TITLE OF INVENTION: Erythropoietin Conjugates
: FILE REFERENCE: Case 20805
: CURRENT APPLICATION NUMBER: US/10/014,363
: CURRENT FILING DATE: 2001-12-11
: NUMBER OF SEQ ID NOS: 5
: SOFTWARE: PatentIn version 3.1
: SEQ ID NO 1
: LENGTH: 165
: TYPE: PRT
: ORGANISM: Homo sapiens

US-10-014-363-1

Query Match 100.0%; Score 846; DB 24; Length 165;

Best Local Similarity 100.0%; Pred. No. 1.2e-89;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 APPRLICDSRVLYRLLEAKAEENITTCGAHCSLNENITVPDTKVNFYAWKRMEVGQQA 60
Db 1 APPRLICDSRVLYRLLEAKAEENITTCGAHCSLNENITVPDTKVNFYAWKRMEVGQQA 60

Qy 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120
Db 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120

Qy 121 PDAASAAPLRITADTFKRLFRVYSNFLRGKLLKLYTGEACRTGD 165
Db 121 PDAASAAPLRITADTFKRLFRVYSNFLRGKLLKLYTGEACRTGD 165

RESULT 13
US-10-241-356-1
; Sequence 1, Application US/10241356
; GENERAL INFORMATION:
; APPLICANT: TISCHER, WILHELM
; TITLE OF INVENTION: DIGLYCOSYLATED ERYTHROPOIETIN
; FILE REFERENCE: 20971
; CURRENT APPLICATION NUMBER: US/10/241.356
; CURRENT FILING DATE: 2002-09-11
; PRIOR FILING DATE: EP 01122555.4
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 165
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-241-356-1

Query Match 100.0%; Score 846; DB 26; Length 165;
Best Local Similarity 100.0%; Pred. No. 1.2e-89;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 APPRLICDSRVLYRLLEAKAEENITTCGAHCSLNENITVPDTKVNFYAWKRMEVGQQA 60
Db 1 APPRLICDSRVLYRLLEAKAEENITTCGAHCSLNENITVPDTKVNFYAWKRMEVGQQA 60

Qy 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120
Db 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120

Qy 121 PDAASAAPLRITADTFKRLFRVYSNFLRGKLLKLYTGEACRTGD 165
Db 121 PDAASAAPLRITADTFKRLFRVYSNFLRGKLLKLYTGEACRTGD 165

RESULT 14
PCT-US98-14497-2
; Sequence 2, Application PC/TUS9814497
; GENERAL INFORMATION:
; APPLICANT: Cox III, George N
; APPLICANT: Bolder Biotechnology, Inc.
; TITLE OF INVENTION: Derivatives of Growth Hormone and Related Proteins
; FILE REFERENCE: BB0011
; CURRENT APPLICATION NUMBER: PCT/US98/14497
; CURRENT FILING DATE: 1998-07-13
; EARLIER APPLICATION NUMBER: 60/052.516
; EARLIER FILING DATE: 1997-07-14
; NUMBER OF SEQ ID NOS: 41
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 166
; TYPE: PRT
; ORGANISM: Homo sapiens
PCT-US98-14497-2

Query Match 100.0%; Score 846; DB 1; Length 166;

Best Local Similarity 100.0%; Pred. No. 1.2e-89;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 APPRLICDSRVLYRLLEAKAEENITTCGAHCSLNENITVPDTKVNFYAWKRMEVGQQA 60
Db 1 APPRLICDSRVLYRLLEAKAEENITTCGAHCSLNENITVPDTKVNFYAWKRMEVGQQA 60

Qy 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120
Db 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120

Qy 121 PDAASAAPLRITADTFKRLFRVYSNFLRGKLLKLYTGEACRTGD 165
Db 121 PDAASAAPLRITADTFKRLFRVYSNFLRGKLLKLYTGEACRTGD 165

RESULT 15
US-07-766-964A-3
; Sequence 3, Application US/07766964A
; GENERAL INFORMATION:
; APPLICANT: Rosen, Jonathan I.
; TITLE OF INVENTION: HYBRID GROWTH FACTORS
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Robert L. Minier
; STREET: 1 Johnson & Johnson Plaza
; CITY: New Brunswick
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 08933
; COMPUTER READABLE FORM: disk
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/766,964A
; FILING DATE: 19910926
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/589,958
; FILING DATE: 28-SEP-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Stark, Michael
; REGISTRATION NUMBER: 32,495
; REFERENCE/DOCKET NUMBER: BCI-15
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 908-524-2817
; TELEFAX: 908-524-2808
; TELEX: 844-481
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 166 amino acids
; TYPE: AMINO ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-07-766-964A-3

Query Match 100.0%; Score 846; DB 3; Length 166;
Best Local Similarity 100.0%; Pred. No. 1.2e-89;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 APPRLICDSRVLYRLLEAKAEENITTCGAHCSLNENITVPDTKVNFYAWKRMEVGQQA 60
Db 1 APPRLICDSRVLYRLLEAKAEENITTCGAHCSLNENITVPDTKVNFYAWKRMEVGQQA 60

Qy 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120
Db 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: June 13, 2003, 15:03:51 ; Search time 108 seconds
(without alignments)
389.731 Million cell updates/sec

Title: US-09-830-964-1

Perfect score: 846

Sequence: 1 APRLLCDSRVLYLLEAK.....SNFLRGKLYTGACRTGD 165

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1155225 seqs, 255096386 residues

Total number of hits satisfying chosen parameters: 1155225

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Pending_Patents_AA_New: *
1: /cgn2_6/ptodata/1/paa/PCT_NEW_COMB.pep: *
2: /cgn2_6/ptodata/1/paa/US06_NEW_COMB.pep: *
3: /cgn2_6/ptodata/1/paa/US07_NEW_COMB.pep: *
4: /cgn2_6/ptodata/1/paa/US08_NEW_COMB.pep: *
5: /cgn2_6/ptodata/1/paa/US09_NEW_COMB.pep: *
6: /cgn2_6/ptodata/1/paa/US10_NEW_COMB.pep: *
7: /cgn2_6/ptodata/1/paa/US10_NEW_COMB.pep: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match % | Length | DB ID | Description |
|------------|-------|---------------|--------|-------|---------------------|
| 1 | 846 | 100.0 | 165 | 5 | US-09-687-981-1 |
| 2 | 846 | 100.0 | 165 | 6 | US-10-293-551-1 |
| 3 | 846 | 100.0 | 165 | 6 | US-10-411-012-73 |
| 4 | 846 | 100.0 | 165 | 6 | US-10-411-026-73 |
| 5 | 846 | 100.0 | 165 | 6 | US-10-410-930-73 |
| 6 | 846 | 100.0 | 165 | 6 | US-10-410-945-73 |
| 7 | 846 | 100.0 | 165 | 6 | US-10-410-962-73 |
| 8 | 846 | 100.0 | 165 | 6 | US-10-410-980-73 |
| 9 | 846 | 100.0 | 165 | 6 | US-10-411-044-73 |
| 10 | 846 | 100.0 | 165 | 6 | US-10-411-049-73 |
| 11 | 846 | 100.0 | 165 | 6 | US-10-410-913-73 |
| 12 | 846 | 100.0 | 165 | 6 | US-10-411-037-73 |
| 13 | 846 | 100.0 | 165 | 6 | US-10-411-043-73 |
| 14 | 846 | 100.0 | 165 | 6 | US-10-410-897-73 |
| 15 | 846 | 100.0 | 165 | 6 | US-10-410-997-73 |
| 16 | 846 | 100.0 | 166 | 5 | US-09-708-506A-2 |
| 17 | 846 | 100.0 | 166 | 6 | US-10-293-551-2 |
| 18 | 846 | 100.0 | 166 | 6 | US-10-298-148-2 |
| 19 | 846 | 100.0 | 166 | 6 | US-10-400-377-2 |
| 20 | 846 | 100.0 | 166 | 6 | US-10-400-708-2 |
| 21 | 846 | 100.0 | 166 | 6 | US-10-360-101-227 |
| 22 | 846 | 100.0 | 192 | 1 | PCT-US02-40891-593 |
| 23 | 846 | 100.0 | 192 | 1 | PCT-US02-40891-594 |
| 24 | 846 | 100.0 | 192 | 1 | PCT-US02-40891-603 |
| 25 | 846 | 100.0 | 192 | 1 | PCT-US02-40891-1689 |
| 26 | 846 | 100.0 | 192 | 1 | PCT-US02-40891-1690 |

27 846 100.0 192 1 PCT-US02-40891-1691
28 846 100.0 192 1 PCT-US02-40891-1828
29 846 100.0 192 1 PCT-US02-40891-1829
30 846 100.0 192 1 PCT-US02-40891-1830
31 846 100.0 193 5 US-09-728-403B-1
32 846 100.0 193 5 US-09-723-955-1
33 846 100.0 193 7 US-60-455-444-5994
34 846 100.0 193 7 US-60-465-241-5994
35 846 100.0 209 6 US-10-230-454-4
36 846 100.0 370 6 US-10-230-454-3
37 846 100.0 428 1 PCT-US03-14428-10
38 846 100.0 428 6 US-10-435-608-10
39 846 100.0 435 5 US-09-932-812A-22
40 846 100.0 436 5 US-09-932-812A-18
41 846 100.0 437 5 US-09-932-812A-20
42 846 100.0 768 1 PCT-US02-40891-1521
43 846 100.0 768 1 PCT-US02-40891-1522
44 846 100.0 768 1 PCT-US02-40891-1523
45 846 100.0 768 1 PCT-US02-40891-1660

ALIGNMENTS

RESULT 1
US-09-687-981-1
; Sequence 1, Application US/09687981
; GENERAL INFORMATION:
; APPLICANT: Burke, Paul
; APPLICANT: Klumb, Lisa
; APPLICANT: Murphy, Keith
; APPLICANT: Herberger, John
; APPLICANT: French, Donna
; TITLE OF INVENTION: BIODEGRADABLE MICROPARTICLES FOR THE SUSTAINED DELIVERY OF NOV
; TITLE OF INVENTION: ERYTHROPOIETIN STIMULATING PROTEIN
; FILE REFERENCE: A-626A
; CURRENT APPLICATION NUMBER: US/09/687,981
; CURRENT FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: 09/426,566
; PRIOR FILING DATE: 1999-10-22
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 165
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-687-981-1

Query Match 100.0%; Score 846; DB 5; Length 165;
Best Local Similarity 100.0%; Pred. No. 7.2e-78;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APRLLCDSRVLYLLEAKENITTCACBHCNLNENITVPTKVNFKYANKRMEVGQQA 60
|||||
Db 1 APRLLCDSRVLYLLEAKENITTCACBHCNLNENITVPTKVNFKYANKRMEVGQQA 60
|||||

QY 61 VEWGGLALLSEAVLRGQALLVNSQPWEPLQHLVDKAVSGRLSLTTLRALGAQKEATS 120
|||||
Db 61 VEWGGLALLSEAVLRGQALLVNSQPWEPLQHLVDKAVSGRLSLTTLRALGAQKEATS 120
|||||

QY 121 PDAASAAPLRTITADTFKRLFRVYSNFLRGKLYTGACRTGD 165
|||||
Db 121 PDAASAAPLRTITADTFKRLFRVYSNFLRGKLYTGACRTGD 165
|||||

RESULT 2
US-10-293-551-1
; Sequence 1, Application US/10293551
; GENERAL INFORMATION:
; APPLICANT: Bailon, Pascal
; TITLE OF INVENTION: ERYTHROPOIETIN CONJUGATES
; FILE REFERENCE: 1097 nonprovisional
; CURRENT APPLICATION NUMBER: US/10/293,551

```

; CURRENT FILING DATE: 2002-11-14
; PRIOR APPLICATION NUMBER: US/09/604,938
; PRIOR FILING DATE: 2000-06-27
; PRIOR APPLICATION NUMBER: 60/166,151
; PRIOR FILING DATE: 1999-11-17
; PRIOR APPLICATION NUMBER: 60/151,548
; PRIOR FILING DATE: 1999-08-13
; PRIOR APPLICATION NUMBER: 60/150,225
; PRIOR FILING DATE: 1999-08-23
; PRIOR APPLICATION NUMBER: 60/142,254
; PRIOR FILING DATE: 1999-07-02
; NUMBER OF SEQ ID NOS: 3
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 165
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-293-551-1

```

```

Query Match      100.0%; Score 846; DB 6; Length 165;
Best Local Similarity 100.0%; Pred. No. 7.2e-78;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APPRLICDSRVLELYLLEAKAEENITTCGAHCSSLNENITVPDTKVNFYAWKRMEVGQQA 60
    |||||||
DB 1 APPRLICDSRVLELYLLEAKAEENITTCGAHCSSLNENITVPDTKVNFYAWKRMEVGQQA 60
    |||||||
QY 61 VEWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLSRLTLLRALGAOKEAIS 120
    |||||||
DB 61 VEWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLSRLTLLRALGAOKEAIS 120
    |||||||
QY 121 PDAASAAPLRTITADTFKFLFRVYSNLFRLGKLYTGEACRTGD 165
    |||||||
DB 121 PDAASAAPLRTITADTFKFLFRVYSNLFRLGKLYTGEACRTGD 165
    |||||||

```

```

RESULT 3
US-10-411-012-73
; Sequence 73, Application US/10411012
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryne
; TITLE OF INVENTION: GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; FILE REFERENCE: 040853-01-5051
; CURRENT APPLICATION NUMBER: US/10/411,012
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 73
; LENGTH: 165
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-411-012-73

```

```

Query Match      100.0%; Score 846; DB 6; Length 165;
Best Local Similarity 100.0%; Pred. No. 7.2e-78;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APPRLICDSRVLELYLLEAKAEENITTCGAHCSSLNENITVPDTKVNFYAWKRMEVGQQA 60
    |||||||
DB 1 APPRLICDSRVLELYLLEAKAEENITTCGAHCSSLNENITVPDTKVNFYAWKRMEVGQQA 60
    |||||||
QY 61 VEWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLSRLTLLRALGAOKEAIS 120
    |||||||
DB 61 VEWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLSRLTLLRALGAOKEAIS 120
    |||||||
QY 121 PDAASAAPLRTITADTFKFLFRVYSNLFRLGKLYTGEACRTGD 165
    |||||||
DB 121 PDAASAAPLRTITADTFKFLFRVYSNLFRLGKLYTGEACRTGD 165
    |||||||

```

```

RESULT 4
US-10-411-026-73
; Sequence 73, Application US/10411026
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; TITLE OF INVENTION: PROTEIN REMODELING METHODS AND PROTEINS/PEPTIDES PRODUCED BY T
; FILE REFERENCE: 040853-01-5053
; CURRENT APPLICATION NUMBER: US/10/411,026
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 73
; LENGTH: 165
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-411-026-73

```

```

Query Match      100.0%; Score 846; DB 6; Length 165;
Best Local Similarity 100.0%; Pred. No. 7.2e-78;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APPRLICDSRVLELYLLEAKAEENITTCGAHCSSLNENITVPDTKVNFYAWKRMEVGQQA 60
    |||||||
DB 1 APPRLICDSRVLELYLLEAKAEENITTCGAHCSSLNENITVPDTKVNFYAWKRMEVGQQA 60
    |||||||
QY 61 VEWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLSRLTLLRALGAOKEAIS 120
    |||||||
DB 61 VEWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLSRLTLLRALGAOKEAIS 120
    |||||||
QY 121 PDAASAAPLRTITADTFKFLFRVYSNLFRLGKLYTGEACRTGD 165
    |||||||
DB 121 PDAASAAPLRTITADTFKFLFRVYSNLFRLGKLYTGEACRTGD 165
    |||||||

```

RESULT 5

US-10-410-930-73
: Sequence 73, Application US/10410930
: GENERAL INFORMATION:
: APPLICANT: Neose Technologies, Inc.
: APPLICANT: DeFrees, Shawn
: APPLICANT: Zopf, David
: APPLICANT: Bayer, Robert
: APPLICANT: Hakes, David
: APPLICANT: Chen, Xi
: APPLICANT: Bowe, Caryn
: TITLE OF INVENTION: INTERFERON BETA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
: FILE REFERENCE: 040853-01-5056
: CURRENT FILING DATE: 2003-04-09
: PRIOR FILING DATE: 2003-04-09
: PRIOR APPLICATION NUMBER: US 60/328,523
: PRIOR FILING DATE: 2001-10-10
: PRIOR APPLICATION NUMBER: US 60/344,692
: PRIOR FILING DATE: 2001-10-19
: PRIOR APPLICATION NUMBER: US 60/387,292
: PRIOR FILING DATE: 2002-06-07
: PRIOR APPLICATION NUMBER: US 60/391,777
: PRIOR FILING DATE: 2002-06-25
: PRIOR APPLICATION NUMBER: US 60/396,594
: PRIOR FILING DATE: 2002-07-17
: PRIOR APPLICATION NUMBER: US 60/404,249
: PRIOR FILING DATE: 2002-08-16
: PRIOR APPLICATION NUMBER: US 60/407,527
: NUMBER OF SEQ ID NOS: 75
: SOFTWARE: Patentin version 3.2
: SEQ ID NO 73
: LENGTH: 165
: TYPE: PRT
: ORGANISM: Homo sapiens
US-10-410-930-73

Query Match 100.0%; Score 846; DB 6; Length 165;
Best Local Similarity 100.0%; Pred. No. 7.2e-78;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 APPLICDSRVLYRLLEAKEAENITTCGAHCSLNENITVPDTKVNFWAKRMEVGOQA 60
Db 1 APPLICDSRVLYRLLEAKEAENITTCGAHCSLNENITVPDTKVNFWAKRMEVGOQA 60

Qy 61 VEVWQGLALLSEAVLRQALLVNSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKEAIS 120
Db 61 VEVWQGLALLSEAVLRQALLVNSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKEAIS 120

Qy 121 PPDAASAAPLRTITADTFKRLFRVYSNFLRGKLYTGEACRTGD 165
Db 121 PPDAASAAPLRTITADTFKRLFRVYSNFLRGKLYTGEACRTGD 165

RESULT 6
US-10-410-945-73
: Sequence 73, Application US/10410945
: GENERAL INFORMATION:
: APPLICANT: Neose Technologies, Inc.
: APPLICANT: DeFrees, Shawn
: APPLICANT: Zopf, David
: APPLICANT: Bayer, Robert
: APPLICANT: Hakes, David
: APPLICANT: Chen, Xi
: APPLICANT: Bowe, Caryn
: TITLE OF INVENTION: ERYTHROPOIETIN: REMODELING AND GLYCOCONJUGATION OF ERYTHROPOIETIN
: FILE REFERENCE: 040853-01-5083
: CURRENT FILING DATE: 2003-04-09
: PRIOR FILING DATE: 2003-04-09
: PRIOR APPLICATION NUMBER: US 60/328,523
: PRIOR FILING DATE: 2001-10-10
: PRIOR APPLICATION NUMBER: US 60/344,692
: PRIOR FILING DATE: 2001-10-19

US-10-410-962-73
: Sequence 73, Application US/10410962
: GENERAL INFORMATION:
: APPLICANT: Neose Technologies, Inc.
: APPLICANT: DeFrees, Shawn
: APPLICANT: Zopf, David
: APPLICANT: Bayer, Robert
: APPLICANT: Hakes, David
: APPLICANT: Chen, Xi
: APPLICANT: Bowe, Caryn
: TITLE OF INVENTION: GRANULOCYTE COLONY STIMULATING FACTOR: REMODELING AND
: FILE REFERENCE: 040853-01-5054
: CURRENT FILING DATE: 2003-04-09
: PRIOR FILING DATE: 2003-04-09
: PRIOR APPLICATION NUMBER: US 60/328,523
: PRIOR FILING DATE: 2001-10-10
: PRIOR APPLICATION NUMBER: US 60/344,692
: PRIOR FILING DATE: 2001-10-19
: PRIOR APPLICATION NUMBER: US 60/387,292
: PRIOR FILING DATE: 2002-06-07
: PRIOR APPLICATION NUMBER: US 60/391,777
: PRIOR FILING DATE: 2002-06-25
: PRIOR APPLICATION NUMBER: US 60/396,594
: PRIOR FILING DATE: 2002-07-17
: PRIOR APPLICATION NUMBER: US 60/404,249
: PRIOR FILING DATE: 2002-08-16
: PRIOR APPLICATION NUMBER: US 60/407,527
: NUMBER OF SEQ ID NOS: 75
: SOFTWARE: Patentin version 3.2
: SEQ ID NO 73
: LENGTH: 165
: TYPE: PRT
: ORGANISM: Homo sapiens
US-10-410-962-73

Query Match 100.0%; Score 846; DB 6; Length 165;
Best Local Similarity 100.0%; Pred. No. 7.2e-78;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 APPLICDSRVLYRLLEAKEAENITTCGAHCSLNENITVPDTKVNFWAKRMEVGOQA 60
Db 1 APPLICDSRVLYRLLEAKEAENITTCGAHCSLNENITVPDTKVNFWAKRMEVGOQA 60

Qy 61 VEVWQGLALLSEAVLRQALLVNSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKEAIS 120
Db 61 VEVWQGLALLSEAVLRQALLVNSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKEAIS 120

Qy 121 PPDAASAAPLRTITADTFKRLFRVYSNFLRGKLYTGEACRTGD 165
Db 121 PPDAASAAPLRTITADTFKRLFRVYSNFLRGKLYTGEACRTGD 165

RESULT 7
US-10-410-962-73
: Sequence 73, Application US/10410962
: GENERAL INFORMATION:
: APPLICANT: Neose Technologies, Inc.
: APPLICANT: DeFrees, Shawn
: APPLICANT: Zopf, David
: APPLICANT: Bayer, Robert
: APPLICANT: Hakes, David
: APPLICANT: Chen, Xi
: APPLICANT: Bowe, Caryn
: TITLE OF INVENTION: GRANULOCYTE COLONY STIMULATING FACTOR: REMODELING AND
: FILE REFERENCE: 040853-01-5054
: CURRENT FILING DATE: 2003-04-09
: PRIOR FILING DATE: 2003-04-09
: PRIOR APPLICATION NUMBER: US 60/328,523
: PRIOR FILING DATE: 2001-10-10
: PRIOR APPLICATION NUMBER: US 60/344,692
: PRIOR FILING DATE: 2001-10-19
: PRIOR APPLICATION NUMBER: US 60/387,292
: PRIOR FILING DATE: 2002-06-07
: PRIOR APPLICATION NUMBER: US 60/391,777
: PRIOR FILING DATE: 2002-06-25
: PRIOR APPLICATION NUMBER: US 60/396,594
: PRIOR FILING DATE: 2002-07-17
: PRIOR APPLICATION NUMBER: US 60/404,249
: PRIOR FILING DATE: 2002-08-16
: PRIOR APPLICATION NUMBER: US 60/407,527
: NUMBER OF SEQ ID NOS: 75
: SOFTWARE: Patentin version 3.2
: SEQ ID NO 73
: LENGTH: 165
: TYPE: PRT
: ORGANISM: Homo sapiens
US-10-410-962-73

Query Match 100.0%; Score 846; DB 6; Length 165;
 Best Local Similarity 100.0%; Pred. No. 7.2e-78;
 Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 APRPLICDSRVLYLLEAKEAENITTCGAHCSLNENITVPDTKVNFYAKRMVEVGQA 60
 Db 1 APRPLICDSRVLYLLEAKEAENITTCGAHCSLNENITVPDTKVNFYAKRMVEVGQA 60

Qy 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKEAIS 120
 Db 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKEAIS 120

Qy 121 PPDAASAAPLRTITADTKFRKLVYNSFLRGKLLKLYTGEACRTGD 165
 Db 121 PPDAASAAPLRTITADTKFRKLVYNSFLRGKLLKLYTGEACRTGD 165

RESULT 8

US-10-410-980-73
 ; Sequence 73, Application US/10410980
 ; GENERAL INFORMATION:
 ; APPLICANT: Neose Technologies, Inc.
 ; APPLICANT: DeFrees, Shawn
 ; APPLICANT: Zopf, David
 ; APPLICANT: Bayer, Robert
 ; APPLICANT: Hakes, David
 ; APPLICANT: Chen, Xi
 ; APPLICANT: Bove, Caryn
 ; TITLE OF INVENTION: INTERLEUKIN-2: REMODELING AND GLYCOCONJUGATION OF IL-2
 ; FILE REFERENCE: 040853-01-5066
 ; CURRENT APPLICATION NUMBER: US/10/410,980
 ; CURRENT FILING DATE: 2003-04-09
 ; PRIOR APPLICATION NUMBER: US 60/328,523
 ; PRIOR FILING DATE: 2001-10-10
 ; PRIOR APPLICATION NUMBER: US 60/344,692
 ; PRIOR FILING DATE: 2001-10-19
 ; PRIOR APPLICATION NUMBER: US 60/387,292
 ; PRIOR FILING DATE: 2002-06-07
 ; PRIOR APPLICATION NUMBER: US 60/391,777
 ; PRIOR FILING DATE: 2002-06-25
 ; PRIOR APPLICATION NUMBER: US 60/396,594
 ; PRIOR FILING DATE: 2002-07-17
 ; PRIOR APPLICATION NUMBER: US 60/404,249
 ; PRIOR FILING DATE: 2002-08-16
 ; PRIOR APPLICATION NUMBER: US 60/407,527
 ; PRIOR FILING DATE: 2002-08-28
 ; NUMBER OF SEQ ID NOS: 75
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 73
 ; LENGTH: 165
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; US-10-410-980-73

Query Match 100.0%; Score 846; DB 6; Length 165;
 Best Local Similarity 100.0%; Pred. No. 7.2e-78;
 Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 APRPLICDSRVLYLLEAKEAENITTCGAHCSLNENITVPDTKVNFYAKRMVEVGQA 60
 Db 1 APRPLICDSRVLYLLEAKEAENITTCGAHCSLNENITVPDTKVNFYAKRMVEVGQA 60

Qy 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKEAIS 120
 Db 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKEAIS 120

Qy 121 PPDAASAAPLRTITADTKFRKLVYNSFLRGKLLKLYTGEACRTGD 165
 Db 121 PPDAASAAPLRTITADTKFRKLVYNSFLRGKLLKLYTGEACRTGD 165

RESULT 9

US-10-411-044-73

; Sequence 73, Application US/10411044
 ; GENERAL INFORMATION:
 ; APPLICANT: Neose Technologies, Inc.
 ; APPLICANT: DeFrees, Shawn
 ; APPLICANT: Zopf, David
 ; APPLICANT: Bayer, Robert
 ; APPLICANT: Hakes, David
 ; APPLICANT: Chen, Xi
 ; APPLICANT: Bove, Caryn
 ; TITLE OF INVENTION: BETA-GLUCOSIDASE: REMODELING AND GLYCOCONJUGATION OF
 ; TITLE OF INVENTION: BETA-GLUCOSIDASE
 ; FILE REFERENCE: 040853-01-5064
 ; CURRENT APPLICATION NUMBER: US/10/411,044
 ; CURRENT FILING DATE: 2003-04-09
 ; PRIOR APPLICATION NUMBER: US 60/328,523
 ; PRIOR FILING DATE: 2001-10-10
 ; PRIOR APPLICATION NUMBER: US 60/344,692
 ; PRIOR FILING DATE: 2001-10-19
 ; PRIOR APPLICATION NUMBER: US 60/387,292
 ; PRIOR FILING DATE: 2002-06-07
 ; PRIOR APPLICATION NUMBER: US 60/391,777
 ; PRIOR FILING DATE: 2002-06-25
 ; PRIOR APPLICATION NUMBER: US 60/396,594
 ; PRIOR FILING DATE: 2002-07-17
 ; PRIOR APPLICATION NUMBER: US 60/404,249
 ; PRIOR FILING DATE: 2002-08-16
 ; PRIOR APPLICATION NUMBER: US 60/407,527
 ; PRIOR FILING DATE: 2002-08-28
 ; NUMBER OF SEQ ID NOS: 75
 ; SOFTWARE: PatentIn version 3.2
 ; SEQ ID NO 73
 ; LENGTH: 165
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; US-10-411-044-73

Query Match 100.0%; Score 846; DB 6; Length 165;
 Best Local Similarity 100.0%; Pred. No. 7.2e-78;
 Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 APRPLICDSRVLYLLEAKEAENITTCGAHCSLNENITVPDTKVNFYAKRMVEVGQA 60
 Db 1 APRPLICDSRVLYLLEAKEAENITTCGAHCSLNENITVPDTKVNFYAKRMVEVGQA 60

Qy 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKEAIS 120
 Db 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKEAIS 120

Qy 121 PPDAASAAPLRTITADTKFRKLVYNSFLRGKLLKLYTGEACRTGD 165
 Db 121 PPDAASAAPLRTITADTKFRKLVYNSFLRGKLLKLYTGEACRTGD 165

RESULT 10

US-10-411-049-73
 ; Sequence 73, Application US/10411049
 ; GENERAL INFORMATION:
 ; APPLICANT: Neose Technologies, Inc.
 ; APPLICANT: DeFrees, Shawn
 ; APPLICANT: Zopf, David
 ; APPLICANT: Bayer, Robert
 ; APPLICANT: Hakes, David
 ; APPLICANT: Chen, Xi
 ; APPLICANT: Bove, Caryn
 ; TITLE OF INVENTION: INTERFERON ALPHA: REMODELING AND GLYCOCONJUGATION OF INTERFERO
 ; TITLE OF INVENTION: ALPHA
 ; FILE REFERENCE: 040853-01-5055
 ; CURRENT APPLICATION NUMBER: US/10/411,049
 ; CURRENT FILING DATE: 2003-04-09
 ; PRIOR APPLICATION NUMBER: US 60/328,523
 ; PRIOR FILING DATE: 2001-10-10
 ; PRIOR APPLICATION NUMBER: US 60/344,692
 ; PRIOR FILING DATE: 2001-10-19

```

; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 73
; LENGTH: 165
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-411-049-73

Query Match      100.0%; Score 846; DB 6; Length 165;
Best Local Similarity 100.0%; Pred. No. 7.2e-78;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APPLICDSRVLELYLLEAKEAENITTCGAHCSLNENITVPDTKVNFKYAWKMEVGGQA 60
DB 1 APPLICDSRVLELYLLEAKEAENITTCGAHCSLNENITVPDTKVNFKYAWKMEVGGQA 60
QY 61 VEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLSRLTTLRALGAQKEAIS 120
DB 61 VEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLSRLTTLRALGAQKEAIS 120
QY 121 PPDAASAAPLRTITADTFRKLFVYSNLFGRGKLKLYTGEACRTGD 165
DB 121 PPDAASAAPLRTITADTFRKLFVYSNLFGRGKLKLYTGEACRTGD 165

RESULT 11
US-10-410-913-73
; Sequence 73, Application US/10410913
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: GLYCOCONJUGATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; FILE REFERENCE: 040853-01-5081
; CURRENT APPLICATION NUMBER: US/10/410,913
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 73
; LENGTH: 165
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-410-913-73

```

```

Query Match      100.0%; Score 846; DB 6; Length 165;
Best Local Similarity 100.0%; Pred. No. 7.2e-78;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APPLICDSRVLELYLLEAKEAENITTCGAHCSLNENITVPDTKVNFKYAWKMEVGGQA 60
DB 1 APPLICDSRVLELYLLEAKEAENITTCGAHCSLNENITVPDTKVNFKYAWKMEVGGQA 60
QY 61 VEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLSRLTTLRALGAQKEAIS 120
DB 61 VEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLSRLTTLRALGAQKEAIS 120
QY 121 PPDAASAAPLRTITADTFRKLFVYSNLFGRGKLKLYTGEACRTGD 165
DB 121 PPDAASAAPLRTITADTFRKLFVYSNLFGRGKLKLYTGEACRTGD 165

RESULT 12
US-10-411-037-73
; Sequence 73, Application US/10411037
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: ALPHA GALACTOSIDASE A: REMODELING AND GLYCOCONJUGATION OF ALPH
; FILE REFERENCE: 040853-01-5082
; CURRENT APPLICATION NUMBER: US/10/411,037
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 73
; LENGTH: 165
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-411-037-73

Query Match      100.0%; Score 846; DB 6; Length 165;
Best Local Similarity 100.0%; Pred. No. 7.2e-78;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APPLICDSRVLELYLLEAKEAENITTCGAHCSLNENITVPDTKVNFKYAWKMEVGGQA 60
DB 1 APPLICDSRVLELYLLEAKEAENITTCGAHCSLNENITVPDTKVNFKYAWKMEVGGQA 60
QY 61 VEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLSRLTTLRALGAQKEAIS 120
DB 61 VEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLSRLTTLRALGAQKEAIS 120
QY 121 PPDAASAAPLRTITADTFRKLFVYSNLFGRGKLKLYTGEACRTGD 165
DB 121 PPDAASAAPLRTITADTFRKLFVYSNLFGRGKLKLYTGEACRTGD 165

RESULT 13

```

US-10-411-043-73
; Sequence 73, Application US/10411043
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: ANTI-TUMOR NECROSIS ALPHA: REMODELING AND GLYCOCONJUGATION OF
; TITLE OF INVENTION: ANTI-TUMOR NECROSIS FACTOR ALPHA
; FILE REFERENCE: 040853-01-5075
; CURRENT APPLICATION NUMBER: US/10/411,043
; PRIOR FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 73
; LENGTH: 165
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-411-043-73

Query Match 100.0%; Score 846; DB 6; Length 165;
Best Local Similarity 100.0%; Pred. No. 7.2e-78;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 APRLLCDSRVRLERYLLEAKEAENITTCGAHCNSLNENITVPDTKVNFKYAKRMEVGQQA 60
Db 1 APRLLCDSRVRLERYLLEAKEAENITTCGAHCNSLNENITVPDTKVNFKYAKRMEVGQQA 60
QY 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120
Db 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120
QY 121 PPDAASAAPLRTITADTFKRLFRVYSNLFRLGKLYTGEACRTGD 165
Db 121 PPDAASAAPLRTITADTFKRLFRVYSNLFRLGKLYTGEACRTGD 165

RESULT 14
US-10-410-997-73
; Sequence 73, Application US/10410897
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: FACTOR IX: REMODELING AND GLYCOCONJUGATION OF FACTOR IX
; FILE REFERENCE: 040853-01-5058
; CURRENT APPLICATION NUMBER: US/10/410,897
; PRIOR FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19

; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 73
; LENGTH: 165
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-410-997-73

Query Match 100.0%; Score 846; DB 6; Length 165;
Best Local Similarity 100.0%; Pred. No. 7.2e-78;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 APRLLCDSRVRLERYLLEAKEAENITTCGAHCNSLNENITVPDTKVNFKYAKRMEVGQQA 60
Db 1 APRLLCDSRVRLERYLLEAKEAENITTCGAHCNSLNENITVPDTKVNFKYAKRMEVGQQA 60
QY 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120
Db 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120
QY 121 PPDAASAAPLRTITADTFKRLFRVYSNLFRLGKLYTGEACRTGD 165
Db 121 PPDAASAAPLRTITADTFKRLFRVYSNLFRLGKLYTGEACRTGD 165

RESULT 15
US-10-410-997-73
; Sequence 73, Application US/10410997
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: FOLLICLE STIMULATING HORMONE: REMODELING AND GLYCOCONJUGATION
; FILE REFERENCE: 040853-01-5059
; CURRENT APPLICATION NUMBER: US/10/410,997
; PRIOR FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 73
; LENGTH: 165
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-410-997-73

Query Match 100.0%; Score 846; DB 6; Length 165;
Best Local Similarity 100.0%; Pred. NO. 7.2e-78;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

| | | | |
|----|-----|--|-----|
| QY | 1 | APPRICDSRVLERYLLLEAKEAENITTCGAHCSLNENITVPDTKVNIFYAKKRMEVGQQA | 60 |
| Db | 1 | APPRICDSRVLERYLLLEAKEAENITTCGAHCSLNENITVPDTKVNIFYAKKRMEVGQQA | 60 |
| QY | 61 | VEVMOGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKEAIS | 120 |
| Db | 61 | VEVMOGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTLLRALGAQKEAIS | 120 |
| QY | 121 | PPDAASAAPLRTITADTFKLFVYSNFLRGKCLKYTGEACRTGD | 165 |
| Db | 121 | PPDAASAAPLRTITADTFKLFVYSNFLRGKCLKYTGEACRTGD | 165 |

Search completed: June 13, 2003, 15:12:17
Job time : 109 secs

GenCore version 5.1.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: June 13, 2003, 15:03:00 ; Search time 24 seconds
(without alignments)
660.924 Million cell updates/sec

Title: US-09-830-964-1

Perfect score: 846

Sequence: 1 APPRLICDSRVLELYLEAK.....SNFLRGKLYTGEACRTGD 165

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283224 seqs, 96134422 residues

Total number of hits satisfying chosen parameters: 283224

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

PIR_73:.*
1: pir1:.*
2: pir2:.*
3: pir3:.*
4: pir4:.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | ID | Description |
|------------|-------|-------------|--------|----------|--------------------|
| 1 | 846 | 100.0 | 193 | 1 ZUHU | erythropoietin pre |
| 2 | 764.5 | 90.4 | 192 | 1 JQ0173 | erythropoietin pre |
| 3 | 759.5 | 89.8 | 192 | 1 I84613 | erythropoietin pre |
| 4 | 713 | 84.3 | 188 | 1 I46083 | erythropoietin pre |
| 5 | 701 | 82.9 | 192 | 1 S28148 | erythropoietin pre |
| 6 | 685.5 | 81.0 | 194 | 1 I46401 | erythropoietin pre |
| 7 | 681 | 80.5 | 192 | 1 A24902 | erythropoietin pre |
| 8 | 680.5 | 80.4 | 195 | 2 JC7699 | erythropoietin - r |
| 9 | 678 | 80.1 | 190 | 2 I46578 | erythropoietin - p |
| 10 | 638 | 75.4 | 175 | 2 I46199 | erythropoietin - d |
| 11 | 90 | 10.6 | 353 | 2 G02729 | erythropoietin - h |
| 12 | 89 | 10.5 | 353 | 2 I80105 | thrombopoietin pre |
| 13 | 88 | 10.4 | 323 | 2 AB0323 | ribonucleoside-dip |
| 14 | 87.5 | 10.3 | 346 | 2 AE0959 | solute binding rec |
| 15 | 86 | 10.2 | 286 | 2 A55530 | megakaryocyte grow |
| 16 | 83 | 9.8 | 286 | 2 AI0443 | probable 2-hydroxy |
| 17 | 83 | 9.8 | 239 | 2 A83274 | UDP-N-acetylpyruvo |
| 18 | 80.5 | 9.5 | 3033 | 1 GNMVJ8 | genome polyprotein |
| 19 | 79.5 | 9.4 | 1829 | 2 T35681 | probable sensory h |
| 20 | 79 | 9.3 | 480 | 2 S56639 | ribosomal protein |
| 21 | 78.5 | 9.3 | 813 | 2 AF0526 | ATP-dependent heli |
| 22 | 78.5 | 9.3 | 897 | 2 A54096 | EGF receptor subst |
| 23 | 78 | 9.2 | 348 | 2 T35450 | ABC transporter AT |
| 24 | 78 | 9.2 | 455 | 2 H97693 | methylamine utiliz |
| 25 | 78 | 9.2 | 455 | 2 AG2919 | conserved hypothet |
| 26 | 78 | 9.2 | 747 | 1 S36741 | probable copper-tr |
| 27 | 77.5 | 9.2 | 242 | 2 AD1928 | hypothetical prote |
| 28 | 77 | 9.1 | 451 | 2 S75569 | hypothetical prote |
| 29 | 76.5 | 9.0 | 154 | 2 H82810 | bacterioferritin x |

RESULT 1

ZUHU

erythropoietin precursor [validated] - human

C:Species: Homo sapiens (man)

C>Date: 27-Nov-1985 #sequence_revision 27-Nov-1985 #text_change 08-Dec-2000

C:Accession: A01855; A24744; A25384; A25210; S56178

R:Jacobs, K.; Shoemaker, C.; Rudersdorf, R.; Neill, S.D.; Kaufman, R.J.; Mufson, A.;

Nature 313, 806-810, 1985

A>Title: Isolation and characterization of genomic and cDNA clones of human erythropo

A:Reference number: A01855; MUID:85137899; PMID:3838366

A:Accession: A01855

A:Molecule type: mRNA; DNA

A:Residues: 1-193 <JAC>

A:Cross-references: GB:X02157; GB:X02158

R:Lin, F.K.; Suggs, S.; Lin, C.H.; Browne, J.K.; Smalling, R.; Egrie, J.C.; Chen, K.K

Proc. Natl. Acad. Sci. U.S.A. 82, 7580-7584, 1985

A>Title: Cloning and expression of the human erythropoietin gene.

A:Reference number: A24744; MUID:86067948; PMID:3865178

A:Accession: A24744

A:Molecule type: DNA

A:Residues: 1-193 <LIN>

A:Cross-references: GB:M11319; MUID:9182197; PIDN:AAA52400.1; PID:g182198

R:Lai, P.H.; Everett, R.; Wang, F.F.; Arakawa, T.; Goldwasser, E.

J. Biol. Chem. 261, 3116-3121, 1986

A>Title: Structural characterization of human erythropoietin.

A:Reference number: A25384; MUID:86140080; PMID:3949763

A:Accession: A25384

A:Molecule type: protein

A:Residues: 28-86, 'Q', 87-193 <LAI>

A:Experimental source: urine

A>Note: forms without the carboxyl-terminal residue and the four carboxyl-terminal re

R:Yanagawa, S.; Hirade, K.; Ohnata, H.; Sasaki, R.; Chiba, H.; Ueda, M.; Goto, M.

J. Biol. Chem. 259, 2707-2710, 1984

A>Title: Isolation of human erythropoietin with monoclonal antibodies.

A:Reference number: A22210; MUID:84135751; PMID:6698989

A:Accession: A22210

A:Molecule type: protein

A:Residues: 28-29, 'X', 31-33, 'L', 35-50, 'X', 52-53, 'D', 55, 'G', 57 <YAN>

R:Matsumoto, S.; Ikura, K.; Ueda, M.; Sasaki, R.

Plant Mol. Biol. 27, 1163-1172, 1995

A>Title: Characterization of a human glycoprotein (erythropoietin) produced in cultur

A:Reference number: S56178; MUID:95284365; PMID:7766897

A:Accession: S56178

A:Molecule type: protein

A:Residues: 28-33, 'X', 35-37 <WTS>

C:Comment: Erythropoietin is produced by kidney or liver of adult mammals and by live

C:Genetics:

A:Gene: GDB:EPO

A:Cross-references: GDB:119110; OMIM:133170

A:Map position: 7q21.3-7q22.1

A:introns: 5/1; 53/3; 82/3; 142/3

C:Function:

mandelate racemase
hypothetical prote
conserved hypothet
rLS beta (AF305057
ATP-dependent heli
RF2 protein - saim
thrombopoietin pre
ribonucleoside-dip
probable transport
hypothetical prote
GCN5 protein - hum
vacB protein XF198
WD-repeat family p
PSE1 protein - yea
NADH2 dehydrogenas
precorrin-6y C5,15

ALIGNMENTS

A:Description: the primary inducer of erythrocyte formation
 C:Superfamily: erythropoietin
 C:Keywords: erythropoiesis; glycoprotein; hormone; kidney; liver
 F:1-27/Domain: signal sequence #status predicted <SIG>
 F:28-193/Product: erythropoietin #status experimental <MAT>
 F:34-188/Disulfide bonds: #status experimental
 F:51,65,110/Binding site: carbohydrate (Asn) (covalent) #status experimental
 F:153/Binding site: carbohydrate (Ser) (covalent) #status experimental

Query Match 100.08; Score 846; DB 1; Length 193;
 Best Local Similarity 100.08; Pred. No. 1.8e-74;
 Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 APPRLICDSRVLYLLEAKEAENITTCGAHCSLNENITVPDTKVNFKYAKRMEVGQQA 60
 |||||
 DB 28 APPRLICDSRVLYLLEAKEAENITTCGAHCSLNENITVPDTKVNFKYAKRMEVGQQA 87
 |||||

QY 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120
 |||||
 DB 88 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 147
 |||||

QY 121 PDAASAAPLRTITADTFKFLFRVYSNLFRLGKLYTGEACRTGD 165
 |||||
 DB 148 PDAASAAPLRTITADTFKFLFRVYSNLFRLGKLYTGEACRTGD 192
 |||||

RESULT 2
 JQ0173
 erythropoietin precursor - crab-eating macaque
 C:Species: Macaca fascicularis (crab-eating macaque)
 C:Date: 07-Sep-1990 #sequence_revision 15-Nov-1996 #text_change 22-Jun-1999
 C:Accession: JQ0173
 R:Lin, F.K.; Lin, C.H.; Lai, P.H.; Browne, J.K.; Egrie, J.C.; Smalling, R.; Fox, G.M.; C
 Gene 44, 201-209; 1986
 A:Title: Monkey erythropoietin gene: cloning, expression and comparison with the human e
 A:Reference number: JQ0173; MUID:87055236; PMID:2877922
 A:Accession: JQ0173
 A:Molecule type: mRNA
 A:Residues: 1-192 <LIN>
 A:Cross-references: GB:M18189; GB:M15818; GB:M15819; GB:M18188; NID:g342093; PIDN:AAA368
 A:Experimental source: kidney
 C:Comment: This protein is the principal hormone involved in the regulation of erythrocy
 C:Function: Erythropoietin is produced by kidney or liver of adult mammals and by liver o
 C:Description: the primary inducer of erythrocyte formation
 C:Superfamily: erythropoietin
 C:Keywords: erythropoiesis; glycoprotein; hormone; kidney; liver
 F:1-27/Domain: signal sequence #status predicted <SIG>
 F:28-192/Product: erythropoietin #status predicted <MAT>
 F:34-187,56-60/Disulfide bonds: #status predicted
 F:51,65,110/Binding site: carbohydrate (Asn) (covalent) #status predicted
 F:152/Binding site: carbohydrate (Ser) (covalent) #status predicted

Query Match 90.4%; Score 764.5; DB 1; Length 192;
 Best Local Similarity 91.5%; Pred. No. 1.4e-66;
 Matches 151; Conservative 7; Mismatches 6; Indels 1; Gaps 1;

QY 1 APPRLICDSRVLYLLEAKEAENITTCGAHCSLNENITVPDTKVNFKYAKRMEVGQQA 60
 |||||
 DB 28 APPRLICDSRVLYLLEAKEAENITTCGAHCSLNENITVPDTKVNFKYAKRMEVGQQA 87
 |||||

QY 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120
 |||||
 DB 88 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 146
 |||||

QY 121 PDAASAAPLRTITADTFKFLFRVYSNLFRLGKLYTGEACRTGD 165
 |||||
 DB 147 LPDAASAAPLRTITADTFKFLFRVYSNLFRLGKLYTGEACRTGD 191
 |||||

RESULT 3
 I84613
 erythropoietin precursor - rhesus macaque

C:Species: Macaca mulatta (rhesus macaque)
 C:Date: 02-Aug-1996 #sequence_revision 15-Nov-1996 #text_change 22-Jun-1999
 C:Accession: I84613
 R:Wen, D.; Boissel, J.
 Blood 82, 1507-1516, 1993
 A:Title: Erythropoietin structure-function relationships: High degree of sequence hom
 A:Reference number: I46083; MUID:93372347; PMID:8364201
 A:Accession: I84613
 A:Status: preliminary; translated from GB/EMBL/DBDJ
 A:Molecule type: mRNA
 A:Residues: 1-192 <RES>
 A:Cross-references: GB:I10609; NID:g342095; PIDN:AAA36842.1; PID:g342096
 C:Comment: Erythropoietin is produced by kidney or liver of adult mammals and by live
 C:Function:
 A:Description: the primary inducer of erythrocyte formation
 C:Superfamily: erythropoietin
 C:Keywords: erythropoiesis; glycoprotein; hormone; kidney; liver
 F:1-27/Domain: signal sequence #status predicted <SIG>
 F:28-192/Product: erythropoietin #status predicted <MAT>
 F:34-187,56-60/Disulfide bonds: #status predicted
 F:51,65,110/Binding site: carbohydrate (Asn) (covalent) #status predicted
 F:152/Binding site: carbohydrate (Ser) (covalent) #status predicted

Query Match 89.8%; Score 759.5; DB 1; Length 192;
 Best Local Similarity 90.3%; Pred. No. 4.3e-66;
 Matches 149; Conservative 9; Mismatches 6; Indels 1; Gaps 1;

QY 1 APPRLICDSRVLYLLEAKEAENITTCGAHCSLNENITVPDTKVNFKYAKRMEVGQQA 60
 |||||
 DB 28 APPRLICDSRVLYLLEAKEAENITTCGAHCSLNENITVPDTKVNFKYAKRMEVGQQA 87
 |||||

QY 61 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120
 |||||
 DB 88 VEVWQGLALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 146
 |||||

QY 121 PDAASAAPLRTITADTFKFLFRVYSNLFRLGKLYTGEACRTGD 165
 |||||
 DB 147 LPDAASAAPLRTITADTFKFLFRVYSNLFRLGKLYTGEACRTGD 191
 |||||

RESULT 4
 I46083
 erythropoietin precursor - cat (fragment)
 C:Species: Felis silvestris catus (domestic cat)
 C:Date: 16-Aug-1996 #sequence_revision 15-Nov-1996 #text_change 22-Jun-1999
 C:Accession: I46083
 R:Wen, D.; Boissel, J.
 Blood 82, 1507-1516, 1993
 A:Title: Erythropoietin structure-function relationships: High degree of sequence hom
 A:Reference number: I46083; MUID:93372347; PMID:8364201
 A:Accession: I46083
 A:Status: translated from GB/EMBL/DBDJ
 A:Molecule type: mRNA
 A:Residues: 1-188 <WEN>
 A:Cross-references: GB:I10606; NID:g163820; PIDN:AAA30807.1; PID:g163821
 C:Comment: Erythropoietin is produced by kidney or liver of adult mammals and by live
 C:Function:
 A:Description: the primary inducer of erythrocyte formation
 C:Superfamily: erythropoietin
 C:Keywords: erythropoiesis; glycoprotein; hormone; kidney; liver
 F:1-22/Domain: signal sequence (fragment) #status predicted <SIG>
 F:23-188/Product: erythropoietin #status predicted <MAT>
 F:29-183,51-55/Disulfide bonds: #status predicted
 F:46,60,105/Binding site: carbohydrate (Asn) (covalent) #status predicted
 F:148/Binding site: carbohydrate (Ser) (covalent) #status predicted

Query Match 84.3%; Score 713; DB 1; Length 188;
 Best Local Similarity 84.2%; Pred. No. 1.3e-61;
 Matches 139; Conservative 9; Mismatches 17; Indels 0; Gaps 0;

QY 1 APPRLICDSRVLYLLEAKEAENITTCGAHCSLNENITVPDTKVNFKYAKRMEVGQQA 60
 |||||
 DB 23 APPRLICDSRVLYLLEAKEAENITTCGAHCSLNENITVPDTKVNFKYAKRMEVGQQA 82
 |||||

QY 61 VEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120
|||||
DB 83 VEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 142
|||||
QY 121 PPDAASAAPLRTITADTKFLFRVYSNPLRGKLLKLYTGEACRTGD 165
|||||
DB 143 LPEATSAAPLRTITADTKFLFRVYSNPLRGKLLKLYTGEACRTGD 187
|||||

RESULT 5

S28148
erythropoietin precursor - rat
C:Species: Rattus norvegicus (Norway rat)
C:Date: 22-Nov-1993 #sequence_revision 15-Nov-1996 #text_change 21-Jul-2000
C:Accession: S28148; I62743
R:Nagao, M.; Suga, H.; Okano, M.; Masuda, S.; Narita, H.; Ikura, K.; Sasaki, R.
Biochim. Biophys. Acta 1171, 99-102, 1992
A:Title: Nucleotide sequence of rat erythropoietin.
A:Reference number: S28148; MUID:93042015; PMID:1420369
A:Accession: S28148
A:Molecule type: mRNA
A:Residues: 1-192 <NAG>
A:Cross-references: GB:D10763; NID:g220735; PIDN:BA01593.1; PID:g220736
R:Wen, D.; Boissel, J.
Blood 82, 1507-1516, 1993
A:Title: Erythropoietin structure-function relationships: High degree of sequence homology
A:Reference number: I46083; MUID:93372347; PMID:8364201
A:Accession: I62743
A:Status: translated from GB/EMBL/DBJ

A:Molecule type: mRNA
A:Residues: 4-192 <RES>
A:Cross-references: GB:L10608; NID:g204060; PIDN:AAA41126.1; PID:g204061
C:Comment: Erythropoietin is produced by kidney or liver of adult mammals and by liver of

C:Function:
A:Description: the primary inducer of erythrocyte formation
C:Superfamily: erythropoietin
C:Keywords: erythropoiesis; glycoprotein; hormone; kidney; liver
F:1-26/Domain: signal sequence #status predicted <SIG>
F:27-192/Product: erythropoietin #status predicted <MAT>
F:33-187,55-165/Disulfide bonds: #status predicted
F:50,64,109/Binding site: carbohydrate (Asn) (covalent) #status predicted

Query Match 82.9%; Score 701; DB 1; Length 192;
- Best Local Similarity 82.4%; Pred. No. 2e-60;
Matches 136; Conservative 13; Mismatches 16; Indels 0; Gaps 0;

QY 1 APPRLICDSRVLYRLEKEAEENITTCGAECSLNENITVPDTKYNFYAWKRMVEVQQA 60
|||||
DB 27 APPRLICDSRVLYRLEKEAEENITTCGAECSPRLSENITVPDTKYNFYAWKRMKVEEQ 86
|||||
QY 61 VEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120
|||||
DB 87 VEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 146
|||||
QY 121 PPDAASAAPLRTITADTKFLFRVYSNPLRGKLLKLYTGEACRTGD 165
|||||
DB 147 PPDAASAAPLRTITADTKFLFRVYSNPLRGKLLKLYTGEACRTGD 191
|||||

RESULT 6

I46401
erythropoietin precursor - sheep
C:Species: Ovis orientalis aries, Ovis ammon aries (domestic sheep)
C:Date: 16-Aug-1996 #sequence_revision 15-Nov-1996 #text_change 22-Jun-1999
C:Accession: I46401; I47077
R:Fu, P.; Evans, B.; Lim, G.B.; Moritz, K.; Wintour, E.M.
Mol. Cell. Endocrinol. 93, 107-116, 1993
A:Title: The sheep erythropoietin gene: molecular cloning and effect of hemorrhage on p
A:Reference number: I46401; MUID:93351736; PMID:8349021
A:Accession: I46401
A:Status: translated from GB/EMBL/DBJ
A:Molecule type: mRNA

A:Residues: 1-194 <FUX>
A:Cross-references: EMBL:224681; NID:g395049; PIDN:CAA0848.1; PID:g395050
R:Wen, D.; Boissel, J.
Blood 82, 1507-1516, 1993
A:Title: Erythropoietin structure-function relationships: High degree of sequence hom
A:Reference number: I46083; MUID:93372347; PMID:8364201
A:Accession: I47077
A:Status: translated from GB/EMBL/DBJ

A:Molecule type: mRNA
A:Residues: 4-15, 'L', 'P', '109-194 <WEN>
A:Cross-references: GB:L10610; NID:g165876; PIDN:AAA31518.1; PID:g165877
C:Comment: Erythropoietin is produced by kidney or liver of adult mammals and by live

C:Function:
A:Description: the primary inducer of erythrocyte formation

C:Superfamily: erythropoietin

C:Keywords: erythropoiesis; glycoprotein; hormone; kidney; liver

F:1-27/Domain: signal sequence #status predicted <SIG>

F:28-194/Product: erythropoietin #status predicted <MAT>

F:34-189,56-60/Disulfide bonds: #status predicted

F:51,65,110/Binding site: carbohydrate (Asn) (covalent) #status predicted

F:154/Binding site: carbohydrate (Ser) (covalent) #status predicted

Query Match 81.0%; Score 685.5; DB 1; Length 194;

- Best Local Similarity 81.9%; Pred. No. 6.3e-59;

Matches 136; Conservative 9; Mismatches 20; Indels 1; Gaps 1;

QY 1 APPRLICDSRVLYRLEKEAEENITTCGAECSLNENITVPDTKYNFYAWKRMVEVQQA 60
|||||

DB 28 APPRLICDSRVLYRLEKEAEENITTCGAECSPRLSENITVPDTKYNFYAWKRMVEVQQA 87
|||||

QY 61 VEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120
|||||

DB 88 LEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 147
|||||

QY 121 PPDAASAAPLRTITADTKFLFRVYSNPLRGKLLKLYTGEACRTGD 165
|||||

DB 148 LPDAPSAAPLRTITADTKFLFRVYSNPLRGKLLKLYTGEACRTGD 193
|||||

erythropoietin precursor - mouse

C:Species: Mus musculus (house mouse)

C:Date: 25-Oct-1987 #sequence_revision 15-Nov-1996 #text_change 22-Jun-1999

C:Accession: A24902; A24901

R:Shoenmaker, C.B.; Mitsock, L.D.

Mol. Cell. Biol. 6, 849-858, 1986

A:Title: Murine erythropoietin gene: cloning, expression, and human gene homology.

A:Reference number: A24902; MUID:87039105; PMID:3773894

A:Accession: A24902

A:Molecule type: DNA

A:Residues: 1-192 <SHO>

A:Note: the authors translated the codon TTA for residue 12 as Phe. TTA for residue 4

R:McDonald, J.D.; Lin, F.K.; Goldwasser, E.

Mol. Cell. Biol. 6, 842-848, 1986

A:Title: Cloning, sequencing, and evolutionary analysis of the mouse erythropoietin g

A:Reference number: A24901; MUID:87039104; PMID:3022133

A:Accession: A24901

A:Molecule type: DNA

A:Residues: 1-67, 'P', '69-192 <MCD>

A:Cross-references: GB:M12930; NID:g193086; PIDN:AAA37570.1; PID:g387152

C:Comment: Erythropoietin is produced by kidney or liver of adult mammals and by live

C:Genetics:

A:Introns: 5/1; 52/3; 81/3; 141/3

C:Function:

A:Description: the primary inducer of erythrocyte formation

C:Superfamily: erythropoietin

C:Keywords: erythropoiesis; glycoprotein; hormone; kidney; liver

F:1-26/Domain: signal sequence #status predicted <SIG>

F:27-192/Product: erythropoietin #status predicted <MAT>

F:33-187,55-165/Disulfide bonds: #status predicted

F:50,64,109/Binding site: carbohydrate (Asn) (covalent) #status predicted

```

Query Match          80.1%; Score 678; DB 2; Length 190;
Best Local Similarity 82.0%; Pred. No. 3.3e-58;
Matches 137; Conservative 7; Mismatches 21; Indels 2; Gaps 1;

QY      1 APPRLICDSVRLERYLLEAKEAENITTCGAHCISLNEITVPDTKYNFYAWKRMEYVQQA 60
Db      1 ||||| ||||| ||||| || |||| || ||||| ||||| ||||| ||||| ||||| |||||
QY      23 APPRLICDSVRLERYLLEAKEGENATMGCAESCSFSENITVPDTKYNFYAWKRMEYVQQA 82
Db      2 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY      61 YEVWQGLALISEAVLRQALLVNSNPWEPLQHLHVDKAVSGLSRLTTLRLALCAQKEAIS 120
Db      6 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY      83 MEVWQGLALISEAILQOALLANSQSEALQHLHVDKAVSGLSRLTTLRLALCAQKEAIP 142
Db      8 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY      121 PPDA--ASAAPLTITADTFERKLFVYSNPLRGKCLKLYTGEACRTGD 165
Db      1 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
QY      143 LPDASPSSATPLRTFAVDTLCKLFRNYSNPLRGKCLKLYTGEACRRRD 189
Db      1 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

RESULT 10
I46199
erythropoietin - dog (fragment)
C:Species: Canis lupus familiaris (dog)
C:Date: 21-Feb-1997 #sequence_revision 21-Feb-1997 #text_change 23-Jul-1999
C:Accession: I46199
R:Wen, D.; Boissel, J.
Blood 82, 1507-1516, 1993
A:Title: Erythropoietin structure-function relationships: High degree of sequence homology between human and dog erythropoietins
A:Reference number: I46083; MUID:93372347; PMID:8364201
A:Accession: I46199
A:Status: preliminary; translated from GB/EMBL/DDBJ
A:Molecule type: mRNA
A:Residues: 1-175 <MEN>
A:Cross-references: GB:I13027; NID:g290087; PIDN:AAA30842.1; PID:g552347
C:Superfamily: erythropoietin

```

```

Query Match          75.4%; Score 638; DB 2; Length 175;
Best Local Similarity 81.0%; Pred. No. 2.2e-54;
Matches 124; Conservative 13; Mismatches 16; Indels 0; Gaps 0;

QY 1 APRRLCDSRVRLERYLLEAKEAENITTCGAEHCSLNENITVPDTKYNFYAWKRMVCGQQA 60
DB 23 APRRLCDSRVRLERYLLEAKEAENITTCGAEHCSLNENITVPDTKYNFYAWKRMVCGQQA 82
QY 61 VEWQGLALLSEALRGQALLVNSSPWEPQLQHVDKAVSGLRSLTLLRLALCAQKEATIS 120
DB 83 LEWQGLALLSEALRGQALLANASQSETPQLQHVDKAVSSLSRLSTLLRLALCAQKEAMS 142
QY 121 PPDAAAGAPLRTITADTFKRLFRVYSNFLRGKL 153
DB 143 LPDEASAPLRTFTVDTLCKLFRISNFLRGKL 175

RESULT 11
G02729
thrombopoietin - human
C:Species: Homo sapiens (man)
C:Date: 21-Dec-1996 #sequence_revision 06-Jun-1997 #text_change 05-Nov-1999
C:Accession: G02729
R:Im, S.
submitted to the EMBL Data Library, May 1996
A:Reference number: H01637
A:Accession: G02729
A:Status: preliminary; translated from GB/EMBL/DDBJ
A:Molecule type: mRNA
A:Residues: 1-353 <IMX>
A:A:Cross-references: EMBL:U59493; NID:g1401245; PIDN:AAB03392.1; PID:g1401246
C:Genetics:
A:Gene: htpo

Query Match          10.6%; Score 90; DB 2; Length 353;
Best Local Similarity 26.3%; Pred. No. 0.6;
Matches 41; Conservative 20; Mismatches 75; Indels 20; Gaps 5;

QY 1 APRRLCDSRVRLERYLLEAKEAENITTCGAEHCSLNENITVPDTKYNFYAWKRMVCGQQA 60

```

Db 24 APP--ACDLRVLSKLLRDSHVLHSHKSCQCEVHPLPTFPVLLPAVDFSLGKWTQMEETKA 81
 QY 61 VEVWQGLALLSEAVL--RGQALLVNSQPWEPLQLHVDKAVSGLSRLSTLLRALGAQKEA 118
 Db 82 QDILGAVTLLLEGVMAARGQLPTCLSLGQLSQSEVRLLLGALQSL-----LGTQ--- 132
 QY 119 ISPPDAASAAPLRTITADTFKRLFRVYSNFLRGK 154
 Db 133 -LPQOG-----RTTAHKDPNAIFLSFOHLLRGKVR 161

RESULT 12
 180105
 N:thrombopoietin precursor - human
 C:Species: Homo sapiens (man)
 C:Date: 24-May-1996 #sequence_revision 24-May-1996 #text_change 20-Jun-2000
 C:Accession: 159281; 180105; S45331; S48740; 138672; 152610
 R:Poster, D.C.; Sprecher, C.A.; Grant, F.J.; Kramer, J.M.; Kuijper, J.L.; Holly, R.D.; W
 Proc. Natl. Acad. Sci. U.S.A. 91, 13023-13027, 1994
 A:Title: Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal
 A:Reference number: 159281; MUID:95108091; PMID:7809166
 A:Accession: 159281
 A:Status: translated from GB/EMBL/DBJ
 A:Molecule type: DNA
 A:Residues: 1-353 <RE2>
 A:Cross-references: GB:L36051; NID:g5332114; PIDN:AAC37568.1; PID:g533215
 A:Accession: 180105
 A:Status: translated from GB/EMBL/DBJ
 A:Molecule type: mRNA
 A:Residues: 1-353 <RES>
 A:Cross-references: GB:L36052; NID:g533216; PIDN:AAC37566.1; PID:g533217
 R:de Sauvage, F.J.; Hass, P.E.; Spencer, S.D.; Malloy, B.E.; Gurney, A.L.; Spencer, S.A.
 D.V.; Eaton, D.L.
 Nature 369, 533-538, 1994
 A:Title: Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand.
 A:Reference number: S45331; MUID:94261202; PMID:8202154
 A:Accession: S45331
 A:Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 1-353 <SAU>
 A:Cross-references: GB:L33410; NID:g506826; PIDN:AAA59857.1; PID:g506827
 R:Sohna, Y.; Akahori, H.; Seki, N.; Hori, T.; Ogami, K.; Kato, T.; Shimada, Y.; Kawamura
 FEBS Lett. 353, 57-61, 1994
 A:Title: Molecular cloning and chromosomal localization of the human thrombopoietin gene
 A:Reference number: S48740; MUID:95010765; PMID:7926023
 A:Accession: S48740
 A:Status: preliminary
 A:Molecule type: DNA
 A:Residues: 1-353 <SOH>
 A:Cross-references: GB:D32046; NID:g577319; PIDN:BAA06807.1; PID:g577320
 R:Bartley, T.D.; Bogenberger, J.; Hunt, P.; Li, Y.S.; Lu, H.S.; Martin, F.; Chang, M.S.;
 Cell 77, 1117-1124, 1994
 A:Title: Identification and cloning of a megakaryocyte growth and development factor tha
 A:Reference number: A54463; MUID:94291201; PMID:8020099
 A:Accession: 138672
 A:Status: preliminary
 A:Molecule type: mRNA
 A:Residues: 1-112, 'E', 114-353 <RES>
 A:Cross-references: EMBL:U11025; NID:g511223; PIDN:AAA50553.1; PID:g558078
 R:Gurney, A.L.; Kuang, W.J.; Xie, M.H.; Malloy, B.E.; Eaton, D.L.; de Sauvage, F.J.
 Blood 85, 981-988, 1995
 A:Title: Genomic structure, chromosomal localization, and conserved alternative splice f
 A:Reference number: 152610; MUID:95152076; PMID:7849319
 A:Accession: 152610
 A:Status: preliminary; translated from GB/EMBL/DBJ
 A:Molecule type: DNA
 A:Residues: 1-353 <RES4>
 A:Cross-references: GB:S76771; NID:g914225; PIDN:AAB33390.1; PID:g914226
 C:Genetics:
 A:Gene: GDB:THPO; MGDF
 A:Cross-references: GDB:374007; OMIM:600044

A:Map position: 3q26.3-3q27
 A:Introns: 5/1; 47/3; 76/3; 132/3
 C:Keywords: alternative splicing; cytokine; glycoprotein

Query Match 10.5%; Score 89; DB 2; Length 353;
 Best Local Similarity 26.3%; Pred. No. 0.75; Mismatches 75; Indels 20; Gaps 5;
 Matches 41; Conservative 20

QY 1 APPRLICDSRVILERYLLEAKEAENITTCGAHCSLNENITVPTKVNIFYANKRMEVGQQA 60
 Db 24 APP--ACDLRVLSKLLRDSHVLHSHKSCQCEVHPLPTFPVLLPAVDFSLGKWTQMEETKA 81

QY 61 VEVWQGLALLSEAVL--RGQALLVNSQPWEPLQLHVDKAVSGLSRLSTLLRALGAQKEA 118
 Db 82 QDILGAVTLLLEGVMAARGQLPTCLSLGQLSQSEVRLLLGALQSL-----LGTQ--- 132

QY 119 ISPPDAASAAPLRTITADTFKRLFRVYSNFLRGK 154
 Db 133 -LPQOG-----RTTAHKDPNAIFLSFOHLLRGKVR 161

RESULT 13
 AB0323
 ribonucleoside-diphosphate reductase (EC 1.17.4.1) beta chain [imported] - Yersinia p
 C:Species: Yersinia pestis
 C:Date: 02-Nov-2001 #sequence_revision 02-Nov-2001 #text_change 27-Nov-2001
 C:Accession: AB0323
 R:Parkhill, J.; Wren, B.W.; Thomson, N.R.; Titball, R.W.; Holden, M.T.G.; Prentice, M
 deno-Tarraga, A.M.; Chillingworth, T.; Cronin, A.; Davies, R.M.; Davis, P.; Dougan, G
 il, M.; Rutherford, K.; Simmonds, M.; Skelton, J.; Stevens, K.; Whitehead, S.; Barrel
 Nature 413, 523-527, 2001
 A:Title: Genome sequence of Yersinia pestis, the causative agent of plague.
 A:Reference number: AB0001; MUID:21470413; PMID:11586360
 A:Accession: AB0323
 A:Status: preliminary
 A:Molecule type: DNA
 A:Residues: 1-333 <KUR>
 A:Cross-references: GB:AL590842; PIDN:CAC92889.1; PID:g15980631; GSPDB:GN00175
 C:Genetics:
 A:Gene: nrdF
 C:Superfamily: ribonucleoside-diphosphate reductase beta
 C:Keywords: oxidoreductase

Query Match 10.4%; Score 88; DB 2; Length 323;
 Best Local Similarity 25.2%; Pred. No. 0.84;
 Matches 34; Conservative 20; Mismatches 59; Indels 22; Gaps 5;

QY 38 NITVPTKVNIFYANKRMEVGQQAQVEWQGLALLSEAVLRGQALLVNSQPWEPLQLHVD- 96
 Db 2 NVVKPITRISAINWNKIE-DDKDLVWN--RUTSNFWLPEKVPVLSNDIPSWATLTPHQOQ 58

QY 97 ---KAVSGLSRLSTLLRALGAO---KEATSPDPAASAAPLRTITADTFKRLFRVYSNFLR 150
 Db 59 LIRIVTGLTLLDTQNTLGAPALIKDAITPHEEAIFSNISMEAVHARSYSSIFSTL-- 116

QY 151 GKULKYTGCACRTGD 165
 Db 117 -----CLTSD 121

RESULT 14
 AB0959
 Solute binding receptor protein [imported] - Salmonella enterica subsp. enterica sero
 C:Species: Salmonella enterica subsp. enterica serovar Typhi
 A:Note: this species has also been called Salmonella typhi
 C:Date: 09-Nov-2001 #sequence_revision 09-Nov-2001 #text_change 09-Nov-2001
 C:Accession: AB0959
 R:Parkhill, J.; Dougan, G.; James, K.D.; Thomson, N.R.; Pickard, D.; Wain, J.; Church
 th, T.; Conneron, P.; Cronin, A.; Davies, P.; Davies, R.M.; Dowd, L.; White, N.; Farr
 , S.; Moule, S.; O'Gaora, P.
 Nature 413, 848-852, 2001
 A:Authors: Parry, C.; Quail, M.; Rutherford, K.; Simmonds, M.; Skelton, J.; Stevens, A
 A:Title: Complete genome sequence of a multiple drug resistant Salmonella enterica se

Search completed: June 13, 2003, 15:04:42
Job time : 33 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: June 13, 2003, 15:03:00 ; Search time 12 seconds
(without alignments)

570.300 Million cell updates/sec

Title: US-09-830-964-1

Perfect score: 846

Sequence: 1 APPRLICDSRLVRLRYLEAK.....SNELRGKILVTGEACRTGD 165

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 112892 seqs, 41476328 residues

Total number of hits satisfying chosen parameters: 112892

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : SwissProt_40.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query % | Match | Length | DB | ID | Description |
|------------|-------|---------|-------|--------|-------------|--------|-------------|
| 1 | 846 | 100.0 | 193 | 1 | EPO_HUMAN | P01588 | homo sapien |
| 2 | 764.5 | 90.4 | 192 | 1 | EPO_HACFA | P07865 | macaca fasc |
| 3 | 759.5 | 89.8 | 192 | 1 | EPO_WACMU | Q28513 | macaca mula |
| 4 | 706 | 83.5 | 192 | 1 | EPO_FELCA | P33708 | felis silve |
| 5 | 701 | 82.9 | 192 | 1 | EPO_RAT | P29676 | rattus norv |
| 6 | 692.5 | 81.9 | 192 | 1 | EPO_BOVIN | P48617 | bos taurus |
| 7 | 689 | 81.4 | 192 | 1 | EPO_MOUSE | P07321 | mus musculu |
| 8 | 685.5 | 81.0 | 194 | 1 | EPO_SHEEP | P33709 | ovis aries |
| 9 | 678 | 80.1 | 190 | 1 | EPO_PIG | P49157 | sus scrofa |
| 10 | 638 | 75.4 | 175 | 1 | EPO_CANFA | P33707 | canis famil |
| 11 | 109 | 12.9 | 352 | 1 | TPO_CANFA | P42705 | canis famil |
| 12 | 89 | 10.5 | 353 | 1 | TPO_HUMAN | P40225 | homo sapien |
| 13 | 80.5 | 9.5 | 3033 | 1 | POLG_HCVJ78 | P26661 | h genome po |
| 14 | 78.5 | 9.3 | 897 | 1 | EP15_MOUSE | P42567 | mus musculu |
| 15 | 78 | 9.2 | 747 | 1 | ATCS_SYN7 | P37279 | synechococc |
| 16 | 77 | 9.1 | 548 | 1 | CH60_BUCNP | O51832 | buchnera ap |
| 17 | 76.5 | 9.0 | 386 | 1 | CTBP_DRONE | O46036 | drosophila |
| 18 | 76 | 9.0 | 551 | 1 | CH60_BUCAP | O59177 | buchnera ap |
| 19 | 74.5 | 8.8 | 552 | 1 | CH60_PSEST | O33500 | pseudomonas |
| 20 | 74.5 | 8.8 | 809 | 1 | HRPB_ECOLI | P37024 | escherichia |
| 21 | 74 | 8.7 | 326 | 1 | TPO_RAT | P49745 | rattus norv |
| 22 | 74 | 8.7 | 1564 | 1 | PDRA_YEAST | P51533 | saccharomyc |
| 23 | 73.5 | 8.7 | 830 | 1 | GCL2_MOUSE | Q9jhd2 | mus musculu |
| 24 | 73.5 | 8.7 | 837 | 1 | GCL2_HUMAN | Q92830 | homo sapien |
| 25 | 73 | 8.6 | 263 | 1 | YH25_DEIRA | O83030 | deinococcus |
| 26 | 73 | 8.6 | 1089 | 1 | IMB3_YEAST | P32337 | saccharomyc |
| 27 | 72.5 | 8.6 | 762 | 1 | SLAP_ACEKI | P22258 | acetogenium |
| 28 | 72 | 8.5 | 356 | 1 | TPO_MOUSE | P40226 | mus musculu |
| 29 | 72 | 8.5 | 548 | 1 | CH60_BUCAI | P25750 | buchnera ap |
| 30 | 70.5 | 8.3 | 217 | 1 | YHND_ECOLI | P76909 | escherichia |
| 31 | 70.5 | 8.3 | 381 | 1 | MODD_MYCAV | Q48919 | mycobacteri |
| 32 | 70.5 | 8.3 | 543 | 1 | CH60_BARBA | P35635 | bartonella |
| 33 | 70.5 | 8.3 | 896 | 1 | EP15_HUMAN | P42566 | homo sapien |

RESULT 1

EPO_HUMAN STANDARD; PRT; 193 AA.
 AC P01588; Q9UHA0; Q9UEZ5; Q9UDZ0;
 DT 21-JUL-1986 (Rel. 01, Created)
 DT 21-JUL-1986 (Rel. 01, Last sequence update)
 DT 16-OCT-2001 (Rel. 40, Last annotation update)
 DE Erythropoietin precursor (Epoetin).
 GN EPO.
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 OX NCBI_TaxID:9606;
 RN [1]
 RP MEDLINE=85137899; PubMed=3838366;
 RA Jacobs K., Shoemaker C., Rudersdorf R., Neill S.D., Kaufman R.J.,
 Mufson A., Seehra J., Jones S.S., Hewick R., Fritsch E.F.,
 Kawakita M., Shimizu T., Miyake T.;
 RT "Isolation and characterization of genomic and cDNA clones of human
 erythropoietin.";
 RL Nature 313:806-810(1985).
 RN [2]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=86087948; PubMed=3865178;
 RA Lin F.-K., Sugus S., Lin C.-H., Browne J.K., Smalling R., Egrle J.C.,
 Chen K.K., Fox G.M., Martin F., Stabinsky Z., Badrawi S.M., Lai P.-H.,
 Goldwasser E.;
 RT "Cloning and expression of the human erythropoietin gene.";
 RL Proc. Natl. Acad. Sci. U.S.A. 82:7580-7584(1985).
 RN [3]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=99018118; PubMed=9799793;
 RA Gloeckner G., Scherer S., Schattevoy R., Boright A., Weber J.,
 Tsui L.-C., Rosenthal A.;
 RT "Large-scale sequencing of two regions in human chromosome 7q22:
 analysis of 650 kb of genomic sequence around the EPO and CUTL1 loci
 reveals 17 genes.";
 RL Genome Res. 8:1060-1073(1998).
 RN [4]
 RP SEQUENCE FROM N.A.
 RX Rupert J.L., Hochachka P.W.;
 RT "Erythropoietin gene sequence in the Quechua, a high altitude native
 population.";
 RL Submitted (NOV-1999) to the EMBL/GenBank/DBJ databases.
 RN [5]
 RP SEQUENCE OF 58-193 FROM N.A. AND VARIANTS HEPATOCELLULAR CARCINOMA.
 RA Funakoshi A., Muta H., Baba T., Shimizu S.;
 RT "Gene expression of mutant erythropoietin in hepatocellular
 carcinoma.";
 RL Biochem. Biophys. Res. Commun. 195:717-722(1993).
 RN [6]
 RP SEQUENCE OF 28-193, AND DISULFIDE BONDS.
 RC TISSUE=Urine;
 RX MEDLINE=86140080; PubMed=3949763;

ALIGNMENTS

| | | | | | | | |
|----|------|-----|------|---|-------------|--------|-------------|
| 34 | 70 | 8.3 | 319 | 1 | RIR4_SALTY | P17424 | salmonella |
| 35 | 70 | 8.3 | 547 | 1 | CH60_LEGPN | P26878 | legionella |
| 36 | 69.5 | 8.2 | 907 | 1 | GACS_PSESV | P48027 | pseudomonas |
| 37 | 69.5 | 8.2 | 1327 | 1 | TNKL_HUMAN | O95271 | homo sapien |
| 38 | 69 | 8.2 | 353 | 1 | NADA_YERPE | Q89gy8 | yersinia pe |
| 39 | 69 | 8.2 | 544 | 1 | CH60_FRATU | P94798 | francisella |
| 40 | 69 | 8.2 | 552 | 1 | CH60_COXBU | P19421 | coxlella bu |
| 41 | 69 | 8.2 | 1128 | 1 | DNBI_HSVSA | P24910 | herpesvirus |
| 42 | 68.5 | 8.1 | 360 | 1 | CYS2_MAIZE | Q10717 | zea mays (m |
| 43 | 68.5 | 8.1 | 418 | 1 | CUN2_TREIRE | P07982 | trichoderma |
| 44 | 68.5 | 8.1 | 778 | 1 | RGL2_MOUSE | Q61193 | mus musculu |
| 45 | 68 | 8.0 | 366 | 1 | QUEA_SYNY3 | Q55850 | synechocyst |

RA Lai P.H., Everett R., Wang F.F., Arakawa T., Goldwasser E.;
 RT "Structural characterization of human erythropoietin";
 RL J. Biol. Chem. 261:3116-3121(1986).
 RN [7]
 RP PRELIMINARY SEQUENCE OF 28-57.
 RX MEDLINE=84135751; PubMed=6698989;
 RA Yanagawa S., Hirade K., Ohnata H., Sasaki R., Chiba H., Ueda M.,
 RA Goto M.;
 RT "Isolation of human erythropoietin with monoclonal antibodies";
 RL J. Biol. Chem. 259:2707-2710(1984).
 RN [8]
 RP STRUCTURE OF CARBOHYDRATES.
 RX MEDLINE=88153657; PubMed=3346214;
 RA Takeuchi M., Takasaki S., Miyazaki H., Kato T., Hoshi S., Kochibe N.,
 RA Kobata A.;
 RT "Comparative study of the asparagine-linked sugar chains of human
 RT erythropoietins purified from urine and the culture medium of
 RT recombinant Chinese hamster ovary cells";
 RL J. Biol. Chem. 263:3657-3663(1988).
 RN [9]
 RP STRUCTURE OF CARBOHYDRATES.
 RX MEDLINE=89118279; PubMed=3219367;
 RA Sasaki H., Ochi N., Dell A., Fukuda M.;
 RT "Site-specific glycosylation of human recombinant erythropoietin:
 RT analysis of glycopeptides or peptides at each glycosylation site by
 RT fast atom bombardment mass spectrometry";
 RL Biochemistry 27:8618-8626(1988).
 RN [10]
 RP STRUCTURE OF CARBOHYDRATES.
 RX MEDLINE=92314463; PubMed=1820196;
 RA Takeuchi M., Kobata A.;
 RT "Structures and functional roles of the sugar chains of human
 RT erythropoietins";
 RL Glycobiology 1:337-346(1991).
 RN [11]
 RP X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS).
 RX MEDLINE=98445092; PubMed=9774108;
 RA Syed R.S., Reid S.W., Li C., Cheetham J.C., Aoki K.H., Liu B.,
 RA Zhan H., Osslund T.D., Chirino A.J., Zhang J., Finer-Moore J.,
 RA Elliott S., Stiney K., Katz B.A., Matthews D.J., Wendoloski J.J.,
 RA Egnie J., Stroud R.M.;
 RT "Efficiency of signalling through cytokine receptors depends
 RT critically on receptor orientation";
 RL Nature 395:511-516(1998).
 CC [1]
 CC FUNCTION: ERYTHROPOIETIN IS THE PRINCIPAL HORMONE INVOLVED IN THE
 CC REGULATION OF ERYTHROCYTE DIFFERENTIATION AND THE MAINTENANCE OF A
 CC PHYSIOLOGICAL LEVEL OF CIRCULATING ERYTHROCYTE MASS.
 CC [2]
 CC SUBCELLULAR LOCATION: Secreted.
 CC [3]
 CC TISSUE SPECIFICITY: PRODUCED BY KIDNEY OR LIVER OF ADULT MAMMALS
 CC AND BY LIVER OF FETAL OR NEONATAL MAMMALS.
 CC [4]
 CC PHARMACEUTICAL: Used for the treatment of anemia. Available under
 CC the names Epogen (Amgen), Epogin (Chugai), Epomax (Eli Lilly), Eprex
 CC (Janssen-Cilag), NeoRecormon or Recormon (Roche), and Procrit
 CC (Ortho Biotech). Variations in the glycosylation pattern of EPO
 CC distinguishes these products. Epogen, Epogin, Eprex and Procrit
 CC are generically known as epoetin alfa, NeoRecormon and Recormon as
 CC epoetin beta and Epomax as epoetin omega.
 CC [5]
 CC SIMILARITY: BELONGS TO THE EPO / TPO FAMILY.
 CC [6]
 CC DATABASE: NAME=Rad Systems' cytokine source book: EPO;
 CC WWW="http://www.rndsystems.com/asp/g_sitebuilder.asp?bodyId=197".
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@sib-sib.ch).
 CC -----
 CC EMBL; X02158; CAA26095.1; -
 CC EMBL; X02157; CAA26094.1; -
 CC EMBL; M11319; AAA52400.1; -
 CC EMBL; AF053356; AAC78791.1; -

DR EMBL; AF202308; AAF23132.1; -
 DR EMBL; AF202306; AAF23132.1; JOINED.
 DR EMBL; AF202307; AAF23132.1; JOINED.
 DR EMBL; AF202310; AAF23133.1; -
 DR EMBL; AF202309; AAF23133.1; -
 DR EMBL; AF202311; AAF17572.1; -
 DR EMBL; AF202314; AAF23134.1; -
 DR EMBL; AF202312; AAF23134.1; JOINED.
 DR EMBL; AF202313; AAF23134.1; JOINED.
 DR EMBL; S65458; AAD13964.1; -
 DR PIR; A01855; ZUHU.
 DR PIR; A25384; A25384.
 DR PIR; A24744; A24744.
 DR PIR; A22210; A22210.
 DR PDB; 1EER; 01-OCT-99.
 DR PDB; 1CN4; 11-AUG-99.
 DR GlycoSuiteDB; P01588; -
 DR Genew; HGNC:3415; EPO.
 DR MIN; 133170; -
 DR InterPro; IPR001323; EPO_TPO.
 DR InterPro; IPR003013; Erythroptn.
 DR Pfam; PF00758; EPO_TPO; 1
 DR PRINTS; PR00272; ERYTHROPTN.
 DR PROSITE; PS00817; EPO_TPO; 1.
 KW Erythrocyte maturation; Glycoprotein; Hormone; Signal; Pharmaceutical;
 KW 3D-structure.
 FT SIGNAL 1 27
 FT CHAIN 28 193 ERYTHROPOIETIN.
 FT PROPEP 190 193 MAY BE REMOVED IN PROCESSED PROTEIN.
 FT DISULFID 34 188
 FT DISULFID 56 60
 FT CARBOHYD 51 51 N-LINKED (GLCNAC...).
 FT CARBOHYD 65 65 /FTID=CAR_000052.
 FT CARBOHYD 110 110 N-LINKED (GLCNAC...).
 FT CARBOHYD 153 153 /FTID=CAR_000166.
 FT VARIANT 131 132 N-LINKED (GLCNAC...).
 FT VARIANT 149 149 SL -> NF (IN AN HEPATOCELLULAR
 FT VARIANT 149 149 /FTID=VAR_009870.
 FT CONFLICT 40 40 P -> Q (IN AN HEPATOCELLULAR CARCINOMA).
 FT CONFLICT 85 85 E -> Q (IN REF. 1; CAA26095).
 FT CONFLICT 140 140 Q -> QQ (IN REF. 5).
 FT CONFLICT 140 140 G -> R (IN REF. 1; CAA26095).
 SQ SEQUENCE 193 AA; 21306 MW; C91F0E4C26A52033 CRC64;
 Query Match 100.0%; Score 846; DB 1; Length 193;
 Best Local Similarity 100.0%; Pred. No. 1.9e-76;
 Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 APRRLICDSRVLELYLLEAKEAENITTCGAEHCNENITVPTKYNFYAWKRMEVGQQA 60
 DB 28 APRRLICDSRVLELYLLEAKEAENITTCGAEHCNENITVPTKYNFYAWKRMEVGQQA 87
 QY 61 VEVWQGLALLSEAVLRQALLVNSQWPEPQLQHVDAKAVSGRLSLTTLRALCAQKEATS 120
 DB 88 VEVWQGLALLSEAVLRQALLVNSQWPEPQLQHVDAKAVSGRLSLTTLRALCAQKEATS 147
 QY 121 PPDAASAAPLRTTADTFKRLFRVYNSFLRGKLUKLYTGACRTGD 165
 DB 148 PPDAASAAPLRTTADTFKRLFRVYNSFLRGKLUKLYTGACRTGD 192
 RESULT 2
 EPO_MACFA
 ID EPO_MACFA STANDARD; PRT; 192 AA.
 AC P07865;
 DT 01-AUG-1988 (Rel. 08, Created)
 DT 01-AUG-1988 (Rel. 08, Last sequence update)
 DT 16-OCT-2001 (Rel. 40, Last annotation update)
 DE Erythropoietin precursor.

GN EPO.
OS Macaca fascicularis (Crab eating macaque) (Cynomolgus monkey).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Cercopithecoidea;
OC Cercopithecoidea; Macaca.
OX NCBI_TaxID=9541;
RN (1)
RP SEQUENCE FROM N.A.
RX MEDLINE=87055236; PubMed=2877922;
RA Lin F.-K., Lin C.-H., Lai P.-H., Browne J.K., Egrie J.C., Smalling R.,
RA Fox G.M., Chen K.K., Castro M., Suggs S.,
RT "Monkey erythropoietin gene: cloning, expression and comparison with
RT the human erythropoietin gene.";
RL Gene 44:201-209(1986).
CC REGULATION OF ERYTHROPOIETIN IS THE PRINCIPAL HORMONE INVOLVED IN THE
CC PHYSIOLOGICAL LEVEL OF CIRCULATING ERYTHROCYTE MASS.
CC -1- SUBCELLULAR LOCATION: Secreted.
CC -1- TISSUE SPECIFICITY: PRODUCED BY KIDNEY OR LIVER OF ADULT MAMMALS
CC AND BY LIVER OF FETAL OR NEONATAL MAMMALS.
CC -1- SIMILARITY: BELONGS TO THE EPO / TPO FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; M18189; AAA36841.1; -
DR PIR; JQ0173; JQ0173.
DR HSSP; P01588; ICN4.
DR InterPro: IPR001323; EPO_TPO.
DR InterPro: IPR003013; Erythroptn.
DR Pfam: PF00758; EPO_TPO; 1.
DR PRINTS; PR00272; ERYTHROPTN.
DR PROSITE; PS00817; EPO_TPO; 1.
KW Erythrocyte maturation; Glycoprotein; Hormone; Signal.
FT SIGNAL 1 27
FT CHAIN 28 192
FT DISULFID 34 187
FT DISULFID 56 60
FT CARBOHYD 51 51
FT CARBOHYD 65 65
FT CARBOHYD 110 110
FT CARBOHYD 152 152
FT CARBOHYD 152 152
SQ SEQUENCE 192 AA; 21113 MW; E8A900F442AD4522 CRC64;

Query Match 90.4%; Score 764.5; DB 1; Length 192;
Best Local Similarity 91.5%; Pred. No. 2.2e-68;
Matches 151; Conservative 7; Mismatches 6; Indels 1; Gaps 1;

QY 1 APRRLICDSRVLELYLLEAKEAENITTCGAHCNENITVPTKYNFYAKRMVEVGQQA 60
DB 28 APRRLICDSRVLELYLLEAKEAENITTCGAHCNENITVPTKYNFYAKRMVEVGQQA 87

QY 61 VEVWQGLALLSEAVLRQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120
DB 88 VEVWQGLALLSEAVLRQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQ- EALS 146

QY 121 PPDAASAAPLRTITADTFRKFLFRVYSNLFGRGKLYTGEACRTGD 165
DB 147 LPDAASAAPLRTITADTFRKFLFRVYSNLFGRGKLYTGEACRRGD 191

RESULT 3
EPO_MACMU STANDARD; PRT; 192 AA.
AC Q28513;
DT 01-NOV-1997 (Rel. 35, Created)
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)

DE Erythropoietin precursor.
GN EPO.
OS Macaca mulatta (Rhesus macaque).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Cercopithecoidea;
OC Cercopithecoidea; Macaca.
OX NCBI_TaxID=9544;
RN (1)
RP SEQUENCE FROM N.A.
RX MEDLINE=93372437; PubMed=8364201;
RA Wen D., Bolssel J.P.R., Tracy T.E., Gruninger R.H., Mulcahy L.S.,
RA Czelusniak J., Goodman M., Bunn H.F.;
RT "Erythropoietin structure-function relationships: high degree of
RT sequence homology among mammals.";
RL Blood 82:1507-1516(1993).
CC REGULATION OF ERYTHROPOIETIN IS THE PRINCIPAL HORMONE INVOLVED IN THE
CC PHYSIOLOGICAL LEVEL OF CIRCULATING ERYTHROCYTE MASS.
CC -1- SUBCELLULAR LOCATION: Secreted.
CC -1- TISSUE SPECIFICITY: PRODUCED BY KIDNEY OR LIVER OF ADULT MAMMALS
CC AND BY LIVER OF FETAL OR NEONATAL MAMMALS.
CC -1- SIMILARITY: BELONGS TO THE EPO / TPO FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; L10609; AAA36842.1; -
DR HSSP; P01588; ICN4.
DR InterPro: IPR001323; EPO_TPO.
DR InterPro: IPR003013; Erythroptn.
DR Pfam: PF00758; EPO_TPO; 1.
DR PRINTS; PR00272; ERYTHROPTN.
DR PROSITE; PS00817; EPO_TPO; 1.
KW Erythrocyte maturation; Glycoprotein; Hormone; Signal.
FT SIGNAL 1 27
FT CHAIN 28 192
FT DISULFID 34 187
FT DISULFID 56 60
FT CARBOHYD 51 51
FT CARBOHYD 65 65
FT CARBOHYD 110 110
FT CARBOHYD 152 152
FT CARBOHYD 152 152
SQ SEQUENCE 192 AA; 21081 MW; 275560A264628CD1 CRC64;

Query Match 89.8%; Score 759.5; DB 1; Length 192;
Best Local Similarity 90.3%; Pred. No. 6.7e-68;
Matches 149; Conservative 9; Mismatches 6; Indels 1; Gaps 1;

QY 1 APRRLICDSRVLELYLLEAKEAENITTCGAHCNENITVPTKYNFYAKRMVEVGQQA 60
DB 28 APRRLICDSRVLELYLLEAKEAENITTCGAHCNENITVPTKYNFYAKRMVEVGQQA 87

QY 61 VEVWQGLALLSEAVLRQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQKEAIS 120
DB 88 VEVWQGLALLSEAVLRQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALGAQ- EALS 146

QY 121 PPDAASAAPLRTITADTFRKFLFRVYSNLFGRGKLYTGEACRTGD 165
DB 147 LPDAASAAPLRTITADTFRKFLFRVYSNLFGRGKLYTGEACRRGD 191

RESULT 4
EPO_FELCA STANDARD; PRT; 192 AA.
AC P33708;
DT 01-FEB-1994 (Rel. 28, Created)
DT 01-OCT-1996 (Rel. 34, Last sequence update)

RESULT 5


```

Db 87 VEVWQGLLSEAILQALQANSSQPPELQHLIDKATISGLRLSLTLRLVGAQKELMS 146
121 PPDAASAAPLRTITADTFRKLFVSNFLRGKLYTGACRTGD 165
147 PPDATAAPLRTITADTFRKLFVSNFLRGKLYTGACRTGD 191

RESULT 6
EPO_BOVIN
ID EPO_BOVIN STANDARD; PRT; 192 AA.
AC P48617:
DT 01-FEB-1996 (Rel. 33, Created)
DT 01-FEB-1996 (Rel. 33, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Erythropoietin precursor.
GN EPO.
OS Bos taurus (Bovine).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Bovinae; Bos.
OX NCBI_TaxID=9913;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Boban; TISSUE=Kidney;
RX MEDLINE=96257233; PubMed=8666286;
RA Suliman H.B., Majlwa P.A.O., Feldman B.F., Mertens B.,
RA Logan-Henfrey L.L.;
RT "Cloning of a cDNA encoding bovine erythropoietin and analysis of its
RT transcritpion in selected tissues.";
RL Gene 171:275-280(1996).
CC -1- FUNCTION: ERYTHROPOIETIN IS THE PRINCIPAL HORMONE INVOLVED IN THE
CC REGULATION OF ERYTHROCYTE DIFFERENTIATION AND THE MAINTENANCE OF A
CC PHYSIOLOGICAL LEVEL OF CIRCULATING ERYTHROCYTE MASS.
CC -1- SUBCELLULAR LOCATION: Secreted.
CC -1- TISSUE SPECIFICITY: PRODUCED BY KIDNEY OR LIVER OF ADULT MAMMALS
CC AND BY LIVER OF FETAL OR NEONATAL MAMMALS.
CC -1- SIMILARITY: BELONGS TO THE EPO / TPO FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; L41354; AAB41268.1; -
DR EMBL; U44762; AAB86653.1; -
DR HSP; P01588; ICM4.
DR InterPro; IPR001323; EPO_TPO.
DR Pfam; PF00758; EPO_TPO; 1.
DR PRINTS; PR00272; ERYTHROPTN.
DR PROSITE; PS00817; EPO_TPO; 1.
KW Erythrocyte maturation; Glycoprotein; Hormone; Signal.
FT SIGNAL 1 25 POTENTIAL.
FT CHAIN 26 192 ERYTHROPOIETIN.
FT DISULFID 32 187 BY SIMILARITY.
FT DISULFID 54 58 BY SIMILARITY.
FT CARBOHYD 49 49 N-LINKED (GLCNAC...) (POTENTIAL).
FT CARBOHYD 63 63 N-LINKED (GLCNAC...) (POTENTIAL).
FT CARBOHYD 108 108 N-LINKED (GLCNAC...) (POTENTIAL).
SQ SEQUENCE 192 AA; 21075 MW; DBC419022F7B483A CRC64;

Query Match 81.98; Score 692.5; DB 1; Length 192;
Best Local Similarity 83.18; Pred. No. 2.8e-61;
Matches 138; Conservative 8; Mismatches 19; Indels 1; Gaps 1;

Qy 1 APPRLICDSRVLYLLEAKEAEENITTCGAHSGSLNENITVPDTKYNFVANKRMEVQQA 60
26 APARLICDSRVLYLLEAKEAEENITTCGAHSGSLNENITVPDTKYNFVANKRMEVQQA 85
Db 61 VEVWQGLLSEAILQALQANSSQPPELQHLIDKATISGLRLSLTLRLVGAQKELMS 120

```

```

Db 86 LEVWQGLLSEAILRQALLANASQPCEALRLHVDKAVSGRLSLTLRLVGAQKEAIS 145
121 PPDAASAAPLRTITADTFRKLFVSNFLRGKLYTGACRTGD 165
146 LPDATPSAAPLRAFTVDALSKLFRIYSNFLRGKLYTGACRRGD 191

RESULT 7
EPO_MOUSE
ID EPO_MOUSE STANDARD; PRT; 192 AA.
AC F07321:
DT 01-APR-1988 (Rel. 07, Created)
DT 01-APR-1988 (Rel. 07, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Erythropoietin precursor.
GN EPO.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sclurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=87039105; PubMed=3773894;
RA Shoemaker C.B., Mitsock L.D.;
RT "Murine erythropoietin gene: cloning, expression, and human gene
RT homology.";
RL Mol. Cell. Biol. 6:849-858(1986).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=87039104; PubMed=3022133;
RA McDonald J.D., Lin F.-K., Goldwasser E.;
RT "Cloning, sequencing, and evolutionary analysis of the mouse
RT erythropoietin gene.";
RL Mol. Cell. Biol. 6:842-848(1986).
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=129/Sv;
RX MEDLINE=21138439; PubMed=11239002;
RA Wilson M.D., Riemer C., Martindale D.W., Schnupf P., Borlight A.P.,
RA Cheung T.L., Hardy D.M., Schwartz S., Scherer S.W., Tsui L.-C.,
RA Miller W., Koop B.F.;
RT "Comparative analysis of the gene-dense ACHE/TFR2 region on human
RT chromosome 7q22 with the orthologous region on mouse chromosome 5.";
RL Nucleic Acids Res. 29:1352-1365(2001).
RN [4]
RP SEQUENCE OF 1-52 FROM N.A.
RC STRAIN=ICFW;
RX MEDLINE=98030528; PubMed=9365246;
RA Chretien S., Duprez V., Maouche L., Gisselbrecht S., Mayeux P.,
RA Lacombe C.;
RT "Abnormal erythropoietin (Epo) gene expression in the murine
RT erythroleukemia IW32 cells results from a rearrangement between the
RT G-protein beta2 subunit gene and the Epo gene.";
RL Oncogene 15:1995-1999(1997).
CC -1- FUNCTION: ERYTHROPOIETIN IS THE PRINCIPAL HORMONE INVOLVED IN THE
CC REGULATION OF ERYTHROCYTE DIFFERENTIATION AND THE MAINTENANCE OF A
CC PHYSIOLOGICAL LEVEL OF CIRCULATING ERYTHROCYTE MASS.
CC -1- SUBCELLULAR LOCATION: Secreted.
CC -1- TISSUE SPECIFICITY: PRODUCED BY KIDNEY OR LIVER OF ADULT MAMMALS
CC AND BY LIVER OF FETAL OR NEONATAL MAMMALS.
CC -1- SIMILARITY: BELONGS TO THE EPO / TPO FAMILY.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; M12482; AAA37568.1; -
DR EMBL; M12930; AAA37570.1; -

```

```

DR EMBL; AF312033; AAK28825.1; -.
DR EMBL; Y11971; CAA72707.1; -.
DR PIR; A24901; A24901.
DR PIR; A24902; A24902.
DR HSP; P01588; 1CN4.
DR MGD; MGI:95407; EPO.
DR InterPro; IPR001323; EPO_TPO.
DR InterPro; IPR003013; Erythroptn.
DR Pfam; PF00758; EPO_TPO; 1.
DR PRINTS; PR00272; ERYTHROPTN.
DR PROSITE; PS00817; EPO_TPO; 1.
KW Erythrocyte maturation; Glycoprotein; Hormone; Signal.
FT SIGNAL 1 26
FT CHAIN 27 192 ERYTHROPOIETIN.
FT DISULFID 33 187 BY SIMILARITY.
FT CARBOHYD 50 50 N-LINKED (GLCNAC. . .) (BY SIMILARITY).
FT CARBOHYD 64 64 N-LINKED (GLCNAC. . .) (BY SIMILARITY).
FT CARBOHYD 109 109 N-LINKED (GLCNAC. . .) (BY SIMILARITY).
SQ SEQUENCE 192 AA; 21365 MW; 65F94E214E0DEF2E CRC64;

Query Match 81.4%; Score 689; DB 1; Length 192;
Best Local Similarity 80.0%; Pred. No. 6.2e-61;
Matches 132; Conservative 14; Mismatches 19; Indels 0; Gaps 0;

QY 1 APRRLCDSRVLELYLLEAKEAENITTCGAHCSLNENITVPDTKYNFYAKRMVEVCQA 60
Dd 27 APRRLCDSRVLELYLLEAKEAENITTCGAHCSPRUSENITVPDTKYNFYAKRMVEVCQA 86
QY 61 VEVWQGLALLSEAVLRGQALLVNSQWPPEQLQHVDAKVGSLRSLTTLRALGAQKEAIS 120
Dd 87 VEVWQGLSLSEAILQAQALLANSQPPETLQHDHDKAISGLRSLTSLRLVLAQKELMS 146
QY 121 PPDASAAPLRITADTFKRLFRVYSNLFRLGKLYTGEACRTGD 165
Dd 147 PPDTPPPAPLRITLTDVTECKLFRVYANFLRGKLYTGEVCRRGD 191

RESULT 8
EPO_SHEEP
ID EPO_SHEEP STANDARD; PRT; 194 AA.
AC P33709; Q28572;
DT 01-FEB-1994 (Rel. 28, Created)
DT 01-FEB-1994 (Rel. 28, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Erythropoietin precursor.
GN EPO.
OS Ovis aries (Sheep).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
OC Bovidae; Caprinae; Ovis.
OX NCBI_TaxID=9940;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Kidney;
RX MEDLINE=93351736; PubMed=8349021;
RA Fu P., Evans B., Lim G.B., Moritz K., Wintour M.E.;
RT "The sheep erythropoietin gene: molecular cloning and effect of
RT hemorrhage on plasma erythropoietin and renal/liver messenger RNA in
RT adult sheep.";
RL Mol. Cell. Endocrinol. 93:107-116(1993).
RN [2]
RP SEQUENCE OF 4-194 FROM N.A.
RC TISSUE=Kidney;
RX MEDLINE=93372347; PubMed=8364201;
RA Wen D., Boissel J.P.R., Tracy T.E., Gruninger R.H., Mulcahy L.S.,
RA Czelusniak J., Goodman M., Bunn H.F.;
RT "Erythropoietin structure-function relationships: high degree of
RT sequence homology among mammals.";
RL Blood 82:1507-1516(1993).
CC -!- FUNCTION: ERYTHROPOIETIN IS THE PRINCIPAL HORMONE INVOLVED IN THE
CC REGULATION OF ERYTHROCYTE DIFFERENTIATION AND THE MAINTENANCE OF A
CC PHYSIOLOGICAL LEVEL OF CIRCULATING ERYTHROCYTE MASS.
CC -!- SUBCELLULAR LOCATION: Secreted.

-!- TISSUE SPECIFICITY: PRODUCED BY KIDNEY OR LIVER OF ADULT MAMMALS
AND BY LIVER OF FETAL OR NEONATAL MAMMALS.
-!- SIMILARITY: BELONGS TO THE EPO / TPO FAMILY.
-----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
-----
CC EMBL; Z24681; CAA80848.1; -.
CC EMBL; L10610; AAA31518.1; -.
CC HSP; P01588; 1CN4.
CC InterPro; IPR001323; EPO_TPO.
CC InterPro; IPR003013; Erythroptn.
CC Pfam; PF00758; EPO_TPO; 1.
CC PRINTS; PR00272; ERYTHROPTN.
CC PROSITE; PS00817; EPO_TPO; 1.
KW Erythrocyte maturation; Glycoprotein; Hormone; Signal.
FT SIGNAL 1 27
FT CHAIN 28 194 ERYTHROPOIETIN.
FT DISULFID 34 189 BY SIMILARITY.
FT DISULFID 56 60 BY SIMILARITY.
FT CARBOHYD 51 51 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 65 65 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CARBOHYD 110 110 N-LINKED (GLCNAC. . .) (POTENTIAL).
FT CONFLICT 16 16 F -> L (IN REF. 2).
FT CONFLICT 108 108 L -> P (IN REF. 2).
SQ SEQUENCE 194 AA; 21335 MW; C025AAB0528131A9 CRC64;

Query Match 81.0%; Score 685.5; DB 1; Length 194;
Best Local Similarity 81.9%; Pred. No. 1.4e-60;
Matches 136; Conservative 9; Mismatches 20; Indels 1; Gaps 1;

QY 1 APRRLCDSRVLELYLLEAKEAENITTCGAHCSLNENITVPDTKYNFYAKRMVEVCQA 60
Dd 28 APRRLCDSRVLELYLLEAKEAENITTCGAHCSPRUSENITVPDTKYNFYAKRMVEVCQA 87
QY 61 VEVWQGLALLSEAVLRGQALLVNSQWPPEQLQHVDAKVGSLRSLTTLRALGAQKEAIS 120
Dd 88 LEVWQGLALLSEAVLRGQALLVNSQWPPEQLQHVDAKVGSLRSLTTLRALGAQKEAIS 147
QY 121 PPDAA-SAAPLRITADTFKRLFRVYSNLFRLGKLYTGEACRTGD 165
Dd 148 LPDAPSAAPLRITADTFKRLFRVYSNLFRLGKLYTGEACRTGD 193

RESULT 9
EPO_PIG
ID EPO_PIG STANDARD; PRT; 190 AA.
AC P49157;
DT 01-FEB-1996 (Rel. 33, Created)
DT 01-FEB-1996 (Rel. 33, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Erythropoietin precursor (Fragment).
GN EPO.
OS Sus scrofa (pig).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
OX NCBI_TaxID=9823;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Kidney;
RX MEDLINE=93372347; PubMed=8364201;
RA Wen D., Boissel J.P.R., Tracy T.E., Gruninger R.H., Mulcahy L.S.,
RA Czelusniak J., Goodman M., Bunn H.F.;
RT "Erythropoietin structure-function relationships: high degree of
RT sequence homology among mammals.";
RL Blood 82:1507-1516(1993).
CC -!- FUNCTION: ERYTHROPOIETIN IS THE PRINCIPAL HORMONE INVOLVED IN THE
CC REGULATION OF ERYTHROCYTE DIFFERENTIATION AND THE MAINTENANCE OF A

```

CC PHYSIOLOGICAL LEVEL OF CIRCULATING ERYTHROCYTE MASS.
 CC -!- SUBCELLULAR LOCATION: Secreted.
 CC -!- TISSUE SPECIFICITY: PRODUCED BY KIDNEY OR LIVER OF ADULT MAMMALS
 CC AND BY LIVER OF FETAL OR NEONATAL MAMMALS.
 CC -!- SIMILARITY: BELONGS TO THE EPO / TPO FAMILY.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----

DR EMBL; L10607; AAA31029.1; -
 DR HSSP; P01588; 1CN4.
 DR InterPro: IPR001323; EPO_TPO.
 DR Pfam; PF00758; EPO_TPO; 1.
 DR PROSITE; PS00817; EPO_TPO; 1.
 KW Erythrocyte maturation; Glycoprotein; Hormone; Signal.
 FT SIGNAL 1 22 POTENTIAL.
 FT CHAIN 23 190 ERYTHROPOIETIN.
 FT DISULFID 29 185 BY SIMILARITY.
 FT DISULFID 51 55 BY SIMILARITY.
 FT CARBOHYD 46 46 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 60 60 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 105 105 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 168 168 N-LINKED (GLCNAC. . .) (POTENTIAL).
 SQ SEQUENCE 190 AA; 20888 MW; A75BD6CCE5077E2A CRC64;

Query Match 80.1%; Score 678; DB 1; Length 190;
 Best Local Similarity 82.0%; Pred. No. 7.5e-60;
 Matches 137; Conservative 7; Mismatches 21; Indels 2; Gaps 1;

QY 1 APRLLCDSRVLYRLYLEAKEAENITTCGAHCSLNENITVPTKYNFYAKRMVEGQQA 60
 DB 23 APRLLCDSRVLYRLYLEAKEAENITTCGAHCSLNENITVPTKYNFYAKRMVEGQQA 82
 QY 61 VEVWQGLALLSEALVLRQALLVNSQPWEPLQLHVDKAVSLRLTLLRALGAQKEAIS 120
 DB 83 MEVWQGLALLSEALVLRQALLVNSQPWEPLQLHVDKAVSLRLTLLRALGAQKEAIP 142
 QY 121 PPDA-ASAAPLRITADTFRKLRVYNSFLRGKLYTGEACRTGD 165
 DB 143 LPDASPSSATPLRTFAVDTLCKLFRNYSNLFRLGKLYTGEACRRRD 189

RESULT 10
 ID EPO_CANFA STANDARD; PRT; 175 AA.
 AC P33707;
 DT 01-FEB-1994 (Rel. 28, Created)
 DT 01-FEB-1994 (Rel. 28, Last sequence update)
 DT 16-OCT-2001 (Rel. 40, Last annotation update)
 DE Erythropoietin precursor (fragment).
 GN EPO.
 OS Canis familiaris (Dog).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
 OX NCBI_TaxID=9615;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=93372347; PubMed=8364201;
 RA Wen D., Boissel J.P.R., Tracy T.E., Gruninger R.H., Mulcahy L.S.,
 RA Czelusniak J., Goodman M., Bunn H.F.;
 RT "Erythropoietin structure-function relationships: high degree of
 RT sequence homology among mammals."
 RL Blood 82:1507-1516(1993).
 CC -!- FUNCTION: ERYTHROPOIETIN IS THE PRINCIPAL HORMONE INVOLVED IN THE
 CC REGULATION OF ERYTHROCYTE DIFFERENTIATION AND THE MAINTENANCE OF A
 CC PHYSIOLOGICAL LEVEL OF CIRCULATING ERYTHROCYTE MASS.
 CC -!- SUBCELLULAR LOCATION: Secreted.


CC -!- TISSUE SPECIFICITY: PRODUCED BY KIDNEY OR LIVER OF ADULT MAMMALS
 CC AND BY LIVER OF FETAL OR NEONATAL MAMMALS.
 CC -!- SIMILARITY: BELONGS TO THE EPO / TPO FAMILY.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----

DR EMBL; L13027; AAA30842.1; -
 DR HSSP; P01588; 1CN4.
 DR InterPro: IPR001323; EPO_TPO.
 DR Pfam; PF00758; EPO_TPO; 1.
 DR PROSITE; PS00817; EPO_TPO; 1.
 KW Erythrocyte maturation; Glycoprotein; Hormone; Signal.
 FT SIGNAL 1 22 BY SIMILARITY.
 FT CHAIN 23 >175 ERYTHROPOIETIN.
 FT DISULFID 29 >175 BY SIMILARITY.
 FT DISULFID 51 55 BY SIMILARITY.
 FT CARBOHYD 46 46 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 60 60 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 105 105 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT NON_TER 175 175
 SQ SEQUENCE 175 AA; 19193 MW; B504F8DE86678BF4 CRC64;

Query Match 75.4%; Score 638; DB 1; Length 175;
 Best Local Similarity 81.0%; Pred. No. 6e-56;
 Matches 124; Conservative 13; Mismatches 16; Indels 0; Gaps 0;

QY 1 APRLLCDSRVLYRLYLEAKEAENITTCGAHCSLNENITVPTKYNFYAKRMVEGQQA 60
 DB 23 APRLLCDSRVLYRLYLEAKEAENITTCGAHCSLNENITVPTKYNFYAKRMVEGQQA 82
 QY 61 VEVWQGLALLSEALVLRQALLVNSQPWEPLQLHVDKAVSLRLTLLRALGAQKEAIS 120
 DB 83 LEVWQGLALLSEALVLRQALLVNSQPWEPLQLHVDKAVSLRLTLLRALGAQKEAMS 142
 QY 121 PPDAASAAPLRITADTFRKLRVYNSFLRGKLYTGEACRTGD 153
 DB 143 LPDASPAPLRITFTVDTLCKLFRNYSNLFRLGKLYTGEACRTGD 175

RESULT 11
 ID TPO_CANFA STANDARD; PRT; 352 AA.
 AC P42705;
 DT 01-NOV-1995 (Rel. 32, Created)
 DT 01-NOV-1995 (Rel. 32, Last sequence update)
 DT 16-OCT-2001 (Rel. 40, Last annotation update)
 DE Thrombopoietin precursor (Megakaryocyte colony stimulating factor)
 DE (C-MPL ligand) (ML) (Megakaryocyte growth and development factor)
 DE (MGDF).
 GN THPO OR TPO.
 OS Canis familiaris (Dog).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
 OX NCBI_TaxID=9615;
 RN [1]
 RP SEQUENCE FROM N.A., AND SEQUENCE OF 24-44.
 RX MEDLINE=94291201; PubMed=8020099;
 RA Bartley T.D., Bogenberger J., Hunt P., Li Y.-S., Lu H.S., Martin F.,
 RA Chang M.-S., Samal B.B., Nichol J.B., Swift S., Johnson M.J.,
 RA Hsu R.-Y., Parker V.P., Suggs S., Skrine J.D., Merewether L.A.,
 RA Clogson C., Hsu E., Hokom M.M., Hornkohl A., Choi E., Pangellinan M.,
 RA Sun Y., Mar V., McNich J., Simonet L., Jacobsen F., Xie C.,
 RA Shuttler J., Chute H., Basu R., Selander L., Trollinger D., Sieu L.,
 RA Padilla D., Trail G., Elliott G., Izumi R., Covey T., Crouse J.,
 RA Garcia A., Xu W., del Castillo J., Biron J., Cole S., Hu M.C.-T.,



GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: June 13, 2003, 15:04:06 ; Search time 34 Seconds
(without alignments)
999.935 Million cell updates/sec

Title: US-09-830-964-1
Perfect score: 846
Sequence: 1 APRRLICDSRVLYLEAK.....SNFLRGKLYTGEACRTGD 165

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 671580 seqs, 206047115 residues

Total number of hits satisfying chosen parameters: 671580

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

SPTREMBL_21:*

- 1: sp_archaea:*
- 2: sp_bacteria:*
- 3: sp_fungi:*
- 4: sp_human:*
- 5: sp_invertebrate:*
- 6: sp_mammal:*
- 7: sp_mmc:*
- 8: sp_organelle:*
- 9: sp_phase:*
- 10: sp_plant:*
- 11: sp_rodent:*
- 12: sp_virus:*
- 13: sp_vertebrate:*
- 14: sp_unclassified:*
- 15: sp_rvirus:*
- 16: sp_bacteriap:*
- 17: sp_archaeap:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | DB ID | Description |
|------------|-------|-------------|--------|-----------|--------------------|
| 1 | 680.5 | 80.4 | 195 | 6 Q9GKA3 | Q9gka3 oryctolagus |
| 2 | 680.5 | 80.4 | 195 | 6 Q9GKA2 | Q9gka2 oryctolagus |
| 3 | 678 | 80.1 | 194 | 6 Q9MYN8 | Q9myn8 sus scrofa |
| 4 | 188 | 22.2 | 50 | 11 Q9QV40 | Q9qv40 rattus sp. |
| 5 | 88 | 10.4 | 323 | 16 Q8ZBC8 | Q8zbc8 yersinia pe |
| 6 | 87.5 | 10.3 | 346 | 16 Q8ZK24 | Q8zkd4 salmonella |
| 7 | 87.5 | 10.3 | 346 | 16 Q8Z2M5 | Q8z2m5 salmonella |
| 8 | 85 | 10.0 | 3722 | 2 P94873 | P94873 lysobacter |
| 9 | 83 | 9.8 | 296 | 16 Q8ZAY4 | Q8zay4 yersinia pe |
| 10 | 83 | 9.8 | 339 | 16 Q9HZM7 | Q9hzm7 pseudomonas |
| 11 | 82.5 | 9.8 | 3033 | 12 Q9DDH6 | Q9ddh6 hepatitis c |
| 12 | 82 | 9.7 | 815 | 10 Q9FK91 | Q9fk91 arabidopsis |
| 13 | 79.5 | 9.4 | 1829 | 16 Q86808 | Q86808 streptomyce |
| 14 | 79.5 | 9.4 | 3033 | 12 Q9IZA1 | Q9izal hepatitis c |
| 15 | 79 | 9.3 | 480 | 10 Q43380 | Q43380 avena sativ |
| 16 | 79 | 9.3 | 2364 | 5 Q22896 | Q22896 caenorhabdi |

ALIGNMENTS

RESULT 1

Q9GKA3 ID Q9GKA3 PRELIMINARY: PRT; 195 AA.
AC Q9GKA3;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE Erythropoietin.
OS Oryctolagus cuniculus (Rabbit).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.
OX NCBI_TaxID=9986;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=21290682; PubMed=11396976;
RA Vilalta A., Wu D., Margalith M., Hobart P.;
RT "Rabbit EPO Gene and cDNA: Expression of Rabbit EPO after
RT Intramuscular Injection of pDNA."
RL Biochem. Biophys. Res. Commun. 284:823-827(2001).
DR EMBL; AF290943; AAC36961.1; -;
DR HSSP; P01586; ICN4.
DR InterPro; IPR001323; EPO_TPO.
DR InterPro; IPR003013; Erythroptn.
DR Pfam; PF00758; EPO_TPO; 1.
DR PRINTS; PR00272; ERYTHROPTN.
DR PROSITE; PS00817; EPO_TPO; 1.
SQ SEQUENCE 195 AA; 21053 MW; 0999DA7D852713F3 CRC64;

Query Match 80.4%; Score 680.5; DB 6; Length 195;

Best Local Similarity 81.3%; Pred. No. 1.4e-60;

Matches 135; Conservative 12; Mismatches 18; Indels 1; Gaps 1;

QY 1 APRRLICDSRVLYLEAKEAENITTCGAHCNLENITVPDTKYNFYANKRMEVGQQA 60

Db 29 APARLICDSRVLYLEAKEAENITVPDTKYNFYANKRMEVGQQA 88

QY 61 VEWQGLALLSEAVLRGQALLVNSSQPWEPLQHVDPKAVSGRLSLTLLRALCAQKEATS 120

Db 89 VEWQGLALLSEAVLRGQALLVNSSQPWEPLQHVDPKAVSGRLSLTLLRALCAQKEATS 148

QY 121 PDAA-SAAPLRTITADTFRKLFVYSNFLRGKLYTGEACRTGD 165
 Db 149 PPEAASSAAPLRTVAADTLCFLFRIYSNFLRGKLYTGEACRRGD 194

RESULT 2
 Q9GKA2 PRELIMINARY; PRT; 195 AA.
 ID Q9GKA2
 AC Q9GKA2; 201 (TREMBlrel. 16, Created)
 DT 01-MAR-2001 (TREMBlrel. 16, Last sequence update)
 DT 01-JUN-2002 (TREMBlrel. 21, Last annotation update)
 DE Erythropoietin.
 OS Oryctolagus cuniculus (Rabbit).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.
 OX NCBI_TaxID=9986;
 RN [1]
 RP .SEQUENCE FROM N.A.
 RX MEDLINE=21290682; PubMed=11396976;
 RA Villalta A., Wu D., Margalith M., Hobart P.;
 RT "Rabbit EPO Gene and cDNA: Expression of Rabbit EPO after
 RT Intramuscular Injection of PDNA";
 RL Biochem. Biophys. Res. Commun. 284:823-827(2001).
 DR EMBL; AF290944; AAG36962.1; .
 DR HSSP; P01588; 1CN4.
 DR InterPro: IPR001323; EPO_TPO.
 DR InterPro: IPR003013; Erythroptn.
 DR Pfam: PF00758; EPO_TPO; 1.
 DR PRINTS; PR00272; ERYTHROPTN.
 DR PROSITE; PS00817; EPO_TPO; 1.
 SQ SEQUENCE 195 AA; 21025 MW; 1FIDC7F403A303EC CRC64;

Query Match 80.4%; Score 680.5; DB 6; Length 195;
 Best Local Similarity 81.3%; Pred. No. 1.4e-60;
 Matches 135; Conservative 12; Mismatches 18; Indels 1; Gaps 1;

QY 1 APRLICDSRVLYRLLYLEAKAEANTTGCACGCSLGNITVPDTKVNFKYAKRMEVQQA 60
 Db 29 APARLICDSRVLYRLLYLEAKAEANTTGCACGCSLGNITVPDTKVNFKYAKRMEVQQA 88

QY 61 VEVWOGALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALCAQKEAIS 120
 Db 89 VEVWOGALLSEAVLRGQALLVNSQPWEPLQLHVDKAVSGLSRLTLLRALCAQKEAIS 148

QY 121 PDAA-SAAPLRTITADTFRKLFVYSNFLRGKLYTGEACRTGD 165
 Db 149 PPEAASSAAPLRTVAADTLCFLFRIYSNFLRGKLYTGEACRRGD 194

RESULT 3
 Q9MYM8 PRELIMINARY; PRT; 194 AA.
 ID Q9MYM8
 AC Q9MYM8; 15 (Created)
 DT 01-OCT-2000 (TREMBlrel. 15, Last sequence update)
 DT 01-JUN-2002 (TREMBlrel. 21, Last annotation update)
 DE Erythropoietin precursor.
 GN EPO.
 OS Sus scrofa (Pig).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
 OX NCBI_TaxID=9823;
 RN [1]
 RP .SEQUENCE FROM N.A.
 RX STRAIN-NORWEGIAN LANDRACE; TISSUE-KIDNEY;
 RA David B., Harbitz I.;
 RT "The porcine erythropoietin gene: cDNA and genomic sequences and
 RT expression analyses";
 RL Submitted (SEP-1999) to the EMBL/GenBank/DBJ databases.
 DR EMBL; AJ249375; CAB96416.1; .
 DR EMBL; AJ249746; CAB96417.1; .

OC Yersinia.
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN-CO-92 / BIOVAR ORIENTALIS;
 RX MEDLINE=21470413; PubMed=11586360;
 RA Pathill J., Wren B.W., Thomson N.R., Titball R.W., Holden M.T.G.,
 RA Prentice M.B., Sebahia M., James K.D., Churcher C., Mungall K.L.,
 RA Baker S., Basham D., Bentley S.D., Brooks K., Cerdono-Tarraga A.M.,
 RA Chillingworth T., Cronin A., Davies R.M., Davis P., Dougan G.,
 RA Feltwell T., Hamlin N., Holroyd S., Jagels K., Karlyshev A.V.,
 RA Leather S., Moule S., Oyston P.C.F., Quail M., Rutherford K.,
 RA Simmonds M., Skelton J., Stevens K., Whitehead S., Bartell B.G.,
 RT "Genome sequence of Yersinia pestis, the causative agent of plague."
 RL Nature 413:523-527(2001).
 DR EMBL: AJ414153; CAC92889.1; "
 DR InterPro: IPR000358; RibonucL_redctse.
 DR Pfam: PF02688; ribonucL_red_sm; 1.
 DR PROSITE: PS00368; RIBORED_SMALL; 1.
 KW Oxidoreductase; Complete proteome.
 SQ SEQUENCE 323 AA; 36823 MW; 87C21F7BB9B7FD2 CRC64;

Query Match 10.4%; Score 88; DB 16; Length 323;
 Best Local Similarity 25.2%; Pred. No. 1.3;
 Matches 34; Conservative 20; Mismatches 59; Indels 22; Gaps 5;

QY 38 NITVPDTKVNFAKMEVGOQAVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVD- 96
 DB 2 NVVKPITRISAINNKIE-DQKDLVNN--RLTSNFWLPKVPPLSDIPSWATLTPHQQ 58
 QY 97 ---KAVSGLSRLTLLRALGQ----KEAISPPDAASAAPLRTITADTKLFRVYSNLR 150
 DB 59 LTRVFTGLTLDITQNTLGALIKDAITPHEAIFSNISFMEAVHARSYSSIFSTL-- 116
 QY 151 GKLYTGEACRTGD 165
 DB 117 -----CUTSD 121

RESULT 6
 Q8ZK24 PRELIMINARY; PRT; 346 AA.
 AC Q8ZK24
 DT 01-MAR-2002 (TremBLrel. 20, Created)
 DT 01-MAR-2002 (TremBLrel. 20, Last sequence update)
 DT 01-JUN-2002 (TremBLrel. 21, Last annotation update)
 DE Periplasmic sensor in multi-component regulatory system with Tors
 DE (sensory kinase) and TorR (regulator), regulates tor operon.
 GN TOR OR STM3825.
 OS Salmonella typhimurium.
 OC Bacteria; Proteobacteria; gamma subdivision; Enterobacteriaceae;
 OC Salmonella.
 OX NCBI_TaxID=602;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN-LT2 / SGSC1412 / ATCC 700720;
 RX MEDLINE=21534948; PubMed=11677609;
 RA McClelland M., Sanderson K.E., Spieth J., Clifton S.W., Latreille P.,
 RA Courtney L., Porwollik S., Ali J., Dante M., Du F., Hou S., Layman D.,
 RA Leonard S., Nguyen C., Scott K., Holmes A., Grewal N., Mulvaney E.,
 RA Ryan E., Sun H., Florea L., Miller W., Stoneking T., Nhan M.,
 RA Waterston R., Wilson R.K.;
 RT "Complete genome sequence of Salmonella enterica serovar Typhimurium
 LT2."
 RL Nature 413:852-856(2001).
 DR EMBL: AE008878; AAL22684.1; "
 DR InterPro: IPR001761; PeriplaBP/LacI.
 DR Pfam: PF00532; Peripla_BP_like; 1.
 KW Complete proteome.
 SQ SEQUENCE 346 AA; 38440 MW; E37CAB58E49FD716 CRC64;

Query Match 10.3%; Score 87.5; DB 16; Length 346;
 Best Local Similarity 26.7%; Pred. No. 1.5;
 Matches 44; Conservative 22; Mismatches 48; Indels 51; Gaps 9;

QY 10 RVLERYLLEAKEAENITTG--CAEHCSLNE--NITVPDTKVNFAKMEVGOQAVEVWQ 65
 DB 217 RNLQEMLERHPDANVAGSAIAAAMGEGRNLTPTLTVSYL-----THQVYR 267
 QY 66 GLALLSEAVLRGQALLVNSSQ-PWEPLQLHVDKAVSGLSRLTLLRALGQ--KEAISPP 122
 DB 268 GLK-----RGHILMALSDQMAWQ-----GELAITOSIKVLOGQPPVPENISPP 309
 QY 123 -----DAASAAPLRTITADTKLFRVYSNLRGKLYTGEA 160
 DB 310 VLILTHNNADSRVRKSLSPGFRPVY-----LYQYTSEA 344

RESULT 7
 Q8Z2M5 PRELIMINARY; PRT; 346 AA.
 AC Q8Z2M5
 DT 01-MAR-2002 (TremBLrel. 20, Created)
 DT 01-MAR-2002 (TremBLrel. 20, Last sequence update)
 DT 01-JUN-2002 (TremBLrel. 21, Last annotation update)
 DE Solute binding receptor protein.
 GN Str3952.
 OS Salmonella typhi.
 OC Bacteria; Proteobacteria; gamma subdivision; Enterobacteriaceae;
 OC Salmonella.
 OX NCBI_TaxID=601;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=CT18;
 RX MEDLINE=21534947; PubMed=11677608;
 RA Parkhill J., Dougan G., James K.D., Thomson N.R., Pickard D., Wain J.,
 RA Churcher C., Mungall K.L., Bentley S.D., Holden M.T.G., Sebahia M.,
 RA Baker S., Basham D., Brooks K., Chillingworth T., Connor P.,
 RA Cronin A., Davis P., Davies R.M., Dowd L., White N., Farrar J.,
 RA Feltwell T., Hamlin N., Haque A., Hien T.T., Holroyd S., Jagels K.,
 RA Krogh A., Larsen T.S., Leather S., Moule S., O'Gaora P., Parry C.,
 RA Quail M., Rutherford K., Simmonds M., Skelton J., Stevens K.,
 RA Whitehead S., Bartell B.G.;
 RT "Complete genome sequence of a multiple drug resistant Salmonella
 enterica serovar typhi CT18."
 RL Nature 413:848-852(2001).
 DR EMBL: AL627280; CAD03169.1; "
 DR InterPro: IPR001761; PeriplaBP/LacI.
 DR Pfam: PF00532; Peripla_BP_like; 1.
 KW Receptor; Complete proteome.
 GN TOR OR STM3825.
 SQ SEQUENCE 346 AA; 38546 MW; F80FB1688BC83A8F CRC64;

Query Match 10.3%; Score 87.5; DB 16; Length 346;
 Best Local Similarity 26.7%; Pred. No. 1.5;
 Matches 44; Conservative 22; Mismatches 48; Indels 51; Gaps 9;

QY 10 RVLERYLLEAKEAENITTG--CAEHCSLNE--NITVPDTKVNFAKMEVGOQAVEVWQ 65
 DB 217 RNLQEMLERHPDANVAGSAIAAAMGEGRNLTPTLTVSYL-----THQVYR 267
 QY 66 GLALLSEAVLRGQALLVNSSQ-PWEPLQLHVDKAVSGLSRLTLLRALGQ--KEAISPP 122
 DB 268 GLK-----RGHILMALSDQMAWQ-----GELAITOSIKVLOGQPPVPENISPP 309
 QY 123 -----DAASAAPLRTITADTKLFRVYSNLRGKLYTGEA 160
 DB 310 VLILTHNNADSRVRKSLSPGFRPVY-----LYQYTSEA 344

RESULT 8
 P94873 PRELIMINARY; PRT; 3722 AA.
 AC P94873
 DT 01-MAY-1997 (TremBLrel. 03, Created)
 DT 01-MAY-1997 (TremBLrel. 03, Last sequence update)
 DT 01-MAR-2002 (TremBLrel. 20, Last annotation update)

| RA | Chillingworth T., Cronin A., Davies R.M., Davis P., Dougan G., |
|-----|--|
| RA | Feltwell T., Hamlin N., Holroyd S., Jagels K., Karlyshev A.V., |
| RA | Leather S., Moule S., Oyston P.C.F., Quail M., Rutherford K., |
| RA | Simmonds M., Skelton J., Stevens K., Whitehead S., Barrell B.G.; |
| RT | "Genome sequence of <i>Yersinia pestis</i> , the causative agent of plague." |
| RL | Nature 413:523-527(2001). |
| DR | ENBL; AJ414158; CAC93117.1; - |
| DR | InterPro: IPR002204; 3hydroxisobut_dh. |
| DR | InterPro: IPR001744; 6PGD. |
| DR | Pfam: PF03446; NAD_binding_2; 1. |
| DR | PROSITE: PS00895; 3-HYDROXYISOBUT_DH; UNKNOWN1. |
| KW | Oxidoreductase: Hypothetical protein; Complete proteome. |
| SEQ | SEQUENCE 296 AA; 32140 MW; C883AFC6868429D CRC64; |

| Query Match | 9.8%; | Score 83; | DB 16; | Length 296; |
|-----------------------|------------------|----------------|------------|-------------|
| Best Local Similarity | 24.2%; | Pred. No. 3.6; | | |
| Matches 48; | Conservative 34; | Mismatches 62; | Indels 54; | Gaps |

| Qy | 6 | ICDSRVLELYLLEAK-EAENITTCGAEHCSLNENIT-VPDTKVFYAKRWVGQQAQV |
|----|-----|---|
| Db | 32 | ICCDADITKQVILITAEIENAEISLVDNA--ASLDALITMLPNSE---AVEQVLLGSDGIS |
| Qy | 64 | WQGLALSEAVIRGQALLVNSSP-----WE-----PLQLHVDKAVSG- |
| Db | 86 | W--VAQLSQAIV---VIDMSSDPERSRRRLATLAVWELDYLDAPVSGVKKQACNTLS |
| Qy | 102 | -----LRLSTLLRALCAQAEATSPDASAP-----LRTIADTRFKLE |
| Db | 141 | LIGGEDRVRLKSCYITALAAMGEQLFVGPAGSGHAAKALNNVYSATGLLATIEALHVAQR |
| Qy | 143 | RVYSNFRGLGKLYTGEA 160 |
| Db | 201 | GIPEVMTVEVLTSTGRS 218 |

| RESULT 10 | Q9H2M7 | PRELIMINARY; | PRT; 339 AA. |
|-----------|---|--------------|--------------|
| ID | Q9H2M7 | | |
| AC | Q9H2M7; | | |
| DT | 01-MAR-2001 (TremBrel. 16, Created) | | |
| DT | 01-MAR-2001 (TremBrel. 16, Last sequence update) | | |
| DT | 01-JUN-2002 (TremBrel. 21, Last annotation update) | | |
| DE | UDP-N-acetylpyruvoylglucosamine reductase. | | |
| GN | MURB OR PA2977. | | |
| OS | Pseudomonas aeruginosa. | | |
| OC | Bacteria; Proteobacteria; gamma subdivision; Pseudomonadaceae; | | |
| OC | Pseudomonas. | | |
| OX | NCBI_TaxID=287; | | |
| RP | [1] | | |
| RN | SEQUENCE FROM N.A. | | |
| RC | STRAIN-ATCC 15692 / PA01; | | |
| RC | MEDLINE=20437337; PubMed=10984043; | | |
| RA | Stover C.K., Pham X.-O.T., Erwin A.L., Miziochichi S.D., Warren P., | | |
| RA | Hickey M.J., Brinkman F.S.L., Hufnagle W.O., Kowalik D.J., Lagrou M., | | |
| RA | Garber R.L., Goltzy L., Tolentino E., Westbrook-Wadman S., Yuan Y., | | |
| RA | Brody L.A., Coulter S.N., Folger K.R., Kas A., Larbig K., Lim R.M., | | |
| RA | Smith K.A., Spencer D.H., Wong G.K.-S., Wu Z., Paulsen I.T., | | |
| RA | Reizer J., Sailer M.H., Hancock R.E.W., Lory S., Olson M.V.; | | |
| RT | "Complete genome sequence of <i>Pseudomonas aeruginosa</i> PA01, an | | |
| RT | opportunistic pathogen." | | |
| RL | Nature 406:959-964(2000). | | |
| RL | EMBL; AE004723; AAC06365.1; - | | |
| DR | HSSP; P08373; ZMBR. | | |
| DR | InterPro: IPR003170; MurB. | | |
| DR | InterPro: IPR001575; Oxid_FAD_bind. | | |
| DR | InterPro: IPR000531; TonB_boxC. | | |
| DR | Pfam: PF01565; FAD_binding_4; 1. | | |
| DR | Pfam: PF02873; MurB_C; 1 | | |
| DR | PROSITE: PS00430; TONB_DEPENDENT_REC_1; UNKNOWN1. | | |
| KW | Complete proteome. | | |
| SEQ | SEQUENCE 339 AA; 37627 MW; C0C8EF9F2938FE27 CRC64; | | |

| Query Match | 9.8%; | Score 83; | DB 16; | Length 339; |
|-------------|-------|-----------|--------|-------------|
|-------------|-------|-----------|--------|-------------|

Best Local Similarity 22.7%; Pred. No. 4.3;
Matches 41; Conservative 22; Mismatches 48; Indels 70; Gaps 8;

QY 31 EHCSLNE-NITVPDTRVNYAKRMEVGGQAVEVWQGLALLSEAVLRGQALLV-----82

Db 7 EHCSLKPYNTFGIDVRARLLAHARDE-----ADVREALALARE---RGPLLVIGGSGNL 58

QY 83 -----NSSQWEP-LQLHVDKAVSGLSRLTTL 109

Db 59 LLTRDVEALVLRNASOGRRIIVSDAADSVLVEAEAGEAWDPFVQWSLRLGLAGLNL 117

QY 110 RALGAOKEAISPPDAASAAPLRTITA-----DTFRKLFRVYSNFRGLKLYTGEACRT 163

Db 118 -----PGTVGAAPMQNIGAYGVELKDVFDSLAL--DRODGTREFDRQACRF 163

QY 164 G 164

Db 164 G 164

RESULT 11

Q9DHD6 PRELIMINARY; PRT; 3033 AA.

AC Q9DHD6; 01-MAR-2001 (Tremblrel. 16, Created)

DT 01-MAR-2001 (Tremblrel. 16, Last sequence update)

DT 01-JUN-2002 (Tremblrel. 21, Last annotation update)

DE Genome polyprotein [Contains: envelope glycoprotein E2 (GP68) (GP70) (NS1)]

DE (NS1)]

OS Hepatitis C virus type 2b.

OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;

OC Hepacivirus.

OX NCBI_TaxID=31650;

RN [1]

RC STRAIN=MA;

RX MEDLINE=21296595; PubMed=11402859;

RA Murakami K., Abe M., Kageyama T., Kamoshita N., Nomoto A.;

RT "Down-regulation of translation driven by hepatitis C virus internal

RL Arch. Virol. 146:729-741(2001).

CC -1- SIMILARITY: TO HEPATITIS C VIRUS ENVELOPE GLYCOPROTEIN E1.

DR EMBL; AB030907; HAV08107.1; -;

DR HSP; P27958; IAI.

DR InterPro; IPR000345; CytC_heme_bind.

DR InterPro; IPR001410; DEAD.

DR InterPro; IPR002522; HCV_capsid.

DR InterPro; IPR002521; HCV_core.

DR InterPro; IPR002519; HCV_env.

DR InterPro; IPR002531; HCV_NS1.

DR InterPro; IPR002518; HCV_NS2.

DR InterPro; IPR004109; HCV_NS3.

DR InterPro; IPR000745; HCV_NS4a.

DR InterPro; IPR001490; HCV_NS4b.

DR InterPro; IPR002868; HCV_NS5a.

DR InterPro; IPR002166; HCV_RdRp.

DR Pfam; PF01543; HCV_capsid; 1.

DR Pfam; PF01542; HCV_core; 1.

DR Pfam; PF01539; HCV_env; 1.

DR Pfam; PF01560; HCV_NS1; 1.

DR Pfam; PF01538; HCV_NS2; 1.

DR Pfam; PF02907; HCV_NS3; 1.

DR Pfam; PF01006; HCV_NS4a; 1.

DR Pfam; PF01001; HCV_NS4b; 1.

DR Pfam; PF01506; HCV_NS5a; 1.

DR Pfam; PF00998; HCV_RdRp; 1.

DR ProDom; PD186062; HCV_NS1; 1.

DR SMART; SM00487; DEXDC; 1.

DR PROSITE; PS00190; CYTOCHROME_C; UNKNOWN_1.

KW Coat protein; Envelope protein; Glycoprotein; Nonstructural protein;

KW Polyprotein; RNA-directed RNA polymerase; Transmembrane.

FT CHAIN 1 191 CORE PROTEIN.

FT CHAIN 192 383 E1 PROTEIN.

FT CHAIN 384 750

FT CHAIN 751 813

FT CHAIN 814 1030

FT CHAIN 1031 1561

FT CHAIN 1562 1715

FT CHAIN 1716 1976

FT CHAIN 1977 2442

FT CHAIN 2443 3033

SQ SEQUENCE 3033 AA; 329981 MW; 6B183PED090872B4 CRC64;

Query Match 9.8%; Score 82.5; DB 12; Length 3033;

Best Local Similarity 27.0%; Pred. No. 78;

Matches 40; Conservative 21; Mismatches 60; Indels 27; Gaps 7;

QY 11 VLRYLLLEAKAEENITTCGAE---HCSLNENITV-PDTKVNFYAKRM-----EV 56

Db 1665 VLAGGVLAAYCYLATGCSIIGRIHLNDVVVAPQKEILYEADEMEECASKAALIEE 1724

QY 57 GQAVEVWQ--LALLSEAVLRGQALLVNSQPWEPLQ-----LHVDKAVSGLSRLTTLR 110

Db 1725 GORMAEMLSKILGLLQATKQADIQAPMGSSWPKTEQFWARHWNWFISGIQVLAGLST 1784

QY 111 ALG-----AQEKAISPPDAASAAPLRTIT 134

Db 1785 LPGNPAVASMMAFS---AALTSPULTST 1809

RESULT 12

Q9FK91 PRELIMINARY; PRT; 815 AA.

AC Q9FK91; 01-MAR-2001 (Tremblrel. 16, Created)

DT 01-MAR-2001 (Tremblrel. 16, Last sequence update)

DT 01-DEC-2001 (Tremblrel. 19, Last annotation update)

DE Seed maturation protein PM38 protein.

OS Arabidopsis thaliana (Mouse-ear cress).

OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae;

OC eurosids II; Brassicales; Brassicaceae; Arabidopsids.

OX NCBI_TaxID=3702;

RN [1]

RC SEQUENCE FROM N.A.

RC STRAIN=COLUMBIA;

RX MEDLINE=98403884; PubMed=9734815;

RA Kotani H., Nakamura Y., Sato S., Asamizu E., Kaneko T., Miyajima N.,

RT Tabata S.;

RT "Structural analysis of Arabidopsis thaliana chromosome 5. VI.

RT Sequence features of the regions of 1,367,185 bp covered by 19

RT Physically assigned pl and TAC clones.";

RL DNA Res. 5:203-216(1998).

DR EMBL; AB012244; BAB09119.1; -;

DR InterPro; IPR002086; Aldehyde_dehydr.

DR InterPro; IPR001357; BRCT.

DR InterPro; IPR001290; PARP.

DR Pfam; PF00533; BRCT; 1.

DR Pfam; PF00644; PARP; 1.

DR SMART; SM00292; BRCT; 1.

DR PROSITE; PS00070; ALDEHYDE_DEHYDR_CYS; UNKNOWN_1.

DR PROSITE; PS0172; BRCT; 1.

SQ SEQUENCE 815 AA; 91534 MW; 4B1B602057D46B60 CRC64;

Query Match 9.7%; Score 82; DB 10; Length 815;

Best Local Similarity 21.8%; Pred. No. 16;

Matches 42; Conservative 29; Mismatches 52; Indels 70; Gaps 12;

QY 21 EAENITTCGA-----EHCSLNENITV-PDTKVNFYAKRMEVG-----QOAVEVW 64

Db 328 EKDGLLYNCAFSICDLGKRNEYC-IMQLVTVPDSNLNMY-FKRKGVDDDDNAERLGEW 385

QY 65 QGLALLSEAVLRGQALLV-----NSSQWEP-----PLQ-----LHVDKAVSGL 102

Db 386 ED-----EAAIKFEARLFEELAGNEFEPEWEREKKTKQKPKHFFIDMDGDIETVRSGL 441

```

Qy 103 RSL-----TTLLRALGAQ-----KEAISPPDASAAPLRTITADTFKRL 141
Db 442 RQLGASAHCKLDSFVANEIKVLCGGEIYNVALMELGLDPPD-----LPMGLTDLHLKRC 497
Qy 142 FRYNSFLRCKLK 154
Db 498 EEVLLFEVE-KVK 509

RESULT 13
O86808 PRELIMINARY; PRT; 1829 AA.
AC O86808;
DT 01-NOV-1998 (TrEMBLrel. 08, Created)
DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE Putative sensory histidine kinase.
GN SC05748 OR SC7C7.03.
OS Streptomyces coelicolor.
OC Bacteria; Firmicutes; Actinobacteria; Actinobacteridae;
OC Actinomycetales; Streptomycineae; Streptomycetaceae; Streptomyces.
OX NCBI_TaxID=1902;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=A3(2);
RA Harris D., Taylor K.;
RA Submitted (JUL-1998) to the EMBL/GenBank/DBJ databases.
[2]
RP SEQUENCE FROM N.A.
RC STRAIN=A3(2);
RA Parkhill J., Barrell B.G., Rajandream M.A.;
RA Submitted (JUL-1998) to the EMBL/GenBank/DBJ databases.
[3]
RP SEQUENCE FROM N.A.
RC STRAIN=A3(2);
RA MEDLINE=97000351; PubMed=8843436;
RA Redenbach M., Kieser H.M., Denapate D., Eichner A., Cullum J.,
RA Kinashi H., Hopwood D.A.;
RA "A set of ordered cosmids and a detailed genetic and physical map for
RT the 8 Mb Streptomyces coelicolor A3(2) chromosome.";
RL Mol. Microbiol. 21:77-96(1996).
[4]
RP SEQUENCE FROM N.A.
RC STRAIN=A3(2) / M145;
RA Bentley S.D., Chater K.F., Cerdeno-Tarraga A.-M., Challis G.L.,
RA Thomson N.R., James K.D., Harris D.E., Quail M.A., Kieser H.,
RA Harper D., Bateman A., Brown S., Chandra G., Chen C.W., Collins M.,
RA Cronin A., Fraser A., Goble A., Hidalgo J., Hornsby T., Howarth S.,
RA Huang C.-H., Kieser T., Larke L., Murphy L., Oliver K., O'Neill S.,
RA Rabinovitch E., Rajandream M.A., Rutherford K., Rutter S.,
RA Seeger K., Saunders D., Sharp S., Squares R., Squares S., Taylor K.,
RA Warren T., Wietzorrek A., Woodward J., Barrell B.G., Parkhill J.,
RA Hopwood D.A.;
RA "Complete genome sequence of the model actinomycete Streptomyces
RT coelicolor A3(2).";
RL Nature 417:141-147(2002).
CC -1- SIMILARITY: TO OTHER PROKARYOTIC SENSORY TRANSDUCTION HISTIDINE
CC KINASES.
DR EMBL; AL031031; CAAL9849.1; -.
DR HSSP; P52934; 1D23.
DR InterPro; IPR003594; Atpbind_Atpase.
DR InterPro; IPR004358; Bact_sens_pr_C.
DR InterPro; IPR003018; GAF.
DR InterPro; IPR003660; HAMP.
DR InterPro; IPR003661; His_kinA.
DR InterPro; IPR004359; His_kinA.
DR InterPro; IPR001789; Response_reg.
DR Pfam; PF01590; GAF; 1.
DR Pfam; PF00572; HAMP; 11.
DR Pfam; PF02518; HATPase_c; 1.
DR Pfam; PF00072; response_reg; 1.
DR Pfam; PF00512; signal; 1.
DR PRINTS; PR00344; BCTRLSENSOR.

```

```

DR ProDom; PD000039; Response_reg; 1.
DR SMART; SM00065; GAF; 1.
DR SMART; SM00304; HAMP; 12.
DR SMART; SM00387; HATPase_c; 1.
DR SMART; SM00388; HSKA; 1.
DR SMART; SM00448; REC; 1.
KW Kinase; Phosphorylation; Sensory transduction; Transferase.
SQ SEQUENCE 1829 AA; 195751 MW; C9C8699938C956A4 CRC64;

Query Match 9.4%; Score 79.5; DB 16; Length 1829;
Best Local Similarity 22.8%; Pred. No. 82;
Matches 37; Conservative 29; Mismatches 61; Indels 35; Gaps 6;

Qy 18 EAKEENITTCGAECSCINENITVPDTKVNFYAKRMEVQQAVVWQGLALL----- 70
Db 328 QVREISHVTTAVA-NGDLSKRVTVP-----ARGEVAQLAETINQMTELRIFADEV 377
Qy 71 -----SEAVLRGQALVNSSQPWEPLQHLHVDKAVSGLRSLTTLRLALGAOKEAISPP 122
Db 378 TRVANETGGEGQLGGQANVPCAAGINKDL--TDSVNTVFNLTQVRDIAAVTTAVASG 434
Qy 123 DAASAAPLRTITADTFKRLFRVYS--NFLRGKCLKLYTGEACR 162
Db 435 DLS-----QKVTVDVAGEMLELKNVTNTMTVDLSAFGAQEVTR 471

RESULT 14
Q91ZAI PRELIMINARY; PRT; 3033 AA.
AC Q91ZAI;
DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)
DE Genome polyprotein [Contains: envelope glycoprotein E2 (GP68) (GP70) (NS1)].
DE (NS1)].
OS Hepatitis C virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Flaviviridae;
OC Hepacivirus.
OX NCBI_TaxID=11103;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=MD2B-1;
RA Itakura J., Nagayama K., Enomoto N., Kurosaki M., Watanabe H.,
RA Sato C.;
RA "Full length cDNA sequence of HCV genotype 2b, strain MD2B-1.";
RT Submitted (FEB-2000) to the EMBL/GenBank/DBJ databases.
CC -1- SIMILARITY: TO HEPATITIS C VIRUS ENVELOPE GLYCOPROTEIN E1.
DR EMBL; AF238486; AAF59945.1; -.
DR HSP; P27958; IHEI.
DR MEROPS; S29.001; -.
DR InterPro; IPR000345; CytC_heme_bind.
DR InterPro; IPR001410; DEAD.
DR InterPro; IPR002522; HCV_capsid.
DR InterPro; IPR002521; HCV_core.
DR InterPro; IPR002519; HCV_env.
DR InterPro; IPR002531; HCV_NS1.
DR InterPro; IPR002518; HCV_NS2.
DR InterPro; IPR004109; HCV_NS3.
DR InterPro; IPR000745; HCV_NS4a.
DR InterPro; IPR001490; HCV_NS4b.
DR InterPro; IPR002866; HCV_NS5a.
DR InterPro; IPR002166; HCV_RdRP.
DR Pfam; PF01543; HCV_capsid; 1.
DR Pfam; PF01542; HCV_core; 1.
DR Pfam; PF01539; HCV_env; 1.
DR Pfam; PF01560; HCV_NS1; 1.
DR Pfam; PF01538; HCV_NS2; 1.
DR Pfam; PF02907; HCV_NS3; 1.
DR Pfam; PF01006; HCV_NS4a; 1.
DR Pfam; PF01001; HCV_NS4b; 1.
DR Pfam; PF01506; HCV_NS5a; 1.
DR Pfam; PF00998; HCV_RdRP; 1.

```

DR ProDom: PD186062; HCV_NSI; 1.
DR PROSITE; PS00190; CYTOCHROME_C; UNKNOWN_1.
KW Coat protein; Envelope protein; Glycoprotein; Nonstructural protein;
KW Polyprotein; RNA-directed RNA polymerase; Transmembrane.
SQ SEQUENCE 3033 AA; 330723 MW; FE04FEC7C385A13A CRC64;

Query Match 9.4%; Score 79.5; DB 12; Length 3033;
Best Local Similarity 26.6%; Pred. No. 1.6e+02;
Matches 41; Conservative 22; Mismatches 64; Indels 27; Gaps 7;
QY 5 LICDSRVLELYLLEAKENITTCAC---HCSLNENITV-PDTKYNFYAKRM----- 54
DB 1659 IITSSWLAGVLAAVAAYCLATCISIIIGRLHLNDQVVVAPDKKILLYEAFDEMECAK 1718
QY 55 -----EVGQAVVWQG--LALLSEAVLRGQALLVNSQPWEPLQ----LHVDRAVSGLR 104
DB 1719 AALIEGQRMALKSKIOGLLOQATROAQDIHPAIOSSWPKLEQFWAKHWNFISGIQY 1778
QY 105 LTTLLRALG-----AQEKAISPPDAASAPLRTIT 134
DB 1779 LAGLSTLPGNPAVAMMAFS---AALTSPPLTST 1809

RESULT 15

Q43380 PRELIMINARY; PRT; 480 AA.
AC Q43380;
DT 01-NOV-1996 (TREMBlrel. 01, Created)
DT 01-NOV-1996 (TREMBlrel. 01, Last sequence update)
DT 01-MAR-2002 (TREMBlrel. 20, Last annotation update)
DE Putative pp70 ribosomal protein S6 Kinase.
GN ASPK11.
OS Avena sativa (Oat).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Poideae;
OC Aveneae; Avena.
OX NCBI_taxid=4498;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CV. RHIANNON; TISSUE=ALEURONE;
RX MEDLINE=9528431; PubMed=7766874;
RA Huttly A.K., Phillips A.L.;
RT "gibberellin regulated expression in oat aleurone cells of two kinases
that show homology to nap kinase and a ribosomal protein kinase.";
RL Plant Mol. Biol. 27:1043-1052(1995).
CC -!- SIMILARITY: BELONGS TO THE SER/THR FAMILY OF PROTEIN KINASES.
DR EMBL: X79992; CAA56313.1; -
DR HSP; P05132; ICTP.
DR InterPro; IPR000719; Euk_pkinase.
DR InterPro; IPR000961; Pkinase_C.
DR InterPro; IPR002290; Ser_thr_pkinase.
DR Pfam; PF00069; pkinase; 1.
DR Pfam; PF00433; pkinase_C; 1.
DR ProDom; PD000001; Euk_pkinase; 1.
DR SMART; SM00220; S_trc; 1.
DR SMART; SM00133; S_TK_X; 1.
DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR PROSITE; PS00111; PROTEIN_KINASE_DOM; 1.
DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
KW ATP-binding; Kinase; Ribosomal protein;
KW Serine/threonine-protein kinase; Transferase.
SQ SEQUENCE 480 AA; 53532 MW; 33596A101DBB077D CRC64;

Query Match 9.3%; Score 79; DB 10; Length 480;
Best Local Similarity 22.4%; Pred. No. 17;
Matches 32; Conservative 26; Mismatches 65; Indels 20; Gaps 4;
QY 30 AEHCSLNENITVPDTKYNFYAKRMVEYQQQAVEVWQGLALISEA--VLRGQALLVNSQP 87
DB 51 AVHPTPEASIVTPDSPA-----PLAESGEVYNDPVVITKRSLSHVGFTLLVSQSLP 102
QY 88 WEPLQLHVVDKAVSGLRSLTTLRLALGAQKEAISPPDAASAPLRTITADTRKL----- 141

Db 103 LSKLTLHESESSDL--LECLSKKQSNQAEALSDELSNTRKNEAVGLDNFEVLKLVGG 160
QY 142 --FRVYSNFRGKGLKLYTGEACR 162
Db 161 AFGKYVQVRMKGTSSEIYANKVMR 183

Search completed: June 13, 2003, 15:13:05
Job time : 43 secs



STIC SEARCH RESULTS

Biotech-Chem Library

Questions about the scope or the results of the search? Contact *the searcher or contact*:

Mary Hale, Information Branch Supervisor
308-4258, CM1-1E01

Voluntary Results Feedback Form

➤ I am an examiner in Workgroup: Example: 1610

➤ Relevant prior art **found**, search results used as follows:

- ☐ 102 rejection
- ☐ 103 rejection
- ☐ Cited as being of interest.
- ☐ Helped examiner better understand the invention.
- ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
(journal articles, conference proceedings, new product announcements etc.)


➤ Relevant prior art **not found**:

- ☐ Results verified the lack of relevant prior art (helped determine patentability).
- ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC/Biotech-Chem Library CM1 – Circ. Desk







STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number 96531

TO: Patricia Patten
Location: cm1/11E09.
Art Unit: 1654
Friday, June 13, 2003

Case Serial Number: 830964

From: Edward Hart
Location: Biotech-Chem Library
CM1-6B02
Phone: 305-9203

edward.hart@uspto.gov


Search Notes

Examiner Patten,

Here are the results of the search you requested.

Please feel free to contact me if you have any questions.

Edward Hart



STIC-Biotech/ChemLib

96531

From: Patten, Patricia
Sent: Friday, June 13, 2003 11:45 AM
To: STIC-Biotech/ChemLib
Subject: Sequence search

Please search SEQ ID No. 1 of 09/830,964

Thank you.

Patricia Patten
1654 CM1 11E09
308-1189

Edward Hari
Technical Info. Specialist
STIC/Biotech
CMI 6B02 Tel: 305-9203

Searcher: _____
Phone: _____
Location: _____
Date Picked Up: 6/13/03
Date Completed: 6/13/03
Searcher Prep/Review: _____
Clerical: _____
Online time: _____

TYPE OF SEARCH:

NA Sequences: _____
AA Sequences: _____
Structures: _____
Bibliographic: _____
Litigation: _____
Full text: _____
Patent Family: _____
Other: _____

VENDOR/COST (where applic.)

STN: _____
DIALOG: _____
Questel/Orbit: _____
DRLink: _____
Lexis/Nexis: _____
Sequence Sys.: 02
WWW/Internet: _____
Other (specify): _____

